[exhibit103001.jpg]
EXHIBIT 10.3 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND
REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS
EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE
HARM TO THE COMPANY IF DISCLOSED. 1. THIS CONTRACT IS A RATED ORDER RATING PAGE
OF PAGES AWARD/CONTRACT UNDER DPAS (15 CFR 700) 1 53 2. CONTRACT (Proc. Inst.
Ident.) NO. 3. EFFECTIVE DATE 4. REQUISITION/PURCHASE REQUEST/PROJECT NO.
W911QY20C0100 09 Aug 2020 0011534693 5. ISSUED BY CODE W911QY 6. ADMINIST ERED
BY (If other than Item 5) CODE S2206A W6QK ACC-APG NATICK DEFENSE CONTRACT
MANAGEMENT AGENCY CONTRACTING DIVISION DCMA BOSTON BLDG 1 GENERAL GREENE AVENUE
495 SUMMER STREET NATICK MA 01760-5011 BOSTON MA 02210-2138 7. NAME AND ADDRESS
OF CONTRACTOR (No., street, city, county, state and zip code) 8. DELIVERY
MODERNATX, INC. [ ] FOB ORIGIN [ X ] OTHER (See below) [***] 9. DISCOUNT FOR
PROMPT PAYMENT 200 TECHNOLOGY SQ CAMBRIDGE MA 02139-3578 10. SUBMIT INVOICES 1
ITEM (4 copies unless otherwise specified) TO THE ADDRESS Section G CODE 6RP85
FACILITY CODE SHOWN IN: 11. SHIP TO/MARK FOR CODE 12. PAYMENT WILL BE MADE BY
CODE HQ0337 DEFENSE FINANCE AND ACCOUNTING SERVICE DFAS - COLUMBUS CENTER
(HQ0337) NORTH ENTITLEMENT OPERATIONS P.O. BOX 182317 See Schedule COLUMBUS OH
43218-2266 13. AUTHORITY FOR USING OTHER THAN FULL AND OPEN 14. ACCOUNTING AND
APPROPRIATION DATA COMPETITION: See Schedule [ X ] 10 U.S.C. 2304(c)( 2 ) [ ] 41
U.S.C. 253(c)( ) 15A. ITEM NO. 15B. SUPPLIES/ SERVICES 15C. QUANTITY 15D. UNIT
15E. UNIT PRICE 15F. AMOUNT SEE SCHEDULE 15G. TO TAL AMOUNT OF CONTRACT
$1,525,000,000.00 16. TABLE OF CONTENTS (X) SEC. DESCRIPTION PAGE(S) (X) SEC.
DESCRIPTION PAGE(S) PART I - THE SCHEDULE PART II - CONTRACT CLAUSES X A
SOLICITATION/ CONTRACT FORM 1 - 2 X I CONTRACT CLAUSES 45 - 51 X B SUPPLIES OR
SERVICES AND PRICES/ COSTS 3 - 18 PART III – LIST OF DOCUMENTS, EXHIBITS AND O
THER ATTACH. X C DESCRIPTION/ SPECS./ WORK STATEMENT 19 - 27 X J LIST OF
ATTACHMENTS 52 - 53 X D PACKAGING AND MARKING 28 PART IV - REPRESENTATIONS AND
INSTRUCTIONS X E INSPECT ION AND ACCEPTANCE 29 - 30 REPRESENTATIONS,
CERTIFICATIONS AND K X F DELIVERIES OR PERFORMANCE 31 - 33 OTHER STATEMENTS OF
OFFERORS X G CONTRACT ADMINISTRATION DATA 34 - 38 L INST RS., CONDS., AND
NOTICES TO OFFERORS X H SPECIAL CONTRACT REQUIREMENTS 39 - 44 M EVALUATION
FACTORS FOR AWARD CONTRACTING OFFICER WILL COMPLETE ITEM 17 (SEALED-BID OR
NEGOTIATED PROCUREMENT) OR 18 (SEALED-BID PROCUREMENT) AS APPLICABLE 17. [ ]
CONTRACTOR'S NEGOTIATED AGREEMENT Contractor is required to sign this 18. [ ]
SEALED-BID AWARD (Contractor is not required to sign this document.) document
and return1 copies to issuing office.) Contractor agrees to furnish and deliver
all Your bid on Solicitation Number W911QY20R0043 items or perform all the
services set forth or otherwise identified above and on any continuation sheets
for the consideration stated herein. The rights and obligations of the parties
to this contract shall be subject to and governed by the following documents:
(a) this award/contract, including the additions or changes made by you which
additions or changes are set forth in full above, is hereby accepted as (b) the
solicitation, if any, and (c) such provisions, representations, certifications,
and specifications, to the terms listed above and on any continuation sheets.
This award consummates the contract which consists of the as are attached or
incorporated by reference herein. following documents: (a) the Government's
solicitation and your bid, and (b) this award/contract. No further contractual
(Attachments are listed herein.) document is necessary. (Block 18 should be
checked only when awarding a sealed-bid contract.) 19A. NAME AND TITLE OF SIGNER
( Type or print) 20A. NAME OF CONTRACTING OFFICER CONNELL-MAGAW, CAMILLE /
BRANCH CHIEF Stéphane Bancel, CEO TEL: EMAIL: [***] 19B. NAME OF CONTRACTOR 19C.
DATE SIGNED 20B. UNITED STATES OF AMERICA 20C. DATE SIGNED 11-Aug-2020 BY /s/
Stéphane Bancel 8/11/2020 BY /s/ Camille B. Connell-Magaw (Signature of person
authorized to sign) (Signature of Contracting Officer) AUTHORIZED FOR LOCAL
REPRODUCTION STANDARD FORM 26 (REV. 5/2011) Previous edition is NOT usable
Prescribed by GSA – FAR (48 CFR) 53.214(a)

--------------------------------------------------------------------------------

 
[exhibit103002.jpg]
W911QY20C0100 Page 2 of 53 Section A - Solicitation/Contract Form A.1 The U.S.
Army Contracting Command - Aberdeen Proving Ground (ACC-APG), Natick Division
has a requirement for up to 500 million SARS-CoV-2 mRNA-1273 Vaccine doses (100
μg) in support of Joint Program Executive Office - Chemical Biological
Radiological Nuclear Defense (JPEO-CBRND), the Assistant Secretary for
Preparedness and Response (ASPR), and Biomedical Advanced Research and
Development Authority (BARDA). All doses of mRNA-1273 Vaccine referenced herein
are 100 μg doses. All doses will be delivered in a multi- dose vial with a
volume sufficient for 10 doses per vial.

--------------------------------------------------------------------------------

 
[exhibit103003.jpg]
W911QY20C0100 Page 3 of 53 Section B - Supplies or Services and Prices ITEM NO
SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 0001 $0.00 SARS-CoV-2
mRNA-1273 Vaccine FFP The contractor shall produce and deliver 100M doses of the
SARS-CoV-2 mRNA- 1273 Vaccine filled drug product (FDP), IAW Section C,
Statement of Work (SOW) and CDRLs (Exhibit A) on this contract. PROJECT:
Operation Warp Speed NET AMT $0.00 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT
PRICE AMOUNT 0001AA 15,000,000 Each $12.25 $183,750,000.00 15M Doses FFP FOB:
Origin (Shipping Point) PURCHASE REQUEST NUMBER: 0011534693 PROJECT: Operation
Warp Speed PSC CD: 6505 NET AMT $183,750,000.00 ACRN AA $183,750,000.00 CIN:
GFEBS001153469300001

--------------------------------------------------------------------------------

 
[exhibit103004.jpg]
W911QY20C0100 Page 4 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE
AMOUNT 0001AB 22,000,000 Each $12.25 $269,500,000.00 22M Doses FFP FOB: Origin
(Shipping Point) PURCHASE REQUEST NUMBER: 0011534693 PROJECT: Operation Warp
Speed PSC CD: 6505 NET AMT $269,500,000.00 ACRN AB $269,500,000.00 CIN:
GFEBS001153469300002 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT
0001AC 30,000,000 Each $12.25 $367,500,000.00 30M Doses FFP FOB: Destination
PURCHASE REQUEST NUMBER: 0011534693 PROJECT: Operation Warp Speed PSC CD: 6505
NET AMT $367,500,000.00 ACRN AA $367,500,000.00 CIN: GFEBS001153469300003

--------------------------------------------------------------------------------

 
[exhibit103005.jpg]
W911QY20C0100 Page 5 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE
AMOUNT 0001AD 33,000,000 Each $12.25 $404,250,000.00 33M Doses FFP FOB:
Destination PURCHASE REQUEST NUMBER: 0011534693 PROJECT: Operation Warp Speed
PSC CD: 6505 NET AMT $404,250,000.00 ACRN AA $404,250,000.00 CIN:
GFEBS001153469300004 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT
0002 1 Job $0.00 TBN Vendor Managed Inventory FFP a. The contractor shall
secure, manage and maintain storage for up to 100M doses of mRNA-1273 vaccine
and deliver to the designated government facility in accordance with Section F.
b. [***] FOB: Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT
$0.00

--------------------------------------------------------------------------------

 
[exhibit103006.jpg]
W911QY20C0100 Page 6 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE
AMOUNT 0003 $0.00 EUA or BLA Incentive FFP This is an incentive CLIN and will be
earned only if an Emergency Use Authorization (EUA) or Biologics License
Application (BLA) is obtained no later than 31 January 2021. PROJECT: Operation
Warp Speed NET AMT $0.00 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE
AMOUNT 0003AA 15,000,000 Each $3.00 $45,000,000.00 EUA or BLA Incentive FFP If
earned, this incentive shall be paid at final acceptance of subCLIN 0001AA. FOB:
Destination PSC CD: 6505 NET AMT $45,000,000.00

--------------------------------------------------------------------------------

 
[exhibit103007.jpg]
W911QY20C0100 Page 7 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE
AMOUNT 0003AB 22,000,000 Each $3.00 $66,000,000.00 EUA or BLA Incentive FFP If
earned, this incentive shall be paid at final acceptance of subCLIN 0001AB. FOB:
Destination PSC CD: 6505 NET AMT $66,000,000.00 ITEM NO SUPPLIES/SERVICES
QUANTITY UNIT UNIT PRICE AMOUNT 0003AC 30,000,000 Each $3.00 $90,000,000.00 EUA
or BLA Incentive FFP If earned, this incentive shall be paid at final acceptance
of subCLIN 0001AC. FOB: Destination PSC CD: 6505 NET AMT $90,000,000.00 ITEM NO
SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 0003AD 33,000,000 Each $3.00
$99,000,000.00 EUA or BLA Incentive FFP If earned, this incentive shall be paid
at final acceptance of subCLIN 0001AD. FOB: Destination PSC CD: 6505 NET AMT
$99,000,000.00

--------------------------------------------------------------------------------

 
[exhibit103008.jpg]
W911QY20C0100 Page 8 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE
AMOUNT 0004 1 Job NSP Technical Data FFP The contractor shall deliver technical
Data IAW Contract Data Requirements List (CDRL) IAW deliveries in Section C.4
and Section J, Exhibit A. FOB: Destination PROJECT: Operation Warp Speed PSC CD:
6505 NET AMT ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 1001
$0.00 OPTION SARS-CoV-2 mRNA-1273 Vaccine FFP The contractor shall produce and
deliver 100M doses of the SARS-CoV-2 mRNA- 1273 Vaccine filled drug product
(FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this
contract. PROJECT: Operation Warp Speed NET AMT $0.00

--------------------------------------------------------------------------------

 
[exhibit103009.jpg]
W911QY20C0100 Page 9 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE
AMOUNT 1001AA 33,200,000 Each $16.50 $547,800,000.00 OPTION 33.2M Doses FFP a.
If executed, the option shall be awarded upon EUA or no later than [***]. b. The
government shall provide [***] notification to exercise the option. FOB:
Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $547,800,000.00
ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 1001AB 33,400,000 Each
$16.50 $551,100,000.00 OPTION 33.4M Doses FFP a. If executed, the option shall
be awarded upon EUA or no later than [***]. b. The government shall provide
[***] notification to exercise the option. FOB: Destination PROJECT: Operation
Warp Speed PSC CD: 6505 NET AMT $551,100,000.00

--------------------------------------------------------------------------------

 
[exhibit103010.jpg]
W911QY20C0100 Page 10 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE
AMOUNT 1001AC 33,400,000 Each $16.50 $551,100,000.00 OPTION 33.4M Doses FFP a.
If executed, the option shall be awarded upon EUA or no later than [***]. b. The
government shall provide [***] notification to exercise the option. FOB:
Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $551,100,000.00
ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 1002 1 Job $0.00 TBN
OPTION Vendor Managed Inventory FFP a. The contractor shall secure, manage and
maintain storage for up to 100M doses of mRNA-1273 vaccine and deliver to the
designated government facility in accordance with Section F. b. [***] FOB:
Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $0.00

--------------------------------------------------------------------------------

 
[exhibit103011.jpg]
W911QY20C0100 Page 11 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE
AMOUNT 2001 $0.00 OPTION SARS-CoV-2 mRNA-1273 Vaccine FFP The contractor shall
produce and deliver 100M doses of the SARS-CoV-2 mRNA- 1273 Vaccine filled drug
product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on
this contract. PROJECT: Operation Warp Speed NET AMT $0.00 ITEM NO
SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 2001AA 33,400,000 Each $16.50
$551,100,000.00 OPTION 33.4M Doses FFP a. If executed, the option shall be
awarded upon EUA or no later than [***]. b. The government shall provide [***]
notification to exercise the option. FOB: Destination PROJECT: Operation Warp
Speed PSC CD: 6505 NET AMT $551,100,000.00

--------------------------------------------------------------------------------

 
[exhibit103012.jpg]
W911QY20C0100 Page 12 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE
AMOUNT 2001AB 33,400,000 Each $16.50 $551,100,000.00 OPTION 33.4M Doses FFP a.
If executed, the option shall be awarded upon EUA or no later than [***]. b. The
government shall provide [***] notification to exercise the option. FOB:
Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $551,100,000.00
ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 2001AC 33,200,000 Each
$16.50 $547,800,000.00 OPTION 33.2M Doses FFP a. If executed, the option shall
be awarded upon EUA or no later than [***]. b. The government shall provide
[***] notification to exercise the option. FOB: Destination PROJECT: Operation
Warp Speed PSC CD: 6505 NET AMT $547,800,000.00

--------------------------------------------------------------------------------

 
[exhibit103013.jpg]
W911QY20C0100 Page 13 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE
AMOUNT 2002 1 Job $0.00 TBN OPTION Vendor Managed Inventory FFP a. The
contractor shall secure, manage and maintain storage for up to 100M doses of
mRNA-1273 vaccine and deliver to the designated government facility in
accordance with Section F. b. [***] FOB: Destination PROJECT: Operation Warp
Speed PSC CD: 6505 NET AMT $0.00 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT
PRICE AMOUNT 3001 $0.00 OPTION SARS-CoV-2 mRNA-1273 Vaccine FFP The contractor
shall produce and deliver 100M doses of the SARS-CoV-2 mRNA- 1273 Vaccine filled
drug product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A)
on this contract. PROJECT: Operation Warp Speed NET AMT $0.00

--------------------------------------------------------------------------------

 
[exhibit103014.jpg]
W911QY20C0100 Page 14 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE
AMOUNT 3001AA 33,400,000 Each $16.50 $551,100,000.00 OPTION 33.4M Doses FFP a.
If executed, the option shall be awarded upon EUA or no later than [***]. b. The
government shall provide [***] notification to exercise the option. FOB:
Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $551,100,000.00
ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 3001AB 33,400,000 Each
$16.50 $551,100,000.00 OPTION 33.4M Doses FFP a. If executed, the option shall
be awarded upon EUA or no later than [***]. b. The government shall provide
[***] notification to exercise the option. FOB: Destination PROJECT: Operation
Warp Speed PSC CD: 6505 NET AMT $551,100,000.00

--------------------------------------------------------------------------------

 
[exhibit103015.jpg]
W911QY20C0100 Page 15 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE
AMOUNT 3001AC 33,200,000 Each $16.50 $547,800,000.00 OPTION 33.2M Doses FFP a.
If executed, the option shall be awarded upon EUA or no later than [***]. b. The
government shall provide [***] notification to exercise the option. FOB:
Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $547,800,000.00
ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 3002 1 Job $0.00 TBN
OPTION Vendor Managed Inventory FFP The contractor shall secure, manage and
maintain storage for up to 100M doses of mRNA-1273 vaccine and deliver to the
designated government facility in accordance with Section F. b. [***] FOB:
Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $0.00

--------------------------------------------------------------------------------

 
[exhibit103016.jpg]
W911QY20C0100 Page 16 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE
AMOUNT 4001 $0.00 OPTION SARS-CoV-2 mRNA-1273 Vaccine FFP The contractor shall
produce and deliver 100M doses of the SARS-CoV-2 mRNA- 1273 Vaccine filled drug
product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on
this contract. PROJECT: Operation Warp Speed NET AMT $0.00 ITEM NO
SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 4001AA 33,400,000 Each $16.50
$551,100,000.00 OPTION 33.4M Doses FFP a. If executed, the option shall be
awarded upon EUA or no later than [***]. b. The government shall provide [***]
notification to exercise the option. FOB: Destination PROJECT: Operation Warp
Speed PSC CD: 6505 NET AMT $551,100,000.00

--------------------------------------------------------------------------------

 
[exhibit103017.jpg]
W911QY20C0100 Page 17 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE
AMOUNT 4001AB 33,400,000 Each $16.50 $551,100,000.00 OPTION 33.4M Doses FFP a.
If executed, the option shall be awarded upon EUA or no later than [***]. b. The
government shall provide [***] notification to exercise the option. FOB:
Destination PROJECT: Operation Warp Speed PSC CD: 6505 NET AMT $551,100,000.00
ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 4001AC 33,200,000 Each
$16.50 $547,800,000.00 OPTION 33.2M Doses FFP a. If executed, the option shall
be awarded upon EUA or no later than [***]. b. The government shall provide
[***] notification to exercise the option. FOB: Destination PROJECT: Operation
Warp Speed PSC CD: 6505 NET AMT $547,800,000.00

--------------------------------------------------------------------------------

 
[exhibit103018.jpg]
W911QY20C0100 Page 18 of 53 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE
AMOUNT 4002 1 Job $0.00 TBN OPTION Vendor Managed Inventory FFP The contractor
shall secure, manage and maintain storage for up to 100M doses of mRNA-1273
vaccine and deliver to the designated government facility in accordance with
Section F. b. [***] FOB: Destination PROJECT: Operation Warp Speed PSC CD: 6505
NET AMT $0.00

--------------------------------------------------------------------------------

 
[exhibit103019.jpg]
W911QY20C0100 Page 19 of 53 Section C - Descriptions and Specifications
STATEMENT OF WORK LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE C.1 SCOPE. The
Department of Defense and Health and Human Services (HHS) require large scale
manufacturing of vaccine doses in support of the national emergency response to
the Coronavirus Disease 2019 (COVID-19) for the United States Government (USG)
and the US population. C.1.1 Background. In December 2019, a novel coronavirus
now known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People’s
Republic of China, causing outbreaks of the coronavirus disease COVID-19 that
has now spread globally. The Secretary of Health and Human Service declared a
public health emergency on January 31, 2020, under section 319 of the Public
Health Service Act (42 U.S.C. 247d), in response to COVID-19. On March 1, 2020,
the President of the United States, pursuant to sections 01 and 301 of the
National Emergencies Act (50 U.S.C. 1601 et seq.) and consistent with section
1135 of the Social Security Act (SSA), as amended (42 U.S.C. 1320b-5),
proclaimed that the COVID-19 outbreak in the United States constitutes a
national emergency. C.1.1.1 Under Operation Warp Speed (OWS), the Department of
Defense and HHS are leading a whole of nation effort to ensure development of
promising vaccine, diagnostic and therapeutic candidates and ensure that these
medical countermeasures are available in the quantities required to reduce
SARS-CoV-2 transmission, identify prior and/or current infection, and improve
patient care, thereby mitigating the impact of COVID-19 on the nation and its
people. The DoD Joint Program Executive Office for Chemical, Biological,
Radiological and Nuclear Defense (JPEO-CBRD) is providing expertise and
contracting support to HHS, in compliance with PL 115-92 Authorization Letter
for DoD Medical Priorities, through an Interagency Agreement, signed April 23,
2020. As OWS products progress to clinical trials to evaluate the safety and
efficacy of vaccines and therapeutics, it is critical that, in parallel, the USG
supports large scale manufacturing so that vaccine doses or therapeutic
treatment courses are immediately available for nationwide access as soon as a
positive efficacy signal is obtained and the medical countermeasures are
authorized for widespread use. C.1.2 Objective: The objective of this effort is
to obtain the following: a. Base Period: Large scale manufacturing of 100
million vaccine doses b. Option Period 1: Large scale manufacturing of 100
million vaccine doses c. Option Period 2: Large scale manufacturing of 100
million vaccine doses d. Option Period 3: Large scale manufacturing of 100
million vaccine doses e. Option Period 4: Large scale manufacturing of 100
million vaccine doses The Base Period is 9 months, with overlapping options for
a total of 20 months if all options are exercised. C.2 APPLICABLE DOCUMENTS.
C.2.1 Federal Documents: C.2.1.1 Title 21 Code of Federal Regulations (CFR),
Food and Drugs: Part 210, Current Good Manufacturing Practice in Manufacturing,
Processing, Packing, or Holding of Drugs; General; and, Part 211, Current Good
Manufacturing Practice In Manufacturing, Processing, Packing, or Holding of
Drugs; General. (https://www.ecfr.gov/cgi-bin/text-
idx?SID=a95cab20f443897a400bb7e44a27cf4c&mc=true&tpl=/ecfrbrowse/Title21/21cfrv4_02.tpl#0)
C.3 REQUIREMENTS. Independently, and not as an agent of the USG, in accordance
with the Proposal submitted by ModernaTX, Inc. in response to Solicitation
Number W911QY20R0043, Titled, “Advanced Procurement of mRNA-1273 Vaccine for
Prevention of SARS-CoV-2 Coronavirus (COVID-19)”), dated July 10, 2020 (and any
subsequent USG-approved revisions thereto), the contractor shall provide all
necessary services,

--------------------------------------------------------------------------------

 
[exhibit103020.jpg]
W911QY20C0100 Page 20 of 53 qualified personnel, material, equipment and
facilities (not otherwise provided by the USG under the terms of this contract)
to perform the specific tasks set forth below. C.3.1 C ontract Line Item Number
(CLIN) 0001 - Base Period: Large Scale Manufacturing of 100 Million V accine
Doses. C.3.1.1 The contractor shall complete all scope required for the
production, release and delivery use of 100 million Final Drug Product (FDP)
doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include, the following tasks
and other activities reasonably contemplated by such task: C.3.1.1.1 Storage of
FDP doses prior to delivery consistent with all FDA requirements to ensure that
the product remains available for use in target populations. Storage and
maintenance of the vaccine prior to delivery shall be under conditions and at
temperatures necessary to retain stability for use as prescribed in this
contract for a period of 12 months. (Based on FDP stability data that supports a
12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.)
Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing
of Drugs in Commercial Distribution are met prior to distribution to the CDC.
Documents shall be provided under CDRL A002, FDA Interactions and Inspections
Documentation. C.3.1.1.2 cGMP manufacturing of 100 million doses fully compliant
with 21 CFR 210 and 211. C.3.1.1.3 Ensuring that vial labeling and packaging is
consistent with FDA guidance for use in target populations and that labeling is
updated as appropriate. C.3.1.1.4 Coordinating with FDA to establish an approved
commercial vial label, carton and packaging insert (printed or electronic).
C.3.1.1.5 Ensuring the product complies with the Drug Supply Chain Security Act
(DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 22013), including product
verification, serialization, traceability and detection and response
requirements, subject to any exceptions established by or the enforcement
discretion of the FDA, including “Exemption from Certain Product Tracing and
Product Identification Requirements Under Section 582 of the FD&C Act” (April
2020). C.3.1.1.6 In coordination with the USG, the contractor shall conduct a
demonstration of the vaccine shipping process prior to the first delivery of FDP
doses at a time mutually agreed to by the contractor and the USG. Moderna shall
provide specifications and details associated with the shipping process and
containers (IAW CDRL A005) to enable the USG to adequately plan and prepare for
potential distribution of the vaccine. C.3.1.1.7 Following release of product
the contractor shall, promptly deliver product to the designated delivery site
via a qualified distribution vendor in accordance with Section F and paragraph
C.7 below. In the unforeseen event that a designated delivery site cannot
receive product and the contractor provides storage beyond 20 days of product
release, the contract will be subject to modification for acceptance purposes.
C.3.1.2 Site Visits and Audits. The contractor shall accommodate periodic or ad
hoc site visits by BARDA and FDA representatives for required site visits and
audits at facilities used to support this contract throughout the period of
performance of the contract. C.3.1.2.1 BARDA Audits. If issues are identified
during an audit, the contractor shall submit a report detailing the finding and
corrective action(s) in accordance with CDRL A001. C.3.1.2.2 FDA Audits. The
Contractor shall notify the Contracting Officer and Contracting Officer’s
Representative (COR) within [***] of a scheduled FDA audit or within [***] of an
ad hoc site visit or audit if the FDA does not provide advance notice. The
contractor shall provide copies of any FDA Audit Report received from
subcontractors that occur as a result of this contract or for this product
within [***] of receiving correspondence from the FDA or third party in
accordance with CDRL A002. The Contractor shall

--------------------------------------------------------------------------------

 
[exhibit103021.jpg]
W911QY20C0100 Page 21 of 53 provide the Contracting Officer with a plan for
addressing areas of nonconformance, if any are identified, within [***] of
submittal of the audit report in accordance with CDRL A002. C.3.1.2.3 FDA
Interactions. The contractor shall provide copies of the plan and processes that
will ensure the USG has visibility and input on all FDA communications regarding
the drugs and biologics for the following, but not limited to: FDA interactions,
FDA meetings, communications, submissions, inspections, and enforcement
documentation in accordance with CDRL A002. C.3.2 C LIN 1001 - Option Period 1:
Large Scale Manufacturing of 100 Million Vaccine Doses. C.3.2.1 The contractor
shall complete all scope required for the production, release and delivery use
of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include
the following tasks and other activities reasonably contemplated by such tasks:
C.3.2.1.1 Storage of FDP doses prior to delivery consistent with all FDA
requirements to ensure that the product remains available for use in target
populations. Storage and maintenance of the vaccine prior to delivery shall be
under conditions and at temperatures necessary to retain stability for use as
prescribed in this contract for a period of 12 months. (Based on FDP stability
data that supports a 12-month shelf-life, subject to FDA confirmation of the
assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers
of Drugs and Listing of Drugs in Commercial Distribution are met prior to
distribution to the CDC. Documents shall be provided under CDRL A002, FDA
Interactions and Inspections Documentation. C.3.2.1.2 cGMP manufacturing of 100
million doses, subject to any exceptions established by or the enforcement
discretion of the FDA. C.3.2.1.3 Ensuring that vial labeling and packaging is
consistent with FDA guidance for use in target populations and that labeling is
updated. C.3.2.1.4 Ensuring the product complies with the Drug Supply Chain
Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 22013), including
product verification, serialization, traceability and detection and response
requirements subject to any exceptions established by or the enforcement
discretion of the FDA. C.3.2.1.5 Following release of the product the contractor
shall deliver the product to the designated distribution site via a qualified
distribution vendor in accordance with Section F and paragraph C.7 below. To the
extent a natural disaster or other emergency affecting a designated delivery
site restricts such site’s ability to receive product, the Contractor and the
USG will promptly agree on an alternate USG delivery location, or storage as
Vendor Managed Inventory (VMI) at the contractor site. C.3.2.2 Site Visits and
Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA
and FDA representatives for required site visits and audits at facilities used
to support this contract throughout the period of performance of the contract.
C.3.2.2.1 BARDA Audits. If issues are identified during an audit, the contractor
shall submit a report detailing the finding and corrective action(s) in
accordance with CDRL A001. C.3.2.2.2 FDA Audits. The Contractor shall notify the
Contracting Officer and COR within [***] of a scheduled FDA audit or within
[***] of an ad hoc site visit or audit if the FDA does not provide advance
notice. The contractor shall provide copies of any FDA Audit Report received
from subcontractors that occur as a result of this contract or for this product
within [***] of receiving correspondence from the FDA or third party in
accordance with CDRL A015. The Contractor shall provide the Contracting Officer
with a plan for addressing areas of nonconformance, if any are identified,
within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.2.2.3 FDA Interactions. The contractor shall provide copies of the plan and
processes that will ensure the USG has visibility and input on all FDA
communications regarding the drugs and biologics for the following, but

--------------------------------------------------------------------------------

 
[exhibit103022.jpg]
W911QY20C0100 Page 22 of 53 not limited to: FDA interactions, FDA meetings,
communications, submissions, inspections, and enforcement documentation in
accordance with CDRL A002. C.3.3 C LIN 2001 - Option Period 2: Large Scale
Manufacturing of 100 Million Vaccine Doses. C.3.3.1 The contractor shall
complete all scope required for the production, release and delivery use of 100
million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the
following tasks and other activities reasonably contemplated by such tasks:
C.3.3.1.1 Storage of FDP doses prior to delivery consistent with all FDA
requirements to ensure that the product remains available for use in target
populations. Storage and maintenance of the vaccine prior to delivery shall be
under conditions and at temperatures necessary to retain stability for use as
prescribed in this contract for a period of 12 months. (Based on FDP stability
data that supports a 12-month shelf-life, subject to FDA confirmation of the
assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers
of Drugs and Listing of Drugs in Commercial Distribution are met prior to
distribution to the CDC. Documents shall be provided under CDRL A002, FDA
Interactions and Inspections Documentation. C.3.3.1.2 cGMP manufacturing of 100
million doses, subject to any exceptions established by or the enforcement
discretion of the FDA. C.3.3.1.3 Ensuring that vial labeling and packaging is
consistent with FDA guidance for use in target populations and that labeling is
updated as appropriate. C.3.3.1.4 Ensuring that the product complies with the
Drug Supply Chain Security Act (DSCSA), Sections 581- 585 of PL 113-54 (Nov. 27,
2013), including product verification, serialization, traceability and detection
and response requirements, subject to any exceptions established by or the
enforcement discretion of the FDA. C.3.3.1.5 Following release the contractor
shall deliver product to the nearest designated distribution site via a
qualified distribution vendor in accordance with Section F and paragraph C.7
below. To the extent a natural disaster or other emergency affecting a
designated delivery site restricts such site’s ability to receive product, the
Contractor and the USG will promptly agree on an alternate USG delivery
location, or storage as Vendor Managed Inventory (VMI) at the contractor site.
C.3.3.2 Site Visits and Audits. The contractor shall accommodate periodic or ad
hoc site visits by BARDA and FDA representatives for required site visits and
audits at facilities used to support this contract throughout the period of
performance of the contract. C.3.3.2.1 BARDA Audits. If issues are identified
during an audit, the contractor shall submit a report detailing the finding and
corrective action(s) in accordance with CDRL A001. C.3.3.2.2 FDA Audits. The
Contractor shall notify the Contracting Officer and COR within [***] of a
scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA
does not provide advance notice. The contractor shall provide copies of any FDA
Audit Report received from subcontractors that occur as a result of this
contract or for this product within [***] of receiving correspondence from the
FDA or third party in accordance with CDRL A002. The Contractor shall provide
the Contracting Officer with a plan for addressing areas of nonconformance, if
any are identified, within [***] of submittal of the audit report in accordance
with CDRL A002. C.3.3.2.3 FDA Interactions. The contractor shall provide copies
of the plan and processes that will ensure the USG has visibility and input on
all FDA communications regarding the drugs and biologics for the following, but
not limited to: FDA interactions, FDA meetings, communications, submissions,
inspections, and enforcement documentation in accordance with CDRL A002. C.3.4 C
LIN 3001 - Option Period 3: Large Scale Manufacturing of 100 Million Vaccine
Doses.

--------------------------------------------------------------------------------

 
[exhibit103023.jpg]
W911QY20C0100 Page 23 of 53 C.3.4.1 The contractor shall complete all scope
required for the production, release and delivery use of 100 million FDP doses
of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the following tasks and
other activities reasonably contemplated by such tasks: C.3.4.1.1 Storage of FDP
doses prior to delivery consistent with all FDA requirements to ensure that the
product remains available for use in target populations. Storage and maintenance
of the vaccine prior to delivery shall be under conditions and at temperatures
necessary to retain stability for use as prescribed in this contract for a
period of 12 months. (Based on FDP stability data that supports a 12-month
shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure
requirements of 21CFR207, Registration of Producers of Drugs and Listing of
Drugs in Commercial Distribution are met prior to distribution to the CDC.
Documents shall be provided under CDRL A002, FDA Interactions and Inspections
Documentation. C.3.4.1.2 cGMP manufacturing of 100 million doses, subject to any
exceptions established by or the enforcement discretion of the FDA. C.3.4.1.3
Ensuring that vial labeling and packaging is consistent with FDA guidance for
use in target populations and that labeling is updated. C.3.4.1.4 Ensuring the
product complies with the Drug Supply Chain Security Act (DSCSA), Sections
581-585 of PL 113-54 (Nov. 27, 22013), including product verification,
serialization, traceability and detection and response requirements subject to
any exceptions established by or the enforcement discretion of the FDA.
C.3.4.1.5 Following release of the product the contractor shall deliver the
product to the designated distribution site via a qualified distribution vendor
in accordance with Section F and paragraph C.7 below. To the extent a natural
disaster or other emergency affecting a designated delivery site restricts such
site’s ability to receive product, the Contractor and the USG will promptly
agree on an alternate USG delivery location, or storage as Vendor Managed
Inventory (VMI) at the contractor site. C.3.4.2 Site Visits and Audits. The
contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA
representatives for required site visits and audits at facilities used to
support this contract throughout the period of performance of the contract.
C.3.4.2.1 BARDA Audits. If issues are identified during an audit, the contractor
shall submit a report detailing the finding and corrective action(s) in
accordance with CDRL A001. C.3.4.2.2 FDA Audits. The Contractor shall notify the
Contracting Officer and COR within [***] of a scheduled FDA audit or within
[***] of an ad hoc site visit or audit if the FDA does not provide advance
notice. The contractor shall provide copies of any FDA Audit Report received
from subcontractors that occur as a result of this contract or for this product
within [***] of receiving correspondence from the FDA or third party in
accordance with CDRL A015. The Contractor shall provide the Contracting Officer
with a plan for addressing areas of nonconformance, if any are identified,
within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.4.2.3 FDA Interactions. The contractor shall provide copies of the plan and
processes that will ensure the USG has visibility and input on all FDA
communications regarding mRNA-1273 for the following, but not limited to: FDA
interactions, FDA meetings, communications, submissions, inspections, and
enforcement documentation in accordance with CDRL A002. C.3.5 C LIN 4001 -
Option Period 4: Large Scale Manufacturing of 100 Million Vaccine Doses. C.3.5.1
The contractor shall complete all scope required for the production, release and
delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This
shall include the following tasks and other activities reasonably contemplated
by such tasks:

--------------------------------------------------------------------------------

 
[exhibit103024.jpg]
W911QY20C0100 Page 24 of 53 C.3.5.1.1 Storage of FDP doses prior to delivery
consistent with all FDA requirements to ensure that the product remains
available for use in target populations. Storage and maintenance of the vaccine
prior to delivery shall be under conditions and at temperatures necessary to
retain stability for use as prescribed in this contract for a period of 12
months. (Based on FDP stability data that supports a 12-month shelf-life,
subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of
21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial
Distribution are met prior to distribution to the CDC. Documents shall be
provided under CDRL A002, FDA Interactions and Inspections Documentation.
C.3.5.1.2 cGMP manufacturing of 100 million doses, subject to any exceptions
established by or the enforcement discretion of the FDA. C.3.5.1.3 Ensuring that
vial labeling and packaging is consistent with FDA guidance for use in target
populations and that labeling is updated. C.3.5.1.4 Ensuring the product
complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL
113-54 (Nov. 27, 22013), including product verification, serialization,
traceability and detection and response requirements subject to any exceptions
established by or the enforcement discretion of the FDA. C.3.5.1.5 Following
release of the product the contractor shall deliver the product to the
designated distribution site via a qualified distribution vendor in accordance
with Section F and paragraph C.7 below. To the extent a natural disaster or
other emergency affecting a designated delivery site restricts such site’s
ability to receive product, the Contractor and the USG will promptly agree on an
alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at
the contractor site. C.3.5.2 Site Visits and Audits. The contractor shall
accommodate periodic or ad hoc site visits by BARDA and FDA representatives for
required site visits and audits at facilities used to support this contract
throughout the period of performance of the contract. C.3.5.2.1 BARDA Audits. If
issues are identified during an audit, the contractor shall submit a report
detailing the finding and corrective action(s) in accordance with CDRL A001.
C.3.5.2.2 FDA Audits. The Contractor shall notify the Contracting Officer and
COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site
visit or audit if the FDA does not provide advance notice. The contractor shall
provide copies of any FDA Audit Report received from subcontractors that occur
as a result of this contract or for this product within [***] of receiving
correspondence from the FDA or third party in accordance with CDRL A015. The
Contractor shall provide the Contracting Officer with a plan for addressing
areas of nonconformance, if any are identified, within [***] of submittal of the
audit report in accordance with CDRL A002. C.3.5.2.3 FDA Interactions. The
contractor shall provide copies of the plan and processes that will ensure the
USG has visibility and input on all FDA communications regarding the drugs and
biologics for the following, but not limited to: FDA interactions, FDA meetings,
communications, submissions, inspections, and enforcement documentation in
accordance with CDRL A002. C.4 C LIN 0002: Data Deliverables. The contractor
shall provide the following in accordance with the Contract Data Requirements
List (CDRL), DD Forms 1423, provided at Appendix A. C.4.1 Monthly Inventory
Report (CDRL A003), detailing at a minimum, raw materials, Bulk mRNA, formulated
LNPs, and the fill, finish, and released product. C.4.2 Quality Management Plan.
The contractor shall provide a Quality Management Plan, in accordance with CDRL
A004, describing the quality policy and objectives, management review,
competencies and training, process document control, feedback, evaluation,
corrective action and preventive action, process improvement, measurement, and
data analysis processes. The framework is normally divided into infrastructure,
senior

--------------------------------------------------------------------------------

 
[exhibit103025.jpg]
W911QY20C0100 Page 25 of 53 management responsibility, resource management,
lifecycle management, and quality management system evaluation. C.4.3 Shipping
Documentation (CDRL A005) for all Finished Drug Product (FDP) transferring from
the contractor’s fill/finish facility to a USG facility. The contractor shall
obtain concurrence on planned shipment protocols prior to transport. C.4.4
Expiring Items Report (CDRL A006) for all FDP in the USG’s possession. C.4.5 Key
Personnel Listing (CDRL A007). C.4.6 Monthly Technical Progress Report (CDRL
A008), to include an Integrated Master Schedule, identifying key activities and
contract status. C.4.7 Final Technical Report (CDRL A009), documenting the work
performed and results obtained for the entire contract period of performance.
C.4.8 Supply Chain Resiliency Plan (SCRP). The contractor shall provide, in
accordance with CDRL A010 and CDRL Attachment 0001, a comprehensive SCRP that
provides for identification and reporting of critical components associated with
the secure supply of drug substance, drug product, and work-in-process through
to finished goods, and key equipment suppliers and their locations, including
addresses, points of contact, and work performed per location, to include
subcontractors. C.4.9 Risk Management Plan (RMP). The Contractor shall provide
an RMP in accordance with CDRL A011 that outlines the impacts of each risk in
relation to the cost, schedule, and performance objectives. The plan shall
include risk mitigation strategies. Each risk mitigation strategy shall capture
how the corrective action will reduce impacts on cost, schedule and performance.
C.4.10 Manufacturing Reports and Dose Tracking. The Contractor shall provide, in
accordance with CDRL A013, manufacturing reports and manufacturing dose tracking
projections and actuals utilizing the USG-provided “COVID-19 Dose Tracking
Template” (CDRL Attachment 0003). C.4.11 Product Acceptance Report (for each lot
of Drug Product). The contractor shall provide, in accordance with CDRL A014,
pictures of the drug product with lot number, drug product lot tree, list of
associated deviations (from drug substance and product), and a Certificate of
Analysis. C.4.12 Incident Report. The contractor shall communicate to BARDA and
document all critical programmatic concerns, issues, or probable risks that have
or are likely to significantly impact project schedule and/or cost and/or
performance in accordance with CDRL A016. “Significant” is frequently defined as
a 10% or greater cost or schedule variance within a control account, but should
be confirmed in consultation with the COR. Incidents that present liability to
the project even without cost/schedule impact, such as breach of GCP during a
clinical study, shall also be reported. C.4.13 FDA Correspondence. The
contractor shall provide any correspondence between Contractor and FDA relevant
to the scope of this contract and submit in accordance with CDRL A017. C.4.14
Press Releases. The contractor shall accurately and factually represent the work
conducted under this contract in all press releases. The contractor shall
provide an advance copy of any press release in accordance with CDRL A018.
C.4.15 Manufacturing Development Plan. The contractor shall provide a
Manufacturing Development Plan, in accordance with CDRL A025, describing the
manufacturing process for the drug/biologic product to ensure conformity with
§501(a)(2)(B) of the Food, Drug, and Cosmetics Act (FD&C Act, Title 21 United
States Code (USC) §351 (a)(2)(B)), regarding good manufacturing practices (GMP).

--------------------------------------------------------------------------------

 
[exhibit103026.jpg]
W911QY20C0100 Page 26 of 53 C.5 Administration. C.5.1 Post Award Teleconference.
The contractor shall host a Post Award Teleconference within 7 calendar days
after contract award. C.5.1.1 The contractor shall provide an Agenda, IAW CDRL
A020, detailing the planned activities for the subsequent 30 calendar days and
shall discuss agenda items for the Post Award Kickoff Meeting. C.5.1.2 The
contractor shall provide Meeting Minutes IAW CDRL A021. C.5.2 Post Award Kickoff
Meeting. The contracting officer may request the contractor host a contract
Kick-Off Meeting within 30 calendar days after contract award via
teleconference. The contracting officer shall establish the date and time of the
conference and prepare the agenda to include discussion on contract activities
and schedule. C.5.3 Bi-Weekly Teleconference. The contractor shall participate
in bi-weekly teleconferences (or more frequent meetings required by the USG if
warranted based on contract activities) to discuss performance on the contract.
C.5.4 The contractor shall provide an Agenda, IAW CDRL A020; Meeting Minutes in
accordance with CDRL A021; and, Presentation Material in accordance with CDRL
A022 for each of the aforementioned teleconferences or meetings throughout the
contract period of performance. C.5.5 Daily “Check-In”. The contractor shall
participate in a daily “check-in” (via teleconference or email) to address key
cost, schedule and technical updates. Daily updates may be shared with senior
USG leaders during the COVID- 19 response and should be provided on a
non-confidential basis, unless the update includes confidential information in
which case, the contractor shall provide the update in both confidential and
non-confidential formats. Daily check-ins may occur on weekdays, excluding
federal holidays. Upon request of the USG, check-ins may also occur on weekends
and on federal holidays, provided at least 24 hours’ notice. C.6 Security. C.6.1
Access and General Protection/Security Policy and Procedures. The contractor
shall provide all information required for background checks necessary to access
critical information related to OWS, and to meet USG installation access
requirements to be accomplished by the installation Director of Emergency
Services or Security Office. The contractor employees shall comply with all
personnel identity verification requirements as directed by the USG and/or local
policy. In addition to the changes otherwise authorized by the changes clause of
this contract, should the security status of OWS change the USG may require
changes in the contractor’s security matters or processes. In addition to the
industry standards for employment background checks, the contractor shall be
willing to have key individuals, in exceptionally sensitive positions,
identified for additional vetting by the United States USG. C.6.2 Security
Program and Plan. The contractor shall implement a comprehensive security
program that provides overall protection of personnel, information, data, and
facilities associated with fulfilling the USG’s requirement. The contractor’s
security practices and procedures shall be detailed in a Security Plan, in
accordance with CDRL A019, and shall demonstrate how the contractor shall meet
and adhere to the security requirements outlined in CDRL Attachment 0002. This
plan shall be delivered to the USG within 45 days of award, and the USG will
review in detail and submit comments within ten (10) business days to the
Contracting Officer (CO) to be forwarded to the Contractor. The Contractor shall
review the Security Plan comments, and, submit a final Security Plan to the U.S.
USG within thirty (30) calendar days after receipt of the comments. The Security
Plan shall include a timeline for compliance of all the required security
measures outlined in CDRL Attachment 0002. C.6.3 Operational Security (OPSEC).
The contractor shall develop and submit an OPSEC Standard Operating Procedure
(SOP)/Plan IAW CDRL A024. The contractor shall identify in the SOP/Plan critical
information related to this contract, why it needs to be protected, where it is
located, who is responsible for it, and how to protect it.

--------------------------------------------------------------------------------

 
[exhibit103027.jpg]
W911QY20C0100 Page 27 of 53 C.7 C LIN 0002 Vendor Managed Inventory (VMI). The
Contractor shall provide the capability to store the vaccine for up to 52 weeks,
up to 100M doses of mRNA-1273 vaccine, in accordance with product labeling. The
contractor shall, in accordance with paragraph C.3.1.1.6, ensure the product
storage of FDP doses for up to 12 months prior to delivery consistent with all
FDA requirements to ensure that the product remains available for use in target
populations. [***]. The contractor shall store the product to insure product
quality with audible alarms and contacting. The contractor shall notify the USG
within [***] of detection of an incident with the potential to impact product
quality, and implement corrective actions to mitigate the incident. .
BARDA/JPEO- CBRND personnel may conduct Quality Audits of the storage facility,
when deemed necessary. The contractor shall notify the USG of
Corrective/Preventive actions within [***] of detection of an incident with
potential to impacts product quality. BARDA/JPEO-CBRND personnel may conduct
Quality Audits of the storage facility, when deemed necessary. C.7.1 The USG
will provide the contractor advance notice of the required delivery locations
for the vaccine. The contractor shall ship mRNA-1273 vaccines to designated
locations [***] in the United States. The contractor shall be responsible for
shipment of all vaccine product whether acceptance is conducted at origin or
destination. [***]. C.7.2 The vaccine product shall be shipped and tracked by
the distribution vendor’s shipping tracking number, to the USG-designated sites
within the continental United States. C.7.3 [***]. Implementation of a Vendor
Managed Inventory Plan/SOP (CDRL A012) shall be provided to the USG. [***].
Notwithstanding either of the foregoing sentences, the contractor shall not be
liable for loss of or damage to supplies caused by the negligence of officers,
agents, or employees of the USG acting within the scope of their employment.

--------------------------------------------------------------------------------

 
[exhibit103028.jpg]
W911QY20C0100 Page 28 of 53 Section D - Packaging and Marking D.1 Vaccine
markings and labeling will be in accordance with FDA and will be finalized
through a contract modification.

--------------------------------------------------------------------------------

 
[exhibit103029.jpg]
W911QY20C0100 Page 29 of 53 Section E - Inspection and Acceptance INSPECTION AND
ACCEPTANCE TERMS Supplies/services will be inspected/accepted at: CLIN INSPECT
AT INSPECT BY ACCEPT AT ACCEPT BY 0001 N/A N/A N/A N/A 0001AA Origin Government
Origin Government 0001AB Origin Government Origin Government 0001AC Destination
Government Destination Government 0001AD Destination Government Destination
Government 0002 Destination Government Destination Government 0003 N/A N/A N/A
N/A 0003AA Destination Government Destination Government 0003AB Destination
Government Destination Government 0003AC Destination Government Destination
Government 0003AD Destination Government Destination Government 0004 Destination
Government Destination Government 1001 N/A N/A N/A N/A 1001AA Destination
Government Destination Government 1001AB Destination Government Destination
Government 1001AC Destination Government Destination Government 1002 Destination
Government Destination Government 2001 N/A N/A N/A N/A 2001AA Destination
Government Destination Government 2001AB Destination Government Destination
Government 2001AC Destination Government Destination Government 2002 Destination
Government Destination Government 3001 N/A N/A N/A N/A 3001AA Destination
Government Destination Government 3001AB Destination Government Destination
Government 3001AC Destination Government Destination Government 3002 Destination
Government Destination Government 4001 N/A N/A N/A N/A 4001AA Destination
Government Destination Government 4001AB Destination Government Destination
Government 4001AC Destination Government Destination Government 4002 Destination
Government Destination Government CLAUSES INCORPORATED BY REFERENCE 52.246-16
Responsibility For Supplies APR 1984 E1. Inspection:

--------------------------------------------------------------------------------

 
[exhibit103030.jpg]
W911QY20C0100 Page 30 of 53 Initial quality inspection of Filled Drug Product
(FDP) shall occur when the Contractor performs release testing to confirm that
products complies with Contractor’s release specifications and criteria.
Contractor will submit in WAWF to the Contracting Officer or the duly authorized
representative of the Government with a Certificate of Analysis for quality
inspection of all deliverables. Initial Inspection under this contract will be
performed at the Contractor’s facility, or the subcontractor facility, by the
BARDA Contracting Officer Technical Representative (COTR). Final inspection of
product shall occur when the Government inspects each shipment of product
delivered to it hereunder for visible damage and quantity within [***] of such
delivery. In the event Contractor supplies any product to the Government and it
is established that such Product was damaged or does not include the required
quantities at the time of delivery, the Government shall promptly notify
Contractor in writing within [***]. Final inspection shall be conducted at the
CDC location identified as destination. In the event the USG requires storage of
the FDP to a Vendor Managed Inventory (VMI) location, final quantity inspection
shall be conducted by submission into WAWF of shipping or other documentation
confirming quantity to VMI location. Final physical inspection of the FDP shall
be conducted upon receipt of product to USG location. Inspection of all reports
and Contract Data Requirement List (CDRL) under this contract will be performed
at Destination by duly authorized representative of the Government. E.2
Acceptance a. Acceptance at origin shall occur at [***]. Acceptance at
destination shall occur [***]. Regardless of where acceptance occurs, the
contractor is responsible for final delivery of Filled Drug Product (FDP) to a
government designated CDC location. b. Acceptance under this agreement will be
performed by Army Contracting Command Aberdeen Proving Ground (ACC-APG) Natick
Contracting Division (NCD) Contracting Officer. c. Acceptance of services under
VMI SubCLINs ( List CLINS) shall occur upon satisfactory physical and quantity
inspection of FDP upon delivery at USG designated CDC location. d. The parties
acknowledge that acceptance may depend on the compliance with the Contractor’s
product specifications. The KO and COR may prior to acceptance consult with FDA
under its authority under Public Law 115-92 to determine whether the material to
be delivered meets the Contractor’s product specifications. To this end,
Contractor agrees to provide a letter to FDA authorizing the Government to
engage in dialog with FDA about the ultimate compliance of this product with the
Contractor’s product specifications prior to acceptance. BARDA/COR will accept
product according to the approved Product Acceptance Procedure.

--------------------------------------------------------------------------------

 
[exhibit103031.jpg]
W911QY20C0100 Page 31 of 53 Section F - Deliveries or Performance DELIVERY
INFORMATION CLIN DELIVERY DATE QUANTITY SHIP TO ADDRESS DODAAC / CAGE [***]
[***] [***] N/A N/A [***] [***] [***] N/A Origin (Shipping Point) FOB: [***]
[***] [***] N/A Origin (Shipping Point) FOB: [***] [***] [***] N/A Destination
FOB: [***] [***] [***] N/A Destination FOB: [***] [***] [***] N/A Destination
FOB: [***] [***] [***] N/A N/A [***] [***] [***] N/A Destination FOB: [***]
[***] [***] N/A Destination FOB: [***] [***] [***] N/A Destination FOB: [***]
[***] [***] N/A Destination FOB: [***] [***] [***] [***] [***] FOB: Destination
[***] [***] [***] N/A N/A [***] [***] [***] N/A FOB: Destination

--------------------------------------------------------------------------------

 
[exhibit103032.jpg]
W911QY20C0100 Page 32 of 53 [***] [***] [***] Destination N/A FOB: [***] [***]
[***] Destination N/A FOB: [***] [***] [***] Destination N/A FOB: [***] [***]
[***] N/A N/A [***] [***] [***] N/A FOB: Destination [***] [***] [***] N/A FOB:
Destination [***] [***] [***] N/A FOB: Destination [***] [***] [***] N/A FOB:
Destination [***] [***] [***] N/A N/A [***] [***] [***] N/A FOB: Destination
[***] [***] [***] N/A FOB: Destination [***] [***] [***] N/A FOB: Destination
[***] [***] [***] N/A FOB: Destination [***] [***] [***] N/A N/A [***] [***]
[***] N/A FOB: Destination [***] [***] [***] N/A FOB: Destination [***] [***]
[***] N/A FOB: Destination [***] [***] [***] N/A FOB: Destination CLAUSES
INCORPORATED BY REFERENCE

--------------------------------------------------------------------------------

 
[exhibit103033.jpg]
W911QY20C0100 Page 33 of 53 52.211-17 Delivery of Excess Quantities SEP 1989
52.242-15 Stop-Work Order AUG 1989 52.247-34 F.O.B. Destination NOV 1991 F.1 The
contractor shall ship mRNA-1273 vaccines to designated locations [***] in the
United States. The contractor shall be responsible for secure shipment of all
vaccine product whether acceptance is conducted at origin or destination.

--------------------------------------------------------------------------------

 
[exhibit103034.jpg]
W911QY20C0100 Page 34 of 53 Section G - Contract Administration Data ACCOUNTING
AND APPROPRIATION DATA AA: 0212020202120400000664643255 S.0074658.5.6
6100.9000021001 COST CODE: A5XAH AMOUNT: $955,500,000.00 AB:
0212020202120400000664643255 S.0074658.5.6.1 6100.9000021001 COST CODE: A5XAH
AMOUNT: $269,500,000.00 ACRN CLIN/SLIN CIN AMOUNT AA 0001AA GFEBS001153469300001
$183,750,000.00 0001AC GFEBS001153469300003 $367,500,000.00 0001AD
GFEBS001153469300004 $404,250,000.00 AB 0001AB GFEBS001153469300002
$269,500,000.00 CLAUSES INCORPORATED BY REFERENCE 252.204-7006 Billing
Instructions OCT 2005 252.232-7003 Electronic Submission of Payment Requests and
Receiving DEC 2018 Reports CLAUSES INCORPORATED BY FULL TEXT 252.232-7006 WIDE
AREA WORKFLOW PAYMENT INSTRUCTIONS (DEC 2018) (a) Definitions. As used in this
clause— “Department of Defense Activity Address Code (DoDAAC)” is a six position
code that uniquely identifies a unit, activity, or organization. “Document type”
means the type of payment request or receiving report available for creation in
Wide Area WorkFlow (WAWF). “Local processing office (LPO)” is the office
responsible for payment certification when payment certification is done
external to the entitlement system. “Payment request” and “receiving report” are
defined in the clause at 252.232-7003, Electronic Submission of Payment Requests
and Receiving Reports. (b) Electronic invoicing. The WAWF system provides the
method to electronically process vendor payment requests and receiving reports,
as authorized by Defense Federal Acquisition Regulation Supplement (DFARS)
252.232- 7003, Electronic Submission of Payment Requests and Receiving Reports.
(c) WAWF access. To access WAWF, the Contractor shall—

--------------------------------------------------------------------------------

 
[exhibit103035.jpg]
W911QY20C0100 Page 35 of 53 (1) Have a designated electronic business point of
contact in the System for Award Management at https://www.sam.gov; and (2) Be
registered to use WAWF at https://wawf.eb.mil/ following the step-by-step
procedures for self-registration available at this web site. (d) WAWF training.
The Contractor should follow the training instructions of the WAWF Web-Based
Training Course and use the Practice Training Site before submitting payment
requests through WAWF. Both can be accessed by selecting the “Web Based
Training” link on the WAWF home page at https://wawf.eb.mil/. (e) WAWF methods
of document submission. Document submissions may be via web entry, Electronic
Data Interchange, or File Transfer Protocol. (f) WAWF payment instructions. The
Contractor shall use the following information when submitting payment requests
and receiving reports in WAWF for this contract or task or delivery order: (1)
Document type. The Contractor shall submit payment requests using the following
document type(s): COMBO (ii) For fixed price line items— (A) That require
shipment of a deliverable, submit the invoice and receiving report specified by
the Contracting Officer. Invoice and receiving report document type (B) For
services that do not require shipment of a deliverable, submit either the
Invoice 2in1, which meets the requirements for the invoice and receiving report,
or the applicable invoice and receiving report, as specified by the Contracting
Officer. N/A (iii) For customary progress payments based on costs incurred,
submit a progress payment request. (iv) For performance based payments, submit a
performance based payment request. (v) For commercial item financing, submit a
commercial item financing request. (2) Fast Pay requests are only permitted when
Federal Acquisition Regulation (FAR) 52.213-1 is included in the contract. (3)
Document routing. The Contractor shall use the information in the Routing Data
Table below only to fill in applicable fields in WAWF when creating payment
requests and receiving reports in the system. Routing Data Table Field Name in
WAWF Data to be entered in WAWF Pay Official DoDAAC HQ0337 Issue By DoDAAC
W911QY Admin DoDAAC** S2206A

--------------------------------------------------------------------------------

 
[exhibit103036.jpg]
W911QY20C0100 Page 36 of 53 Inspect By DoDAAC S2206A / BARDA Acceptor W911QY
Ship To TDB (4) Payment request. The Contractor shall ensure a payment request
includes documentation appropriate to the type of payment request in accordance
with the payment clause, contract financing clause, or Federal Acquisition
Regulation 52.216-7, Allowable Cost and Payment, as applicable. (5) Receiving
report. The Contractor shall ensure a receiving report meets the requirements of
DFARS Appendix F. (g) WAWF point of contact. (1) The Contractor may obtain
clarification regarding invoicing in WAWF from the following contracting
activity’s WAWF point of contact. [***] / DCMA Boston-AFAW, Administrative
Contracting Officer / [***] (2) Contact the WAWF helpdesk at [***], if
assistance is needed. (End of clause) FOR REFERANCE: DFARS PGI 204.7108 Payment
Instructions Table
https://www.acq.osd.mil/dpap/dars/pgi/pgi_htm/current/PGI204_71.htm#payment_instructions
G.1 GOVERNMENT CONTRACT ADMINISTRATION In no event shall any understanding or
agreement, contract modification, change order, or other matter in deviation
from the terms of this contract between the Contractor and a person other than
the Contracting Officer be effective or binding upon the Government. All such
actions must be formalized by a proper contractual document executed by the
Contracting Officer. Procuring Contracting Officer: [***] Bldg. 1, General Green
Avenue Natick, MA 017650-5011 Contract Specialist:

--------------------------------------------------------------------------------

 
[exhibit103037.jpg]
W911QY20C0100 Page 37 of 53 [***] Bldg. 1, General Green Avenue Natick, MA
017650-5011 G.2 GOVERNMENT TECHNICAL POINT OF CONTACT [***] Biologist/Project
Officer 200 C Street, NW Washington, DC 20201 G.3 CONTRACTOR’S CONTRACT
ADMINISTRATION [***] ModernaTX, Inc. 200 Technology SQ. Cambridge, MA 02139-3578
G.4 PLACES OF PERFORMANCE ModernaTX, Inc. 200 Technology SQ. Cambridge, MA
02139-3578 G.5 NOTIFICATION OF REVISIONS AND CHANGE Notification of revision or
changes to names or email addresses will be provided by official correspondence
from the PCO/ACO or office of the PCO/ACO in lieu of a contract modification.
This does not apply to any such revisions or changes in the event this contract
includes a key personnel clause. G.6 PERFORMANCE BASED PAYMENT Performance-based
payments (PBP) are authorized under this contract in accordance with FAR
52.232-32. The contractor shall bill for the PBP upon achievement of the
completion criteria identified in Attachment 0008, Performance-based Payment
Milestone Table. Upon achievement of the completion criteria, the contractor
shall bill for the PBP for the base and each option IAW the following schedule:
CLIN PERIOD AMOUNT 0001AA BASE $ 90,210,000 0001AA BASE $ 132,308,000 0001AA
BASE $ 180,420,000 0001AA BASE $ 198,462,000 TOTAL $ 601,400,000 [***] [***]
[***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***]

--------------------------------------------------------------------------------

 
[exhibit103038.jpg]
W911QY20C0100 Page 38 of 53 [***] [***] [***] [***] [***] Delivery Invoicing:
PBPs are a type of contract financing and are recouped by the Government through
deductions of payments otherwise due to the contractor for the partial or
complete delivery of contract items. The deductions are made by applying a
liquidation rate to the price of delivered contract items. Attachment 0009,
Performance- based Payment Milestone Billing Plan, identifies the contractor
invoicing schedule for liquidation. The contractor shall submit all invoices IAW
Attachment 0009.

--------------------------------------------------------------------------------

 
[exhibit103039.jpg]
W911QY20C0100 Page 39 of 53 Section H - Special Contract Requirements H.1 Key
Personnel Any key personnel specified in this contract are considered to be
essential to work performance. At least thirty (30) calendar days prior to the
Contractor voluntarily diverting any of the specified individuals to other
programs or contracts the Contractor shall notify the Contracting Officer and
shall submit a justification for the diversion or replacement and a request to
replace the individual. The request must identify the proposed replacement and
provide an explanation of how the replacement's skills, experience, and
credentials meet or exceed the requirements of the contract (including, when
applicable, Human Subjects Testing requirements). If the employee of the
Contractor is terminated for cause or separates from the Contractor voluntarily
with less than thirty (30) calendar-day notice, the Contractor shall provide the
maximum notice practicable under the circumstances. The Contractor shall not
divert, replace, or announce any such change to key personnel without the
written consent of the Contracting Officer. The contract will be modified to add
or delete key personnel as necessary to reflect the agreement of the parties.
The following individuals are determined to be key personnel: Name Title [***]
[***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
H.2 Substitution of Key Personnel The Contractor agrees to assign to the
contract those persons whose resumes/CVs were submitted with the proposal who
are necessary to fill the requirements of the contract. No substitutions shall
be made except in accordance with this clause. All requests for substitution
must provide a detailed explanation of the circumstance necessitating the
proposed substitution, a complete resume for the proposed substitute and any
other information requested by the contracting officer to approve or disapprove
the proposed substitution. All proposed substitutes must have qualifications
that are equal to or higher than the qualifications of the person to be
replaced. The contracting officer or authorized representative will evaluate
such requests and promptly notify the contractor of his approval or disapproval
thereof. H.3 Disclosure of Information: Performance under this contract may
require the Contractor to access non-public data and information proprietary to
a Government agency, another Government Contractor or of such nature that its
dissemination or use other than as specified in the work statement would be
adverse to the interests of the Government or others. Neither the Contractor,
nor Contractor personnel, shall divulge nor release data nor information
developed or obtained under performance of this contract, except authorized by
Government personnel or upon written approval of the CO which the KO will
provide in accordance with OWS or other Government policies and/or guidance. The
Contractor shall not use, disclose, or reproduce proprietary data that bears a
restrictive legend, other than as specified in this contract, or any information
at all regarding this agency. The Contractor shall comply with all applicable
Government requirements for protection of non-public information. Unauthorized
disclosure of nonpublic information is prohibited by the Government’s rules.
Unauthorized disclosure may result in termination of the contract, replacement
of a Contractor employee, or other appropriate redress. Neither the Contractor
nor the Contractor‘s employees shall disclose or cause to be disseminated, any
information concerning the operations of the activity, which could result in, or
increase the likelihood of, the possibility of a breach of the activity‘s
security or interrupt the continuity of its operations.

--------------------------------------------------------------------------------

 
[exhibit103040.jpg]
W911QY20C0100 Page 40 of 53 No information related to data obtained under this
contract shall be released or publicized without the prior written consent of
the COR, whose approval shall not be unreasonably withheld, conditioned, or
delayed, provided that no such consent is required to comply with any law, rule,
regulation, court ruling or similar order; for submission to any government
entity’ for submission to any securities exchange on which the Contractor’s (or
its parent corporation’s) securities may be listed for trading; or to third
parties relating to securing, seeking, establishing or maintaining regulatory or
other legal approvals or compliance, financing and capital raising activities,
or mergers, acquisitions, or other business transactions. The exceptions
identified in this paragraph apply to all disclosures under this Section H.3
except to the extent that a disclosure is otherwise prohibited by law. H.4
Publication and Publicity The contractor shall not release any reports,
manuscripts, press releases, or abstracts about the work being performed under
this contract without written notice in advance to the Government. (a) Unless
otherwise specified in this contract, the contractor may publish the results of
its work under this contract. The contractor shall promptly send a copy of each
submission to the COR for security review prior to submission. The contractor
shall also inform the COR when the abstract article or other publication is
published, and furnish a copy of it as finally published. (b) Unless authorized
in writing by the CO, the contractor shall not display the DoD logo including
Operating Division or Staff Division logos on any publications. (c) The
contractor shall not reference the products(s) or services(s) awarded under this
contract in commercial advertising, as defined in FAR 31.205-1, in any manner
which states or implies DoD approval or endorsement of the product(s) or
service(s) provided. (d) The contractor shall include this clause, including
this section (d) in all subcontracts where the subcontractor may propose
publishing the results of its work under the subcontract. The contractor shall
acknowledge the support of the Department of Health and Human Services, Office
of the Assistant Secretary for Preparedness and Response, Biomedical Advanced
Research and Development Authority whenever publicizing the work under this
contract in any media by including an acknowledgement substantially as follows:
"This project has been funded in whole or in part with Federal funds from the
Office of the Assistant Secretary for Preparedness and Response, Biomedical
Advanced Research and Development Authority, under Contract Number
W911QY-20-C-0100.” H.5 Confidentiality of Information a. Confidential
information, as used in this article, means non-public information or data of a
personal nature about an individual, or proprietary information or data
submitted by or pertaining to an institution or organization. b. The Contracting
Officer and the Contractor may, by mutual consent, identify elsewhere in this
contract specific information and/or categories of information which the
Government will furnish to the Contractor or that the Contractor is expected to
generate which is confidential. Similarly, the Contracting Officer and the
Contractor may, by mutual consent, identify such confidential information from
time to time during the performance of the contract. Failure to agree will be
settled pursuant to the "Disputes" clause. c. If it is established elsewhere in
this contract that information to be utilized under this contract, or a portion
thereof, is subject to the Privacy Act, the Contractor will follow the rules and
procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. 552a,
and implementing regulations and policies, with respect to systems of records
determined to be subject to the Privacy Act. d. Confidential information, as
defined in paragraph (a) of this article, shall not be disclosed without the
prior written consent of the individual, institution, or organization.

--------------------------------------------------------------------------------

 
[exhibit103041.jpg]
W911QY20C0100 Page 41 of 53 e. Whenever the Contractor is uncertain with regard
to the proper handling of material under the contract, or if the material in
question is subject to the Privacy Act or is confidential information subject to
the provisions of this article, the Contractor shall obtain a written
determination from the Contracting Officer prior to any release, disclosure,
dissemination, or publication. f. Contracting Officer Determinations will
reflect the result of internal coordination with appropriate program and legal
officials. g. The provisions of paragraph (d) of this article shall not apply to
conflicting or overlapping provisions in other Federal, State or local laws. ALL
REQUIREMENTS OF THIS SECTION H.5 MUST BE PASSED TO ALL SUB-CONTRACTOR. H.6
Regulatory Rights This contract involves supply of a product that requires FDA
pre-market approval or clearance before commercial authorization. Contractor is
seeking FDA authorization or clearance for the commercialization of mRNA-1273,
Moderna vaccine for SARS-CoV-2 Coronavirus (the “Technology”). The Contractor is
the Sponsor of the Regulatory Application (an investigational new drug
application (IND), investigational device exemption (IDE), emergency use
authorization (EUA), new drug application (NDA), biologics license application
(BLA), premarket approval application (PMA), or 510(k) pre-market notification
filing (510(k)) or another regulatory filing submitted to FDA) for the
technology. As the Sponsor of the Regulatory Application to FDA (as the terms
“sponsor” and “applicant” are defined or used in at 21 CFR §§3.2(c), 312.5,
600.3(t), 812.2(b), 812 Subpart C, or 814.20), the Contractor has certain
standing before the FDA that entitles it to exclusive communications related to
the Regulatory Application. Accordingly, the Contractor and the Government agree
to the following: a. DoD Medical Product Priority. PL 115-92 allows the DoD to
request, and FDA to provide, assistance to expedite development of products to
diagnose, treat, or prevent serious or life-threatening diseases or conditions
facing American military personnel. The contractor recognizes that only the DoD
can utilize PL 115-92. As such, the contractor will work proactively with the
Government to leverage this law to its maximum potential under this contract.
The contractor shall submit Public Law 115-92 Sponsor Authorization Letter that
will be delivered to the designated OWS POC(s) within 30 days of award. [***]
H.7 Performance Based Payment Liquidated under Termination

--------------------------------------------------------------------------------

 
[exhibit103042.jpg]
W911QY20C0100 Page 42 of 53 Performance Based Payments (PBPs) have been
authorized as a method of financing under this contract. In the event the
Moderna’s mRNA-1273 COVID Vaccine is unsuccessful in its bid to obtain EUA or
FDA approval, the Government may issue a Termination for Convenience (T4C) in
whole or in part, on this contract. Upon notice of a T4C, the contractor shall
submit a termination settlement proposal, IAW FAR 52.249-2, Termination for
Convenience of the Government (Fixed-Price). H.8 Public Readiness and Emergency
Preparedness (PREP) Act: In accordance with the Public Readiness and Emergency
Preparedness Act (“PREP Act”), Pub. L. No. 109-148, Division C, Section 2, as
amended (codified at 42 U.S.C. § 247d-6d and 42 U.S.C. § 247d-6e), as well as
the Secretary of HHS’s Declaration Under the Public Readiness and Emergency
Preparedness Act for Medical Countermeasures Against COVID-19, 85 Fed. Reg.
15198 (Mar. 17, 2020, effective Feb. 4, 2020), and amended on April 15, 2020, 85
Fed. Reg. 21012 (together, the “Prep Act Declaration”): (i) This Agreement is
being entered into for purposes of facilitating the manufacture, testing,
development, distribution, administration, and use of “Covered Countermeasures”
for responding to the COVID-19 public health emergency, in accordance with
Section VI of the PREP Act Declaration; (ii) Contractor’s performance of this
Agreement falls within the scope of the “Recommended Activities” for responding
to the COVID-19 public health emergency, to the extent it is in accordance with
Section III of the PREP Act Declaration; and (iii) Contractor is a “Covered
Person” to the extent it is a person defined in Section V of the PREP Act
Declaration. Therefore, in accordance with Sections IV and VII of the PREP Act
Declaration as well as the PREP Act (42 U.S.C. § 247d-6d), the Department of
Defense contracting via assisted acquisition on behalf of the HHS, expressly
acknowledges and agrees that the HHS Declaration cited above, specifically its
language providing immunity from suit and liability is applicable to this
acquisition as long as Contractors activities fall within the terms and
conditions of the PREP Act and the PREP Act Declaration. The Government may not
use, or authorize the use of, any products or materials provided under this
contract, unless such use occurs in the United States (or a U.S. territory where
U.S. law applies such as embassies, military and NATO installations) and is
protected from liability under a declaration issued under the PREP Act, or a
successor COVID-19 PREP Act Declaration of equal or greater scope. Any use where
the application of the PREP Act is in question will be discussed with Moderna
prior to use and, if the parties disagree on such use, the dispute will be
resolved according to the “Disputes Clause” (52.233-1) The items and technology
covered by this Contract are being developed for both civil and military
applications. [***]

--------------------------------------------------------------------------------

 
[exhibit103043.jpg]
W911QY20C0100 Page 43 of 53 H.10 Ensuring Sufficient Supply of the Product 1. In
recognition of the Government’s significant funding for the development and
manufacturing of the product in this contract and the Government’s need to
provide sufficient quantities of a COVID-19 vaccine to protect the United States
population, the Government shall have the remedy described in this section to
ensure sufficient supply of the product to meet the needs of the public health
or national security. This remedy is not available to the Government unless and
until both of the following conditions ((a) and (b)) are met: a. Moderna gives
written notice, required to be submitted to the Government no later than [***],
of: i. any formal management decision to terminate manufacturing of this product
vaccine prior to delivery of any doses to USG under this contract, including all
exercised options, other than as a result of clinical failure, or serious
technical or safety reasons or; ii. any formal management decision to
discontinue sale of this product vaccine to the Government prior to delivery of
any doses to USG under this contract, including all exercised options, other
than as a result of clinical failure, or serious technical or safety reasons; or
iii. any filing that anticipates Federal bankruptcy protection; and b. Moderna
has submitted an Emergency Use Authorization application under §564 of the FD&C
Act or a biologics license application provisions of §351(a) of the Public
Health Service Act (PHSA). 2. If both conditions listed in section 1 occur,
Moderna, upon the request of the Government, shall provide the following items
necessary for the Government to pursue manufacturing of this product vaccine
with a third party for exclusive sale to the U.S. Government: a. a writing
evidencing a non-exclusive, nontransferable, irrevocable (except for cause),
royalty-free paid-up license to practice or have practiced for or on behalf of
the U.S. Government any Moderna Background Patent, Copyright, other Moderna
Intellectual Property, Moderna Know-How, Moderna Technical Data rights necessary
to manufacture doses of the mRNA-1273 vaccine; b. necessary FDA regulatory
filings or authorizations owned or controlled by Moderna related to this product
vaccine and any confirmatory instrument pertaining thereto; and c. any
outstanding Deliverables contemplated or materials purchased under this
contract. 3. This remedy will remain available until the end of the contract.
[***]

--------------------------------------------------------------------------------

 
[exhibit103044.jpg]
W911QY20C0100 Page 44 of 53 H.12 Transportation to Final Destination During the
course of performance under this contract, the Government may require storage of
the filled drug product (FDP) before delivery to the final government location.
In these circumstances, the Government will accept FDP at the contractor
facility (Origin). The contractor; however, shall continue to be responsible for
secure delivery of the vaccine to its final destination as identified on this
contract. [***]. H.13 Validation of IP/Data The Parties acknowledge that
background intellectual property and technical data assertions have been made
and evaluated by the parties. The parties agree that, should additional
information relevant to these assertions become available, the parties will
reevaluate said assertions as necessary in the future. H.14 Novation Upon
Moderna, US, Inc.'s registration in the System for Award Management, the
Government will, at the Contractor's request, complete a novation of this
Contract to recognize Moderna US, Inc. as a counterparty instead of Moderna TX,
Inc. This novation will be completed through a modification executed by the
Government that identifies Moderna US, Inc. as the contracting party for all
purposes as if it had originally executed the Contract.

--------------------------------------------------------------------------------

 
[exhibit103045.jpg]
W911QY20C0100 Page 45 of 53 Section I - Contract Clauses CLAUSES INCORPORATED BY
REFERENCE 52.202-1 Definitions JUN 2020 52.203-3 Gratuities APR 1984 52.203-5
Covenant Against Contingent Fees MAY 2014 52.203-6 Restrictions On Subcontractor
Sales To The Government JUN 2020 52.203-7 Anti-Kickback Procedures JUN 2020
52.203-8 Cancellation, Rescission, and Recovery of Funds for Illegal or MAY 2014
Improper Activity 52.203-10 Price Or Fee Adjustment For Illegal Or Improper
Activity MAY 2014 52.203-12 Limitation On Payments To Influence Certain Federal
JUN 2020 Transactions 52.203-13 Contractor Code of Business Ethics and Conduct
JUN 2020 52.203-17 Contractor Employee Whistleblower Rights and Requirement JUN
2020 To Inform Employees of Whistleblower Rights 52.204-1 Approval of Contract
DEC 1989 52.204-4 Printed or Copied Double-Sided on Postconsumer Fiber MAY 2011
Content Paper 52.204-10 Reporting Executive Compensation and First-Tier JUN 2020
Subcontract Awards 52.204-13 System for Award Management Maintenance OCT 2018
52.204-18 Commercial and Government Entity Code Maintenance JUL 2016 52.204-19
Incorporation by Reference of Representations and DEC 2014 Certifications.
52.204-23 Prohibition on Contracting for Hardware, Software, and JUL 2018
Services Developed or Provided by Kaspersky Lab and Other Covered Entities.
52.204-25 Prohibition on Contracting for Certain Telecommunications AUG 2019 and
Video Surveillance Services or Equipment. 52.209-6 Protecting the Government's
Interest When Subcontracting JUN 2020 With Contractors Debarred, Suspended, or
Proposed for Debarment 52.209-10 Prohibition on Contracting With Inverted
Domestic NOV 2015 Corporations 52.210-1 Market Research JUN 2020 52.215-2 Audit
and Records--Negotiation JUN 2020 52.215-8 Order of Precedence--Uniform Contract
Format OCT 1997 52.215-11 Price Reduction for Defective Certified Cost or
Pricing Data-- JUN 2020 Modifications 52.215-13 Subcontractor Certified Cost or
Pricing Data--Modifications JUN 2020 52.215-14 Integrity of Unit Prices JUN 2020
52.215-15 Pension Adjustments and Asset Reversions OCT 2010 52.215-18 Reversion
or Adjustment of Plans for Postretirement Benefits JUL 2005 (PRB) Other than
Pensions 52.215-19 Notification of Ownership Changes OCT 1997 52.215-21
Requirements for Certified Cost or Pricing Data and Data JUN 2020 Other Than
Certified Cost or Pricing Data -- Modifications 52.217-4 Evaluation Of Options
Exercised At The Time Of Contract JUN 1988 Award 52.217-7 Option For Increased
Quantity-Separately Priced Line Item MAR 1989 52.217-8 Option To Extend Services
NOV 1999 52.219-8 Utilization of Small Business Concerns OCT 2018

--------------------------------------------------------------------------------

 
[exhibit103046.jpg]
W911QY20C0100 Page 46 of 53 52.219-28 Post-Award Small Business Program
Rerepresentation MAY 2020 52.222-1 Notice To The Government Of Labor Disputes
FEB 1997 52.222-3 Convict Labor JUN 2003 52.222-19 Child Labor -- Cooperation
with Authorities and Remedies JAN 2020 52.222-21 Prohibition Of Segregated
Facilities APR 2015 52.222-26 Equal Opportunity SEP 2016 52.222-35 Equal
Opportunity for Veterans JUN 2020 52.222-36 Equal Opportunity for Workers with
Disabilities JUN 2020 52.222-37 Employment Reports on Veterans JUN 2020
52.222-40 Notification of Employee Rights Under the National Labor DEC 2010
Relations Act 52.222-50 Combating Trafficking in Persons JAN 2019 52.222-54
Employment Eligibility Verification OCT 2015 52.223-6 Drug-Free Workplace MAY
2001 52.223-18 Encouraging Contractor Policies To Ban Text Messaging JUN 2020
While Driving 52.225-13 Restrictions on Certain Foreign Purchases JUN 2008
52.227-1 Authorization and Consent JUN 2020 52.227-1 Alt I Authorization And
Consent (JUN 2020) - Alternate I APR 1984 52.227-2 Notice And Assistance
Regarding Patent And Copyright JUN 2020 Infringement 52.227-11 Patent
Rights--Ownership By The Contractor MAY 2014 52.232-9 Limitation On Withholding
Of Payments APR 1984 52.232-17 Interest MAY 2014 52.232-23 Assignment Of Claims
MAY 2014 52.232-25 Prompt Payment JAN 2017 52.232-33 Payment by Electronic Funds
Transfer--System for Award OCT 2018 Management 52.232-39 Unenforceability of
Unauthorized Obligations JUN 2013 52.232-40 Providing Accelerated Payments to
Small Business DEC 2013 Subcontractors 52.233-1 Disputes MAY 2014 52.233-3
Protest After Award AUG 1996 52.233-4 Applicable Law for Breach of Contract
Claim OCT 2004 52.242-13 Bankruptcy JUL 1995 52.243-1 Changes--Fixed Price AUG
1987 52.243-7 Notification Of Changes JAN 2017 52.244-5 Competition In
Subcontracting DEC 1996 52.245-9 Use And Charges APR 2012 52.249-2 Termination
For Convenience Of The Government (Fixed- APR 2012 Price) 52.249-8 Default
(Fixed-Price Supply & Service) APR 1984 52.249-14 Excusable Delays APR 1984
252.203-7000 Requirements Relating to Compensation of Former DoD SEP 2011
Officials 252.203-7002 Requirement to Inform Employees of Whistleblower Rights
SEP 2013 252.203-7003 Agency Office of the Inspector General AUG 2019
252.211-7003 Item Unique Identification and Valuation MAR 2016 252.222-7006
Restrictions on the Use of Mandatory Arbitration Agreements DEC 2010
252.225-7048 Export-Controlled Items JUN 2013 252.227-7013 Rights in Technical
Data--Noncommercial Items FEB 2014 252.227-7014 Rights in Noncommercial Computer
Software and FEB 2014 Noncommercial Computer Software Documentation 252.227-7016
Rights in Bid or Proposal Information JAN 2011

--------------------------------------------------------------------------------

 
[exhibit103047.jpg]
W911QY20C0100 Page 47 of 53 252.227-7017 Identification and Assertion of Use,
Release, or Disclosure JAN 2011 Restrictions 252.227-7019 Validation of Asserted
Restrictions--Computer Software SEP 2016 252.227-7028 Technical Data or Computer
Software Previously Delivered JUN 1995 to the Government 252.227-7030 Technical
Data--Withholding Of Payment MAR 2000 252.227-7037 Validation of Restrictive
Markings on Technical Data SEP 2016 252.232-7007 Limitation Of Government's
Obligation APR 2014 252.244-7000 Subcontracts for Commercial Items JUN 2013
CLAUSES INCORPORATED BY FULL TEXT 52.217-9 OPTION TO EXTEND THE TERM OF THE
CONTRACT (MAR 2000) (a) The Government may extend the term of this contract by
written notice to the Contractor within 5 days for; provided that the Government
gives the Contractor a preliminary written notice of its intent to extend at
least 30 days for Options 1 and 2, 60 days for Option 3 and 4 before the
contract expires. The preliminary notice does not commit the Government to an
extension. (b) If the Government exercises this option, the extended contract
shall be considered to include this option clause. (c) The total duration of
this contract, including the exercise of any options under this clause, shall
not exceed 20 months. (End of clause) 52.232-32 PERFORMANCE-BASED PAYMENTS (APR
2012) (a) Amount of payments and limitations on payments. Subject to such other
limitations and conditions as are specified in this contract and this clause,
the amount of payments and limitations on payments shall be specified in the
contract's description of the basis for payment. (b) Contractor request for
performance-based payment. The Contractor may submit requests for payment of
performance-based payments not more frequently than monthly, in a form and
manner acceptable to the Contracting Officer. Unless otherwise authorized by the
Contracting Officer, all performance-based payments in any period for which
payment is being requested shall be included in a single request, appropriately
itemized and totaled. The Contractor's request shall contain the information and
certification detailed in paragraphs (l) and (m) of this clause. (c) Approval
and payment of requests. (1) The Contractor shall not be entitled to payment of
a request for performance-based payment prior to successful accomplishment of
the event or performance criterion for which payment is requested. The
Contracting Officer shall determine whether the event or performance criterion
for which payment is requested has been successfully accomplished in accordance
with the terms of the contract. The Contracting Officer may, at any time,
require the Contractor to substantiate the successful performance of any event
or performance criterion which has been or is represented as being payable. (2)
A payment under this performance-based payment clause is a contract financing
payment under the Prompt Payment clause of this contract and not subject to the
interest penalty provisions of the Prompt Payment Act. The designated payment
office will pay approved requests on the 30th day after receipt of the request
for performance- based payment by the designated payment office. However, the
designated payment office is not required to provide

--------------------------------------------------------------------------------

 
[exhibit103048.jpg]
W911QY20C0100 Page 48 of 53 payment if the Contracting Officer requires
substantiation as provided in paragraph (c)(1) of this clause, or inquiries into
the status of an event or performance criterion, or into any of the conditions
listed in paragraph (e) of this clause, or into the Contractor certification.
The payment period will not begin until the Contracting Officer approves the
request. (3) The approval by the Contracting Officer of a request for
performance-based payment does not constitute an acceptance by the Government
and does not excuse the Contractor from performance of obligations under this
contract. (d) Liquidation of performance-based payments. (1) Performance-based
finance amounts paid prior to payment for delivery of an item shall be
liquidated by deducting a percentage or a designated dollar amount from the
delivery payment. If the performance-based finance payments are on a delivery
item basis, the liquidation amount for each such line item shall be the percent
of that delivery item price that was previously paid under performance-based
finance payments or the designated dollar amount. If the performance-based
finance payments are on a whole contract basis, liquidation shall be by either
predesignated liquidation amounts or a liquidation percentage. (2) If at any
time the amount of payments under this contract exceeds any limitation in this
contract, the Contractor shall repay to the Government the excess. Unless
otherwise determined by the Contracting Officer, such excess shall be credited
as a reduction in the unliquidated performance-based payment balance(s), after
adjustment of invoice payments and balances for any retroactive price
adjustments. (e) Reduction or suspension of performance-based payments. The
Contracting Officer may reduce or suspend performance-based payments, liquidate
performance-based payments by deduction from any payment under the contract, or
take a combination of these actions after finding upon substantial evidence any
of the following conditions: (1) The Contractor failed to comply with any
material requirement of this contract (which includes paragraphs (h) and (i) of
this clause). (2) Performance of this contract is endangered by the Contractor's
-- (i) Failure to make progress; or (ii) Unsatisfactory financial condition. (3)
The Contractor is delinquent in payment of any subcontractor or supplier under
this contract in the ordinary course of business. (f) Title. (1) Title to the
property described in this paragraph (f) shall vest in the Government. Vestiture
shall be immediately upon the date of the first performance-based payment under
this contract, for property acquired or produced before that date. Otherwise,
vestiture shall occur when the property is or should have been allocable or
properly chargeable to this contract (2) "Property," as used in this clause,
includes all of the following described items acquired or produced by the
Contractor that are or should be allocable or properly chargeable to this
contract under sound and generally accepted accounting principles and practices:
(i) Parts, materials, inventories, and work in process; (ii) Special tooling and
special test equipment to which the Government is to acquire title;

--------------------------------------------------------------------------------

 
[exhibit103049.jpg]
W911QY20C0100 Page 49 of 53 (iii) Nondurable (i.e., noncapital) tools, jigs,
dies, fixtures, molds, patterns, taps, gauges, test equipment and other similar
manufacturing aids, title to which would not be obtained as special tooling
under subparagraph (f)(2)(ii) of this clause; and (iv) Drawings and technical
data, to the extent the Contractor or subcontractors are required to deliver
them to the Government by other clauses of this contract. (3) Although title to
property is in the Government under this clause, other applicable clauses of
this contract (e.g., the termination or clauses) shall determine the handling
and disposition of the property. (4) The Contractor may sell any scrap resulting
from production under this contract, without requesting the Contracting
Officer's approval, provided that any significant reduction in the value of the
property to which the Government has title under this clause is reported in
writing to the Contracting Officer. (5) In order to acquire for its own use or
dispose of property to which title is vested in the Government under this
clause, the Contractor shall obtain the Contracting Officer's advance approval
of the action and the terms. If approved, the basis for payment (the events or
performance criteria) to which the property is related shall be deemed to be not
in compliance with the terms of the contract and not payable (if the property is
part of or needed for performance), and the Contractor shall refund the related
performance-based payments in accordance with paragraph (d) of this clause. (6)
When the Contractor completes all of the obligations under this contract,
including liquidation of all performance-based payments, title shall vest in the
Contractor for all property (or the proceeds thereof) not -- (i) Delivered to,
and accepted by, the Government under this contract; or (ii) Incorporated in
supplies delivered to, and accepted by, the Government under this contract and
to which title is vested in the Government under this clause. (7) The terms of
this contract concerning liability for Government-furnished property shall not
apply to property to which the Government acquired title solely under this
clause. (g) Risk of loss. Before delivery to and acceptance by the Government,
the Contractor shall bear the risk of loss for property, the title to which
vests in the Government under this clause, except to the extent the Government
expressly assumes the risk. If any property is lost (see 45.101), the basis of
payment (the events or performance criteria) to which the property is related
shall be deemed to be not in compliance with the terms of the contract and not
payable (if the property is part of or needed for performance), and the
Contractor shall refund the related performance-based payments in accordance
with paragraph (d) of this clause. (h) Records and controls. The Contractor
shall maintain records and controls adequate for administration of this clause.
The Contractor shall have no entitlement to performance-based payments during
any time the Contractor's records or controls are determined by the Contracting
Officer to be inadequate for administration of this clause. (i) Reports and
Government access. The Contractor shall promptly furnish reports, certificates,
financial statements, and other pertinent information requested by the
Contracting Officer for the administration of this clause and to determine that
an event or other criterion prompting a financing payment has been successfully
accomplished. The Contractor shall give the Government reasonable opportunity to
examine and verify the Contractor's records and to examine and verify the
Contractor's performance of this contract for administration of this clause. (j)
Special terms regarding default. If this contract is terminated under the
Default clause, (1) the Contractor shall, on demand, repay to the Government the
amount of unliquidated performance-based payments, and (2) title shall vest in
the Contractor, on full liquidation of all performance-based payments, for all
property for which

--------------------------------------------------------------------------------

 
[exhibit103050.jpg]
W911QY20C0100 Page 50 of 53 the Government elects not to require delivery under
the Default clause of this contract. The Government shall be liable for no
payment except as provided by the Default clause. (k) Reservation of rights. (1)
No payment or vesting of title under this clause shall -- (i) Excuse the
Contractor from performance of obligations under this contract; or (ii)
Constitute a waiver of any of the rights or remedies of the parties under the
contract. (2) The Government's rights and remedies under this clause -- (i)
Shall not be exclusive, but rather shall be in addition to any other rights and
remedies provided by law or this contract; and (ii) Shall not be affected by
delayed, partial, or omitted exercise of any right, remedy, power, or privilege,
nor shall such exercise or any single exercise preclude or impair any further
exercise under this clause or the exercise of any other right, power, or
privilege of the Government. (l) Content of Contractor's request for
performance-based payment. The Contractor's request for performance-based
payment shall contain the following: (1) The name and address of the Contractor;
(2) The date of the request for performance-based payment; (3) The contract
number and/or other identifier of the contract or order under which the request
is made; (4) Such information and documentation as is required by the contract's
description of the basis for payment; and (5) A certification by a Contractor
official authorized to bind the Contractor, as specified in paragraph (m) of
this clause. (m) Content of Contractor's certification. As required in paragraph
(l)(5) of this clause, the Contractor shall make the following certification in
each request for performance-based payment: I certify to the best of my
knowledge and belief that -- (1) This request for performance-based payment is
true and correct; this request (and attachments) has been prepared from the
books and records of the Contractor, in accordance with the contract and the
instructions of the Contracting Officer; (2) (Except as reported in writing on
), all payments to subcontractors and suppliers under this contract have been
paid, or will be paid, currently, when due in the ordinary course of business;
(3) There are no encumbrances (except as reported in writing on ) against the
property acquired or produced for, and allocated or properly chargeable to, the
contract which would affect or impair the Government's title; (4) There has been
no materially adverse change in the financial condition of the Contractor since
the submission by the Contractor to the Government of the most recent written
information dated ; and (5) After the making of this requested performance-based
payment, the amount of all payments for each deliverable item for which
performance-based payments have been requested will not exceed any limitation in
the contract, and

--------------------------------------------------------------------------------

 
[exhibit103051.jpg]
W911QY20C0100 Page 51 of 53 the amount of all payments under the contract will
not exceed any limitation in the contract. (End of Clause) 52.252-2 CLAUSES
INCORPORATED BY REFERENCE (FEB 1998) This contract incorporates one or more
clauses by reference, with the same force and effect as if they were given in
full text. Upon request, the Contracting Officer will make their full text
available. Also, the full text of a clause may be accessed electronically at
this/these address(es): https://www.acquisition.gov/content/regulations (End of
clause) 52.252-6 AUTHORIZED DEVIATIONS IN CLAUSES (APR 1984) (a) The use in this
solicitation or contract of any Federal Acquisition Regulation (48 CFR Chapter
1) clause with an authorized deviation is indicated by the addition of
"(DEVIATION)" after the date of the clause. (b) The use in this solicitation or
contract of any Defense Federal Acquisition Regulation Supplement (48 CFR
Chapter 2) clause with an authorized deviation is indicated by the addition of
"(DEVIATION)" after the name of the regulation. (End of clause)

--------------------------------------------------------------------------------

 
[exhibit103052.jpg]
W911QY20C0100 Page 52 of 53 Section J - List of Documents, Exhibits and Other
Attachments Document Type Description Page # Date Exhibit A CDRLs 14 18 July
2020 Attachment 0001 Supply Chain Resiliency Plan for CDRL A010 2 23 July 2020
Attachment 0002 Security Plan 6 23 July 2020 Attachment 0003 Dose Tracking
Template Draft Moderna Excel 15 July 2020 Attachment 0004 Data Rights 1 7 August
2020 Attachment 0005 [***] 1 7 August 2020 Attachment 0006 ModernaTx, Inc.
Background Intellectual Property 2 6 August 2020 Attachment 0007 Performance
Base Payment Milestone Schedule 1 7 August 2020 Attachment 0008 Performance Base
Payment Milestone Billing Plan 15 7 August 2020 Exhibit A Contract Data
Requirements List (CDRL) Data Item # Title of Data Item Subtitle Date A001
Quality Audit Finding and Response BARDA Audit Findings Report 18-Jul-20 Record
(QAFRR) A002 Quality Audit Finding and Response FDA Audit Findings Report
18-Jul-20 Record (QAFRR) A003 Contractor Furnished Material (CFM) Monthly
Inventory Report 18-Jul-20 Report A004 Quality Program Plan Quality Program Plan
18-Jul-20 A005 Task Directive Documentation Shipping Documentation - Finished
18-Jul-20 Drag Products (FDP) A006 Task Directive Documentation Expiring Item
Report 18-Jul-20 A007 Contractor's Personnel Roster Key Personnel Listing
18-Jul-20 A008 Status Report Monthly Technical Progress Report 18-Jul-20 A009
Contract Summary Report Final Technical Report 18-Jul-20 A010 Supply Chain Risk
Management Plan Supply Chain Resiliency Plan (SCRP) 18-Jul-20 A011 Contractor's
Risk Management Plan Risk Management Plan (RMP) 18-Jul-20 A012 Research and
Development of Vendor Managed Inventory Plan/SOP 18 Jul 20 Medical Products
Regulated by the U.S. Food and Drug Administration A013 Internal Contractor
Technical Data Manufacturing Reports and Dose 18-Jul-20 Tracking
Projections/Actuals A014 Certificate of Compliance (Analysis) Product Acceptance
Report 18-Jul-20 A015 N/A - - A016 Accident Incident Report Incident Report
18-Jul-20 A017 Internal Contractor Technical Data FDA Correspondence 18-Jul-20
Report A018 Acquisition Support Documentation Press Releases 18-Jul-20 A019
Contractor's Standard Operating Security Plan 18-Jul-20 Procedures A020
Conference Agenda Conference Agenda 18-Jul-20

--------------------------------------------------------------------------------

 
[exhibit103053.jpg]
W911QY20C0100 Page 53 of 53 A021 Report, Record of Meeting/Minutes Meeting
Minutes 18-Jul-20 A022 Presentation Material Presentation Material 18-Jul-20
A023 N/A - - A024 Operations Security (OPSEC) Plan Operational Security (OPSEC)
18 Jul 20 SOP/Plan A025 Research and Development of Manufacturing Development
Plan 18 Jul 20 Medical Products Regulated by the U.S. Food & Drug Administration
(FDA)

--------------------------------------------------------------------------------

 
[exhibit103054.jpg]
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED
WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT
BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO
THE COMPANY IF DISCLOSED. Section J Title Description Page Date Exhibit A
Contract Data Requirement List (CDRL) 15 18 July 2020 Attachment 0001 Supply
Chain Resiliency Plan for CDRL A010 2 23 July 2020 Attachment 0002 Security Plan
6 23 July 2020 Attachment 0003 Dose Tracking Template Draft Moderna Excel 15
July 2020 Attachment 0004 Data Rights 2 7 August 2020 Attachment 0005 [***] 1 7
August 2020 Attachment 0006 ModernaTx, Inc. Background Intellectual 2 6 August
2020 Property Attachment 0007 Performance Based Payment 1 7 August 2020
Milestone Schedule Attachment 0008 Performance Based Payment Milestone 15 7
August 2020 Billing Plan W911QY-20-C-0100 Section J

--------------------------------------------------------------------------------

 
[exhibit103055.jpg]
Contract Data Requirements List (CDRLs) Exhibit A As of 18 July 2020

--------------------------------------------------------------------------------

 
[exhibit103056.jpg]
CONTRACT DATA REQUIREMENTS LIST Form Approved (2 Data Items) OMB No. 0704-0188
The public reporting burden for this collection of information is estimated to
average 220 hours per response, including the time for reviewing instructions,
searching existing data sources, gathering and maintaining the data needed, and
completing and reviewing the collection of information. Send comments regarding
this burden estimate or any other aspect of this collection of information,
including suggestions for reducing the burden, to the Department of Defense,
Executive Services Directorate (0704-0188). Respondents should be aware that
notwithstanding any other provision of law, no person shall be subject to any
penalty for failing to comply with a collection of information if it does not
display a currently valid OMB control number. Please do not return your form to
the above organization. Send completed form to the Government Issuing
Contracting Officer for the Contract/PR No. listed in Block E. A. CONTRACT LINE
ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM ____ Other General/Admin
Data E. CONTRACT/PR NO. F. CONTRACTOR D. SYSTEM/ITEM LARGE SCALE PRODUCTION OF
SARS-CoV-2 VACCINE W911QY-20-C-0100 Moderna TX, Inc. 1. DATA ITEM NO. 2. TITLE
OF DATA ITEM 3. SUBTITLE 17. Price Group A001 Quality Audit Finding and Response
Record (QAFRR) BARDA Audit Findings Report 4. AUTHORITY (Data Acquisition
Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE DI-SESS-81923 C.3.1.2.1,
C.3.2.2.1, C.3.3.2.1 ASPR BARDA 12. DATE OF FIRST 18. Estimated 7. DD 250 REQ
10. FREQUENCY SUBMISSION 14. DISTRIBUTION Total Price N/A ASREQ 9. DIST Refer to
Block 16 STATEMENT 13. DATE OF b. COPIES REQUIRED 8. APP CODE 11. AS OF DATE
SUBSEQUENT C a. ADDRESSEE Final A 0 SUBMISSION Draft Refer to Block 16 Reg Repro
16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description (DID) may be obtained
from http://quicksearch.dla.mil/. The CCAP-SCN** LT 1 0 contractor shall detail
the findings and corrective action(s). 8. The US Government (USG) will respond
with comments or approval within 10 calendar days after receipt. 9. Distribution
Statement C: Distribution authorized to U.S. Government agencies and their
Contractors (Administrative or Operational Use). Determination made July 18,
2020. Distribution guidance is included in DoD Instruction 5230.24. 12. Submit
within 10 business days of an Audit. 13. The contractor shall incorporate USG
comments and provide a final report to the USG upon completion of corrective
action. 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel,
Power Point) via email to the BARDA representative: Marva Taylor ([***]) and the
Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via
email). 15. TOTAL → 2. TITLE OF DATA ITEM 1. DATA ITEM NO. 3. SUBTITLE Research
and Development of Medical Products 17. Price Group A002 FDA Interactions and
Inspections Documents Regulated by the U.S. Food & Drug Administration 4.
AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING
OFFICE DI-TCSP-82040 (Tailored) C.3.1.2.2, C.3.2.2.2, C.3.3.2.2 ASPR BARDA 12.
DATE OF FIRST 18. Estimated 7. DD 250 REQ 10. FREQUENCY SUBMISSION 14.
DISTRIBUTION Total Price N/A ASREQ 9. DIST Refer to Block 16 STATEMENT 13. DATE
OF b. COPIES REQUIRED 8. APP CODE 11. AS OF DATE SUBSEQUENT C a. ADDRESSEE Final
A 0 SUBMISSION Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0
4. The Data Item Description (DID) may be obtained from
http://quicksearch.dla.mil/. The CCAP-SCN** 1 1 0 contractor shall detail the
findings and corrective action(s). 8. The US Government (USG) will respond with
comments or approval within 10 calendar days after receipt. 9. Distribution
Statement C: Distribution authorized to U.S. Government agencies and their
Contractors (Administrative or Operational Use). Determination made July 18,
2020. Distribution guidance is included in DoD Instruction 5230.24. 12. Submit
within 10 business days of an Audit. 13. The contractor shall incorporate USG
comments and provide a final report to the USG upon completion of corrective
action. 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel,
Power Point) via email to the BARDA representative: Marva Taylor ([***]) and the
Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via
email). 15. TOTAL → 2 2 0 G. PREPARED BY H. DATE I. APPROVED BY J. DATE Pamela
Serra July 18, 2020 Marva Taylor July 18, 2020

--------------------------------------------------------------------------------

 
[exhibit103057.jpg]
CONTRACT DATA REQUIREMENTS LIST Form Approved (2 Data Items) OMB No. 0704-0188
The public reporting burden for this collection of information is estimated to
average 220 hours per response, including the time for reviewing instructions,
searching existing data sources, gathering and maintaining the data needed, and
completing and reviewing the collection of information. Send comments regarding
this burden estimate or any other aspect of this collection of information,
including suggestions for reducing the burden, to the Department of Defense,
Executive Services Directorate (0704-0188). Respondents should be aware that
notwithstanding any other provision of law, no person shall be subject to any
penalty for failing to comply with a collection of information if it does not
display a currently valid OMB control number. Please do not return your form to
the above organization. Send completed form to the Government Issuing
Contracting Officer for the Contract/PR No. listed in Block E. A. CONTRACT LINE
ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM ____ Other General/Admin
Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR LARGE SCALE PRODUCTION OF
SARS-CoV-2 W911QY-20-C-0100 Moderna TX, Inc. VACCINE 1. DATA ITEM NO. 2. TITLE
OF DATA ITEM 3. SUBTITLE 17. Price Group A003 Contractor Furnished Material
(CFM) Report Monthly Inventory Report 4. AUTHORITY (Data Acquisition Document
No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated DI-MGMT-82049 C.4.1
ASPR BARDA Total Price 7. DD 250 REQ 9. DIST STATEMENT 10. FREQUENCY 12. DATE OF
FIRST 14. DISTRIBUTION NO REQUIRED MTHLY SUBMISSION C Refer to Block 16 8. APP
CODE 11. AS OF DATE 13. DATE OF b. COPIES NA N SUBSEQUENT a. ADDRESSEE Final
SUBMISSION Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4.
The Data Item Description (DID) may be obtained from
http://quicksearch.dla.mil/. The CCAP-SCN** 0 LT 0 contractor shall detail the
findings and corrective action(s). 8. The US Government (USG) will respond with
comments or approval within 10 calendar days after receipt. 9. Distribution
Statement C: Distribution authorized to U.S. Government agencies and their
Contractors (Administrative or Operational Use). Determination made July 18,
2020. Distribution guidance is included in DoD Instruction 5230.24. 12. Submit
within 10 business days of an Audit. 13. The contractor shall incorporate USG
comments and provide a final report to the USG upon completion of corrective
action. 14. Submit as an electronic file in Microsoft Office (i.e. Word, Excel,
Power Point) via email to the BARDA representative: Marva Taylor ([***]) and the
Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via
email). 15. TOTAL → 1 1 0 1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17.
Price Group A004 Research and Development of Medical Products Quality Management
Plan Regulated by the U.S. Food & Drug Administration 4. AUTHORITY (Data
Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18.
Estimated DI-TCSP-82040 (Tailored) C.4.18 ASPR BARDA Total Price 7. DD 250 REQ
9. DIST STATEMENT 10. FREQUENCY 12. DATE OF FIRST 14. DISTRIBUTION N/A REQUIRED
ASREQ SUBMISSION C Refer to Block 16 8. APP CODE 11. AS OF DATE 13. DATE OF b.
COPIES A 0 SUBSEQUENT Final a. ADDRESSEE SUBMISSION Draft Re Repro Refer to
Block 16 g 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description (DID) may
be obtained from http://quicksearch.dla.mil/. Page 10, CCAP-SCN** LT LT 0
paragraph f.(2) applies. 8. The US Government (USG) will respond with comments
or approval within 10 calendar days after receipt. 9. Distribution Statement C:
Distribution authorized to U.S. Government agencies and their Contractors
(Administrative or Operational Use). Determination made July 18, 2020.
Distribution guidance is included in DoD Instruction 5230.24. 12. Submit within
30 calendar days after contract award. 13. The contractor shall incorporate USG
comments and resubmit within 10 calendar days after receipt. 14. Submit as an
electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to
the BARDA representative: Marva Taylor ([***]) and the Contracting Officer**
(KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 1 1
0 G. PREPARED BY H. DATE I. APPROVED BY J. DATE Pamela Serra July 18, 2020 Marva
Taylor July 18, 2020

--------------------------------------------------------------------------------

 
[exhibit103058.jpg]
CONTRACT DATA REQUIREMENTS LIST Form Approved (1 Data Item) OMB No. 0704-0188
The public reporting burden for this collection of information is estimated to
average 110 hours per response, including the time for reviewing instructions,
searching existing data sources, gathering and maintaining the data needed, and
completing and reviewing the collection of information. Send comments regarding
this burden estimate or any other aspect of this collection of information,
including suggestions for reducing the burden, to Department of Defense,
Washington Headquarters Services, Directorate for Information Operations and
Reports (0701-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA
22202-4302. Respondents should be aware that notwithstanding any other provision
of law, no person shall be subject to any penalty for failing to comply with a
collection of information if it does not display a currently valid OMB control
number. Please DO NOT RETURN your form to the above address. Send completed form
to the Government Issuing Contracting Officer for the Contract/PR No. listed in
Block E. A. CONTRACT LINE ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM
____ Other General/Admin Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR
LARGE SCALE PRODUCTION OF SARS-CoV-2 W911QY-20-C-0100 Moderna TX, Inc. VACCINE
1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group A005 Research
and Development of Medical Products Regulated by the Shipping
Documentation-Finished Drug Product U.S. Food and Drug Administration (FDA)
(FDP) 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6.
REQUIRING OFFICE 18. Estimated DI-TCSP-82040 C.4.3 ASPR BARDA Total Price 7. DD
250 REQ 9. DIST STATEMENT 10. FREQUENCY 12. DATE OF FIRST 14. DISTRIBUTION NA
REQUIRED ASREQ SUBMISSION C Refer to Block 16 8. APP CODE 11. AS OF DATE 13.
DATE OF b. COPIES A 0 SUBSEQUENT a. ADDRESSEE Final SUBMISSION Draft Refer to
Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description
(DID) may be obtained from http://quicksearch.dla.mil/. Provide CCAP-SCN** LT LT
0 shipping document for all FDP transferring from the contractor’s facility to a
USG facility. Provide the following information in order to coordinate the
movement and delivery of vaccine product from manufacturing locations to USG
distribution centers: -Points of Contact information (name, title, phone, email)
for manufacturing / supply chain personnel for each manufacturing, CMO, storage
and distribution locations: - Head of Manufacturing - Production Planning -
Logistics - Distribution - Labeling – Provide vaccine labeling, packaging and
distribution information as soon as it becomes available. At a minimum, include
the following: a) Primary Container Information; b) Number of doses per primary
container; c) Unit of Sale (carton, box, package, other); d) Quantity per Unit
of Sale; National Drug Code (NDC) or NDC-like code under EUA; Unit of Sale
dimensions (H,W,L); e) Unit of Sale weight; f) Intermediate Package; g)
Intermediate Package dimensions; h) Intermediate Package weight; i) Quantity
Unit of Sale per pallet; j) Storage Requirements; and k) Stability Information.
Packaging List: Include the following DSCSA data elements, TI, TH and TS in
packing lists. Include the contract number and CDC’s PO number (which BARDA will
provide at the time the bulk order is submitted) on the packing list for all
shipments. Include a copy of the MSDS (with QR code) in the packing list
envelope with each shipment. Send EDI 856 Advanced Shipment Notice for all
products shipped to a USG directed location. CDC will provide EDI mapping
specifications that include the CDC generated PO number. Send electronic/scanned
copies of all bulk shipment related documents to the COR for three-way matching
on the day shipment occurs. 8. Shipping Process Demo: The US Government (USG)
will respond within 15 calendar days with comments or approval. Subsequent
submission (after USG approval of initial shipping process demo) within 1
calendar day after receipt of the FDP. 9. Distribution Statement C: Distribution
authorized to U.S. Government agencies and their Contractors (Administrative or
Operational Use). Determination made July 18, 2020. Distribution guidance is
included in DoD Instruction 5230.24. 12. 1st Submittal (Demo): 30 calendar days
prior to first shipment. Submit concurrent with each FDP delivery. 13. The
contractor shall incorporate USG comments and resubmit to the USG within 1
calendar day after receipt. 14. Submit as an electronic file in Microsoft Office
(i.e. Word, Excel, Power Point) or Adobe PDF via email to the BARDA
representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny
Soto ([***]). LT: Letter of Transmittal (via email) 15. TOTAL → 1 1 0 G.
PREPARED BY H. DATE I. APPROVED BY J. DATE Pamela Serra July 18, 2020 Marva
Taylor July 18, 2020

--------------------------------------------------------------------------------

 
[exhibit103059.jpg]
CONTRACT DATA REQUIREMENTS LIST Form Approved (2 Data Items) OMB No. 0704-0188
The public reporting burden for this collection of information is estimated to
average 220 hours per response, including the time for reviewing instructions,
searching existing data sources, gathering and maintaining the data needed, and
completing and reviewing the collection of information. Send comments regarding
this burden estimate or any other aspect of this collection of information,
including suggestions for reducing the burden, to the Department of Defense,
Executive Services Directorate (0704-0188). Respondents should be aware that
notwithstanding any other provision of law, no person shall be subject to any
penalty for failing to comply with a collection of information if it does not
display a currently valid OMB control number. Please do not return your form to
the above organization. Send completed form to the Government Issuing
Contracting Officer for the Contract/PR No. listed in Block E. A. CONTRACT LINE
ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM ____ Other General/Admin
Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR LARGE SCALE PRODUCTION OF
SARS-CoV-2 W911QY-20-C-0100 Moderna TX, Inc. VACCINE 1. DATA ITEM NO. 2. TITLE
OF DATA ITEM 3. SUBTITLE 17. Price Group A006 Task Directive Documentation
Expiring Items Report 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT
REFERENCE 6. REQUIRING OFFICE 18. Estimated DI-SESS-82206 (Tailored) C.4.3 ASPR
BARDA Total Price 7. DD 250 REQ 9. DIST STATEMENT 10. FREQUENCY 12. DATE OF
FIRST NA REQUIRED ASREQ SUBMISSION 14. DISTRIBUTION C Refer to Block 16 8. APP
CODE 11. AS OF DATE 13. DATE OF b. COPIES NO NA SUBSEQUENT a. ADDRESSEE Final
SUBMISSION Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 0 1 0 4.
The Data Item Description (DID) may be obtained from
http://quicksearch.dla.mil/. Only CCAP-SCN** 0 LT 0 paragraph cc applies. 9.
Distribution Statement C: Distribution authorized to U.S. Government agencies
and their Contractors (Administrative or Operational Use). Determination made
July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12.
& 13. Submit 30 calendar days prior to product expiration throughout contract
period of performance. 14. Submit as an electronic file in Microsoft Office
(i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva
Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT:
Letter of Transmittal (via email). 15. TOTAL → 0 1 0 1. DATA ITEM NO. 2. TITLE
OF DATA ITEM 3. SUBTITLE 17. Price Group A007 Contractor’s Personnel Roster Key
Personnel Listing 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT
REFERENCE 6. REQUIRING OFFICE 18. Estimated DI-MGMT-81834A C.4.5 ASPR BARDA
Total Price 7. DD 250 REQ 9. DIST STATEMENT 10. FREQUENCY 12. DATE OF FIRST 14.
DISTRIBUTION N/A REQUIRED ASREQ SUBMISSION C Refer to Block 16 8. APP CODE 11.
AS OF DATE 13. DATE OF b. COPIES A 0 SUBSEQUENT Final a. ADDRESSEE SUBMISSION
Draft Re Repro Refer to Block 16 g 16. REMARKS ASPR BARDA* 1 1 0 4. The Data
Item Description (DID) may be obtained from http://quicksearch.dla.mil/.
CCAP-SCN** 0 LT 0 8. The US Government (USG) will respond with comments or
approval within 10 calendar days after receipt. 9. Distribution Statement C:
Distribution authorized to U.S. Government agencies and their Contractors
(Administrative or Operational Use). Determination made July 18, 2020.
Distribution guidance is included in DoD Instruction 5230.24. 12. Submit with
Technical Proposal. 13. The contractor shall incorporate USG comments and
resubmit to the USG within 10 calendar days after receipt. Resubmit for any
changes to key personnel. 14. Submit as an electronic file in Microsoft Office
(i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva
Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT:
Letter of Transmittal (via email). 15. TOTAL → 1 1 0 G. PREPARED BY H. DATE I.
APPROVED BY J. DATE Pamela Serra July 18, 2020 Marva Taylor July 18, 2020

--------------------------------------------------------------------------------

 
[exhibit103060.jpg]
CONTRACT DATA REQUIREMENTS LIST Form Approved (1 Data Item) OMB No. 0704-0188
The public reporting burden for this collection of information is estimated to
average 110 hours per response, including the time for reviewing instructions,
searching existing data sources, gathering and maintaining the data needed, and
completing and reviewing the collection of information. Send comments regarding
this burden estimate or any other aspect of this collection of information,
including suggestions for reducing the burden, to Department of Defense,
Washington Headquarters Services, Directorate for Information Operations and
Reports (0701-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA
22202-4302. Respondents should be aware that notwithstanding any other provision
of law, no person shall be subject to any penalty for failing to comply with a
collection of information if it does not display a currently valid OMB control
number. Please DO NOT RETURN your form to the above address. Send completed form
to the Government Issuing Contracting Officer for the Contract/PR No. listed in
Block E. A. CONTRACT LINE ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM
____ Other General/Admin Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR
LARGE SCALE PRODUCTION OF SARS-CoV-2 W911QY-20-C-0100 Moderna TX, Inc. VACCINE
1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group A008 Status
Report Monthly Technical Progress Report 4. AUTHORITY (Data Acquisition Document
No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated DI-MGMT-80368A
(Tailored) C.4.6 ASPR BARDA Total Price 7. DD 250 REQ 9. DIST STATEMENT 10.
FREQUENCY 12. DATE OF FIRST 14. DISTRIBUTION NA REQUIRED MTHLY SUBMISSION C
Refer to Block 16 8. APP CODE 11. AS OF DATE 13. DATE OF b. COPIES A 0
SUBSEQUENT a. ADDRESSEE Final SUBMISSION Draft Refer to Block 16 Reg Repro 16.
REMARKS ASPR BARDA* 1 1 0 4. The DID may be obtained from
http://quicksearch.dla.mil/. The Monthly Progress report shall address each of
CCAP-SCN** 1 1 0 the below items and be cross-referenced to the Statement of
Work (SOW), Product Delivery Table, and an Integrated Master Schedule (IMS), and
detail the following: ● A cover page that includes the contract number and
title; the type of report and period that it covers; the Contractor’s name,
address, telephone number, fax number, and e-mail address; and the date of
submission; ● SECTION I-EXECUTIVE SUMMARY ● SECTION II - PROGRESS ● SECTION II
Part A: OVERALL PROGRESS - A description of overall progress. ● SECTION II part
B: MANAGEMENT AND ADMINISTRATIVE UPDATE-A description of all meetings,
conference calls, etc. that have taken place during the reporting period.
Include progress on administration and management issues (e.g., evaluating, and
managing subcontractor performance, and personnel changes). ● SECTION II Part C:
TECHNICAL PROGRESS - For each activity related to Gantt chart, document the
results of work completed and cost incurred during the period covered in
relation to proposed progress, effort and budget. The report shall be in
sufficient detail to explain comprehensively the results achieved. The
description shall include pertinent data and/or graphs in sufficient detail to
explain any significant results achieved and preliminary conclusions resulting
from analysis and scientific evaluation of data accumulated to date under the
contract. The report shall include a description of problems encountered and
proposed corrective action; differences between planned and actual progress, why
the differences have occurred and what corrective actions are planned;
preliminary conclusions resulting from analysis and scientific evaluation of
data accumulated to date under the project. ● SECTION II Part D: PROPOSED WORK -
A summary of work proposed related to Gantt chart for the next reporting period
and preprints/reprints of papers and abstracts. ● SECTION III: Estimated and
Actual Expenses. a. This section of the report shall contain a narrative or
table detailing whether there is a significant discrepancy (>10%) at this time
between the % of work completed and the cumulative costs incurred to date.
Monthly and actual expenses should be broken down to the appropriate WBS level.
b. This section of the report should also contain estimates for the
Subcontractors’ expenses from the previous month if the Subcontractor did not
submit a bill in the previous month. If the subcontractor(s) was not working or
did not incur any costs in the previous month, then a statement to this effect
should be included in this report for those respective subcontractors.
Additionally, the report shall detail the following: ● Storage/inventory of
ancillary materials (vials, needles, syringes, etc.) ● Shipment and receipt of
ancillary materials (vials, needles, syringes, etc.) ● Disposal of ancillary
materials (vials, needles, syringes, etc.) ● Bulk drug substance production ●
Fill, finish, and release of product ● Storage/inventory of starting materials,
bulk substance, or filled/final product or adjuvant ● Stability information of
intermediates, bulk substance and/or finished product ● Shipment of bulk
substance of final product ● Disposition of bulk substance or final product ●
Identify doses accepted by the Government in previous submissions 8. The USG
will review the monthly reports with the Contractor and provided feedback with
10 calendar days after receipt. 9. Distribution Statement C: Distribution
authorized to U.S. Government agencies and their Contractors (Administrative or
Operational Use). Determination made July 18, 2020. Distribution guidance is
included in DoD Instruction 5230.24. 12. Submit on the 20th day of the month
covering the preceding month. (A Monthly progress report is not due required
during the month when the Final Report )final version, not draft) is due (see
CDRL A009) 13. The contractor shall incorporate USG comments and resubmit to the
USG within 10 calendar days after receipt. Resubmit for any changes to key
personnel. 14. Submit as an electronic file in Microsoft Office (i.e. Word,
Excel, Power Point) via email to the BARDA representative: Marva Taylor ([***])
and the Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of
Transmittal (via email). 15. TOTAL → 2 2 0 G. PREPARED BY H. DATE I. APPROVED BY
J. DATE Pamela Serra July 18, 2020 Marva Taylor July 18, 2020

--------------------------------------------------------------------------------

 
[exhibit103061.jpg]
CONTRACT DATA REQUIREMENTS LIST Form Approved (2 Data Items) OMB No. 0704-0188
The public reporting burden for this collection of information is estimated to
average 220 hours per response, including the time for reviewing instructions,
searching existing data sources, gathering and maintaining the data needed, and
completing and reviewing the collection of information. Send comments regarding
this burden estimate or any other aspect of this collection of information,
including suggestions for reducing the burden, to the Department of Defense,
Executive Services Directorate (0704-0188). Respondents should be aware that
notwithstanding any other provision of law, no person shall be subject to any
penalty for failing to comply with a collection of information if it does not
display a currently valid OMB control number. Please do not return your form to
the above organization. Send completed form to the Government Issuing
Contracting Officer for the Contract/PR No. listed in Block E. A. CONTRACT LINE
ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM ____ Other General/Admin
Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR LARGE SCALE PRODUCTION OF
SARS-CoV-2 VACCINE W911QY-20-C-0100 Moderna TX, Inc. 1. DATA ITEM NO. 2. TITLE
OF DATA ITEM 3. SUBTITLE 17. Price Group A009 Contract Summary Report Final
Technical Report 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT
REFERENCE 6. REQUIRING OFFICE 18. Estimated Total Price DI-ADMN-80447A C.4.7
ASPR BARDA 7. DD 250 REQ 9. DIST 10. FREQUENCY 12. DATE OF FIRST SUBMISSION 14.
DISTRIBUTION N/A STATEMENT R/ASR Refer to Block 16 REQUIRED 8. APP CODE 11. AS
OF DATE 13. DATE OF SUBSEQUENT b. COPIES C SUBMISSION a. ADDRESSEE Final A 0
Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item
Description (DID) may be obtained from http://quicksearch.dla.mil/. The final
report shall be marked as CCAP-SCN** 1 1 0 'Final’. A cover letter with the
report shall contain a summary (not to exceed 200 words) of salient results
achieved during the performance of the contract and be structured in the
following format: Include the following: Identify doses accepted by the
Government in previous submissions. a. Cover page to include the contract
number, contract title, performance period covered, Contractor's name and
address, telephone number, fax number, email address and submission date. b.
SECTION I: EXECUTIVE SUMMARY - Summarize the purpose and scope of the contract
effort including a summary of the major accomplishments relative to the specific
activities set forth in the Statement of Work. c. SECTION II: RESULTS - A
detailed description of the work performed related to WBS and Gantt chart, the
results obtained, and the impact of the results on the scientific and/or public
health community including a listing of all manuscripts (published and in
preparation) and abstracts presented during the entire period of performance and
a summary of all inventions. 8. The US Government (USG) will respond with
comments or approval within 30 calendar days after receipt of first draft report
and within 15 calendar days of second submission. 9. Distribution Statement C:
Distribution authorized to U.S. Government agencies and their Contractors
(Administrative or Operational Use). Determination made July 18, 2020.
Distribution guidance is included in DoD Instruction 5230.24. 12. Submit Draft
Report 75 calendar days prior to end of contract. Submit Final Report 30
calendar days after contract award. 13. The contractor shall incorporate USG
comments and resubmit to the USG within 30 calendar days after receipt for first
submission and within 10 calendars days after second submission. 14. Submit as
an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email
to the BARDA representative: Marva Taylor ([***]) and the Contracting Officer**
(KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 2 2
0 1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group A010 Supply
Chain Risk Management Plan Supply Chain Resiliency Plan (SCRP) 4. AUTHORITY
(Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18.
Estimated Total Price DI-MGMT-82256 C.4.8 ASPR BARDA 7. DD 250 REQ 9. DIST 10.
FREQUENCY 12. DATE OF FIRST SUBMISSION 14. DISTRIBUTION N/A STATEMENT ASREQ
Refer to Block 16 REQUIRED 8. APP CODE 11. AS OF DATE 13. DATE OF SUBSEQUENT b.
COPIES C SUBMISSION a. ADDRESSEE Final A 0 Draft Refer to Block 16 Reg Repro
ASPR BARDA* 1 1 0 16. REMARKS CCAP-SCN** LT LT 0 4. The Data Item Description
(DID) may be obtained from http://quicksearch.dla.mil/. SPECIFIC CONTENT
INSTRUCTIONS ARE PROVIDED AT ATTACHMENT 0001 TO THIS CDRL. 8. The US Government
(USG) will respond with comments or approval within 10 calendar days after
receipt. 9. Distribution Statement C: Distribution authorized to U.S. Government
agencies and their Contractors (Administrative or Operational Use).
Determination made July 18, 2020. Distribution guidance is included in DoD
Instruction 5230.24. 12. Submit with 30 Calendar days after contract award. 13.
The contractor shall incorporate USG comments and resubmit to the USG within 7
calendar days after receipt. Submit any and all proposed revisions to the Plan
for USG approval 10 calendar days prior to implementation. 14. Submit as an
electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email to
the BARDA representative: Marva Taylor ([***]) and the Contracting Officer**
(KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 1 1
0 G. PREPARED BY H. DATE I. APPROVED BY J. DATE Pamela Serra July 18, 2020 Marva
Taylor July 18, 2020

--------------------------------------------------------------------------------

 
[exhibit103062.jpg]
CONTRACT DATA REQUIREMENTS LIST Form Approved (2 Data Items) OMB No. 0704-0188
The public reporting burden for this collection of information is estimated to
average 220 hours per response, including the time for reviewing instructions,
searching existing data sources, gathering and maintaining the data needed, and
completing and reviewing the collection of information. Send comments regarding
this burden estimate or any other aspect of this collection of information,
including suggestions for reducing the burden, to the Department of Defense,
Executive Services Directorate (0704-0188). Respondents should be aware that
notwithstanding any other provision of law, no person shall be subject to any
penalty for failing to comply with a collection of information if it does not
display a currently valid OMB control number. Please do not return your form to
the above organization. Send completed form to the Government Issuing
Contracting Officer for the Contract/PR No. listed in Block E. A. CONTRACT LINE
ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM ____ Other General/Admin
Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR LARGE SCALE PRODUCTION OF
SARS-CoV-2 VACCINE W911QY-20-C-0100 Moderna TX, Inc. 1. DATA ITEM NO. 2. TITLE
OF DATA ITEM 3. SUBTITLE 17. Price Group A011 Research and Development of
Medical Products Risk Management Plan (RMP) Regulated by the U.S. Food and Drug
Administration 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT
REFERENCE 6. REQUIRING OFFICE 18. Estimated Total Price DI-TCSP-82040 (Tailored)
C.4.9 ASPR BARDA 7. DD 250 REQ 9. DIST 10. FREQUENCY 12. DATE OF FIRST
SUBMISSION 14. DISTRIBUTION N/A STATEMENT R/ASR Refer to Block 16 REQUIRED 8.
APP CODE 11. AS OF DATE 13. DATE OF SUBSEQUENT b. COPIES C SUBMISSION a.
ADDRESSEE Final A 0 Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1
1 0 4. The Data Item Description (DID) may be obtained from
http://quicksearch.dla.mil/. Page CCAP-SCN** 1 1 0 29, Paragraph (4) applies. 8.
The US Government (USG) will respond with comments or approval within 7 calendar
days after receipt. 9. Distribution Statement C: Distribution authorized to U.S.
Government agencies and their Contractors (Administrative or Operational Use).
Determination made July 18, 2020. Distribution guidance is included in DoD
Instruction 5230.24. 12. Submit within XX calendar days after contract award.
13. The contractor shall incorporate USG comments and resubmit to the USG within
20 calendar days after receipt. Submit updates to the RMP concurrent with
Monthly Progress Report. (CDRL A008). The contractor may choose to notify the
USG up to two times every three months if there are no changes from the prior
submission, and not submit an update. 14. Submit as an electronic file in
Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA
representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny
Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 2 2 0 2. TITLE
OF DATA ITEM 17. Price Group 1. DATA ITEM NO. 3. SUBTITLE Research and
Development of Medical Products A012 Vendor Managed Inventory Plan/SOP Regulated
by the U.S. Food and Drug Administration 4. AUTHORITY (Data Acquisition Document
No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated Total Price
DI-TCSP-82040 (Tailored) C.7.1 ASPR BARDA 7. DD 250 REQ 9. DIST 10. FREQUENCY
12. DATE OF FIRST SUBMISSION 14. DISTRIBUTION N/A STATEMENT R/ASR Refer to Block
16 REQUIRED 8. APP CODE 11. AS OF DATE 13. DATE OF SUBSEQUENT b. COPIES C
SUBMISSION a. ADDRESSEE Final A 0 Draft Refer to Block 16 Reg Repro 16. REMARKS
ASPR BARDA* 1 1 0 4. The Data Item Description (DID) may be obtained from
http://quicksearch.dla.mil/. CCAP-SCN** 1 1 0 Page 11, paragraph (13) applies
and Page 29, Paragraph (4) applies. (Subparagraphs (a) through (c) do not
apply.) 8. The US Government (USG) will respond with comments or approval within
7 calendar days after receipt. 9. Distribution Statement C: Distribution
authorized to U.S. Government agencies and their Contractors (Administrative or
Operational Use). Determination made July 18, 2020. Distribution guidance is
included in DoD Instruction 5230.24. 12. Submit within 45 calendar days after
contract award. 13. The contractor shall incorporate USG comments and resubmit
to the USG within 20 calendar days after receipt. Resubmit for any changes to
the USG-approved Plan/SOP. 14. Submit as an electronic file in Microsoft Office
(i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva
Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT:
Letter of Transmittal (via email). 15. TOTAL → 2 2 0 G. PREPARED BY H. DATE I.
APPROVED BY J. DATE Pamela Serra July 18, 2020 Marva Taylor July 18, 2020

--------------------------------------------------------------------------------

 
[exhibit103063.jpg]
CONTRACT DATA REQUIREMENTS LIST Form Approved (2 Data Items) OMB No. 0704-0188
The public reporting burden for this collection of information is estimated to
average 220 hours per response, including the time for reviewing instructions,
searching existing data sources, gathering and maintaining the data needed, and
completing and reviewing the collection of information. Send comments regarding
this burden estimate or any other aspect of this collection of information,
including suggestions for reducing the burden, to the Department of Defense,
Executive Services Directorate (0704-0188). Respondents should be aware that
notwithstanding any other provision of law, no person shall be subject to any
penalty for failing to comply with a collection of information if it does not
display a currently valid OMB control number. Please do not return your form to
the above organization. Send completed form to the Government Issuing
Contracting Officer for the Contract/PR No. listed in Block E. A. CONTRACT LINE
ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM ____ Other General/Admin
Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR LARGE SCALE PRODUCTION OF
SARS-CoV-2 VACCINE W911QY-20-C-0100 Moderna TX, Inc. 1. DATA ITEM NO. 2. TITLE
OF DATA ITEM 3. SUBTITLE 17. Price Group A013 Research and Development of
Medical Products Manufacturing Reports and Dose Tracking Regulated by the U.S.
Food and Drug Administration Projections/Actuals 4. AUTHORITY (Data Acquisition
Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated Total
Price DI-SESS-81309 C.4.10 ASPR BARDA 7. DD 250 REQ 9. DIST 10. FREQUENCY 12.
DATE OF FIRST SUBMISSION 14. DISTRIBUTION N/A STATEMENT ASREQ Refer to Block 16
REQUIRED 8. APP CODE 11. AS OF DATE 13. DATE OF SUBSEQUENT b. COPIES C
SUBMISSION a. ADDRESSEE Final A N/A Draft Refer to Block 16 Reg Repro 16.
REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description (DID) may be obtained
from http://quicksearch.dla.mil/. Pg. 10, CCAP-SCN** 1 LT 0 paragraph e applies.
The contractor shall complete the Dose Tracking Template provided at Attachment
0003. 8. The US Government (USG) will respond with comments or approval within
15 business days after receipt. 9. Distribution Statement C: Distribution
authorized to U.S. Government agencies and their Contractors (Administrative or
Operational Use). Determination made July 18, 2020. Distribution guidance is
included in DoD Instruction 5230.24. 12. Submit Manufacturing Reports 15
business days prior to FDA submission. Submit the Dose Tracking Template within
15 calendar days after contract award and daily thereafter. 13. The contractor
shall incorporate USG comments and resubmit to the USG within 5 business days
after receipt. 14. Submit as an electronic file in Microsoft Excel via email to
the BARDA representative: Marva Taylor ([***]) and the Contracting Officer**
(KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 0 1
0 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group 1. DATA ITEM NO. Research
and Development of Medical Products Product Acceptance Report and Certificates
of A014 Regulated by the U.S. Food and Drug Administration Analyses/Compliance
4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING
OFFICE 18. Estimated Total Price DI-TCSP-82040 C.4.11 ASPR BARDA 7. DD 250 REQ
9. DIST 10. FREQUENCY 12. DATE OF FIRST SUBMISSION 14. DISTRIBUTION N/A
STATEMENT ASREQ Refer to Block 16 REQUIRED 8. APP CODE 11. AS OF DATE 13. DATE
OF SUBSEQUENT b. COPIES C SUBMISSION a. ADDRESSEE Final A N/A Draft Refer to
Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description
(DID) may be obtained from http://quicksearch.dla.mil/. The CCAP-SCN** LT LT 0
contractor shall provide: pictures of the drug product with lot number, drug
product lot tree, list of associated deviations (from drug substance and
product), and a Certificate of Analysis/Compliance. 8. The US Government (USG)
will respond with comments or approval within 5 calendar days after receipt. 9.
Distribution Statement C: Distribution authorized to U.S. Government agencies
and their Contractors (Administrative or Operational Use). Determination made
July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12.
Submit for each lot of FDP delivered. 13. The contractor shall incorporate USG
comments and resubmit to the USG within 3 calendar days after receipt. 14.
Submit as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point)
via email to the BARDA representative: Marva Taylor ([***]) and the Contracting
Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15.
TOTAL → 1 1 0 G. PREPARED BY H. DATE I. APPROVED BY J. DATE Pamela Serra July
18, 2020 Marva Taylor July 18, 2020

--------------------------------------------------------------------------------

 
[exhibit103064.jpg]
CONTRACT DATA REQUIREMENTS LIST Form Approved (2 Data Items) OMB No. 0704-0188
The public reporting burden for this collection of information is estimated to
average 220 hours per response, including the time for reviewing instructions,
searching existing data sources, gathering and maintaining the data needed, and
completing and reviewing the collection of information. Send comments regarding
this burden estimate or any other aspect of this collection of information,
including suggestions for reducing the burden, to the Department of Defense,
Executive Services Directorate (0704-0188). Respondents should be aware that
notwithstanding any other provision of law, no person shall be subject to any
penalty for failing to comply with a collection of information if it does not
display a currently valid OMB control number. Please do not return your form to
the above organization. Send completed form to the Government Issuing
Contracting Officer for the Contract/PR No. listed in Block E. A. CONTRACT LINE
ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM ____ Other General/Admin
Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR LARGE SCALE PRODUCTION OF
SARS-CoV-2 VACCINE W911QY-20-C-0100 Moderna TX, Inc. 1. DATA ITEM NO. 2. TITLE
OF DATA ITEM 3. SUBTITLE 17. Price Group A015 NOT USED 4. AUTHORITY (Data
Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18.
Estimated Total Price A 7. DD 250 REQ 9. DIST 10. FREQUENCY 12. DATE OF FIRST
SUBMISSION 14. DISTRIBUTION STATEMENT REQUIRED 8. APP CODE 11. AS OF DATE 13.
DATE OF SUBSEQUENT b. COPIES SUBMISSION a. ADDRESSEE Final Draft Reg Repro 16.
REMARKS NOT USED 15. TOTAL → 1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE
17. Price Group A016 Accident Incident Report Incident Report 4. AUTHORITY (Data
Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18.
Estimated Total Price DI-MGMT-82188 C.4.12 ASPR BARDA 7. DD 250 REQ 9. DIST 10.
FREQUENCY 12. DATE OF FIRST SUBMISSION 14. DISTRIBUTION N/A STATEMENT ASREQ
Refer to Block 16 REQUIRED 8. APP CODE 11. AS OF DATE 13. DATE OF SUBSEQUENT b.
COPIES C SUBMISSION a. ADDRESSEE Final A N/A Draft Refer to Block 16 Reg Repro
16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description (DID) may be obtained
from http://quicksearch.dla.mil/. CCAP-SCN** 1 LT 0 9. Distribution Statement C:
Distribution authorized to U.S. Government agencies and their Contractors
(Administrative or Operational Use). Determination made July 18, 2020.
Distribution guidance is included in DoD Instruction 5230.24. 12. Submit with 48
hours of activity or incident or within 24 hours for a security activity or
incident. 13. Submit additional updates within 48 hours of additional
developments. If corrective action is deemed necessary by the USG, the
Contractor shall address in writing, its consideration of concerns raised within
5 business days of receipt. 14. Provide via telephone with written follow-ups
and corrective actions to the COR and Contracting Officer. Provide write-up as
an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via email
to the BARDA representative: Marva Taylor ([***]) and the Contracting Officer**
(KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 1 1
0 G. PREPARED BY H. DATE I. APPROVED BY J. DATE Pamela Serra July 18, 2020 Marva
Taylor July 18, 2020

--------------------------------------------------------------------------------

 
[exhibit103065.jpg]
CONTRACT DATA REQUIREMENTS LIST Form Approved (2 Data Items) OMB No. 0704-0188
The public reporting burden for this collection of information is estimated to
average 220 hours per response, including the time for reviewing instructions,
searching existing data sources, gathering and maintaining the data needed, and
completing and reviewing the collection of information. Send comments regarding
this burden estimate or any other aspect of this collection of information,
including suggestions for reducing the burden, to the Department of Defense,
Executive Services Directorate (0704-0188). Respondents should be aware that
notwithstanding any other provision of law, no person shall be subject to any
penalty for failing to comply with a collection of information if it does not
display a currently valid OMB control number. Please do not return your form to
the above organization. Send completed form to the Government Issuing
Contracting Officer for the Contract/PR No. listed in Block E. A. CONTRACT LINE
ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM ____ Other General/Admin
Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR LARGE SCALE PRODUCTION OF
SARS-CoV-2 VACCINE W911QY-20-C-0100 Moderna TX, Inc. 1. DATA ITEM NO. 2. TITLE
OF DATA ITEM 3. SUBTITLE 17. Price Group A017 Research and Development of
Medical Products FDA Correspondence Regulated by the U.S. Food and Drug
Administration 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT
REFERENCE 6. REQUIRING OFFICE 18. Estimated Total Price DI-TCSP-82040 (Tailored)
C.4.13 ASPR BARDA 7. DD 250 REQ 9. DIST 10. FREQUENCY 12. DATE OF FIRST
SUBMISSION 14. DISTRIBUTION N/A STATEMENT ASREQ Refer to Block 16 REQUIRED 8.
APP CODE 11. AS OF DATE 13. DATE OF SUBSEQUENT b. COPIES C SUBMISSION a.
ADDRESSEE Final A 0 Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 0
1 0 4. The Data Item Description (DID) may be obtained from
http://quicksearch.dla.mil/. CCAP-SCN** 0 LT 0 8. The US Government (USG) will
respond with comments or approval within 10 business days after receipt. 9.
Distribution Statement C: Distribution authorized to U.S. Government agencies
and their Contractors (Administrative or Operational Use). Determination made
July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12.
Submit within 2 business days of receipt of FDA correspondence. 13. The
contractor shall incorporate USG comments and resubmit concurrent with FDA
submission or no later than 1 calendar day of its submission to FDA. 14. Submit
as an electronic file in Microsoft Office (i.e. Word, Excel, Power Point) via
email to the BARDA representative: Marva Taylor ([***]) and the Contracting
Officer** (KO), Danny Soto ([***]). LT: Letter of Transmittal (via email). 15.
TOTAL → 0 1 0 1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group
A018 Acquisition Support Documentation Press Releases 4. AUTHORITY (Data
Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18.
Estimated Total Price DI-MGMT-81607 C.4.14 ASPR BARDA 7. DD 250 REQ 9. DIST 10.
FREQUENCY 12. DATE OF FIRST SUBMISSION 14. DISTRIBUTION N/A STATEMENT ASREQ
Refer to Block 16 REQUIRED 8. APP CODE 11. AS OF DATE 13. DATE OF SUBSEQUENT b.
COPIES C SUBMISSION a. ADDRESSEE Final A 0 Draft Refer to Block 16 Reg Repro 16.
REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description (DID) may be obtained
from http://quicksearch.dla.mil/. Only CCAP-SCN** LT LT 0 paragraphs 3.e, 3.f
and 3.g apply. 9. Distribution Statement C: Distribution authorized to U.S.
Government agencies and their Contractors (Administrative or Operational Use).
Determination made July 18, 2020. Distribution guidance is included in DoD
Instruction 5230.24. 12. Submit no less than 5 business days prior to the
issuance of the press release. 13. Submit any final press releases no later than
one (1) calendar day prior to its release. 14. Submit as an electronic file in
Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA
representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny
Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 1 1 0 G.
PREPARED BY H. DATE I. APPROVED BY J. DATE Pamela Serra July 18, 2020 Marva
Taylor July 18, 2020

--------------------------------------------------------------------------------

 
[exhibit103066.jpg]
CONTRACT DATA REQUIREMENTS LIST Form Approved (2 Data Items) OMB No. 0704-0188
The public reporting burden for this collection of information is estimated to
average 220 hours per response, including the time for reviewing instructions,
searching existing data sources, gathering and maintaining the data needed, and
completing and reviewing the collection of information. Send comments regarding
this burden estimate or any other aspect of this collection of information,
including suggestions for reducing the burden, to the Department of Defense,
Executive Services Directorate (0704-0188). Respondents should be aware that
notwithstanding any other provision of law, no person shall be subject to any
penalty for failing to comply with a collection of information if it does not
display a currently valid OMB control number. Please do not return your form to
the above organization. Send completed form to the Government Issuing
Contracting Officer for the Contract/PR No. listed in Block E. A. CONTRACT LINE
ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM ____ Other General/Admin
Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR LARGE SCALE PRODUCTION OF
SARS-CoV-2 VACCINE W911QY-20-C-0100 Moderna TX, Inc. 1. DATA ITEM NO. 2. TITLE
OF DATA ITEM 3. SUBTITLE 17. Price Group A019 Contractor's Standard Operating
Procedures Security Plan 4. AUTHORITY (Data Acquisition Document No.) 5.
CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated Total Price DI-MGMT-81580
C.6 ASPR BARDA 7. DD 250 REQ 9. DIST 10. FREQUENCY 12. DATE OF FIRST SUBMISSION
14. DISTRIBUTION N/A STATEMENT R/ASR Refer to Block 16 REQUIRED 8. APP CODE 11.
AS OF DATE 13. DATE OF SUBSEQUENT b. COPIES C SUBMISSION a. ADDRESSEE Final A
N/A Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4. The Data
Item Description (DID) may be obtained from http://quicksearch.dla.mil/.
CCAP-SCN** 1 1 0 8. The US Government (USG) will respond with comments or
approval within 15 calendar days after receipt. 9. Distribution Statement C:
Distribution authorized to U.S. Government agencies and their Contractors
(Administrative or Operational Use). Determination made July 18, 2020.
Distribution guidance is included in DoD Instruction 5230.24. 12. Submit within
45 calendar days after contract award. 13. The contractor shall incorporate USG
comments and resubmit to the USG within 10 calendar days after receipt. Resubmit
for any and all revisions for USG approval. 14. Submit as an electronic file in
Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA
representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny
Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 2 2 2 1. DATA
ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group A020 Conference
Agenda Agenda 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE
6. REQUIRING OFFICE 18. Estimated Total Price DI-ADMN-81249B C.5.11, C.5.4 ASPR
BARDA 7. DD 250 REQ 9. DIST 10. FREQUENCY 12. DATE OF FIRST SUBMISSION 14.
DISTRIBUTION N/A STATEMENT ASREQ Refer to Block 16 REQUIRED 8. APP CODE 11. AS
OF DATE 13. DATE OF SUBSEQUENT b. COPIES C SUBMISSION a. ADDRESSEE Final A 0
Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item
Description (DID) may be obtained from http://quicksearch.dla.mil/. CCAP-SCN**
LT LT 0 8. Post Award Teleconference: The USG will respond with comments or
approval within 1 calendar days after receipt. Kickoff Meeting: The USG will
respond with comments or approval within 3 calendar days after receipt. 9.
Distribution Statement C: Distribution authorized to U.S. Government agencies
and their Contractors (Administrative or Operational Use). Determination made
July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12.
Post Award Teleconference: Submit at least 3 business days prior to conduct of
meeting and establish a teleconference number, unless otherwise provided by the
USG. Kickoff Meeting: Submit at least 5 business days prior to conduct of
meeting. 13. The contractor shall incorporate USG comments and distribute agenda
at least 2 business days prior to meeting. 14. Submit as an electronic file in
Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA
representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny
Soto ([***]). LT: Letter of Transmittal (via email). 15. TOTAL → 1 2 0 G.
PREPARED BY H. DATE I. APPROVED BY J. DATE Pamela Serra July 18, 2020 Marva
Taylor July 18, 2020

--------------------------------------------------------------------------------

 
[exhibit103067.jpg]
CONTRACT DATA REQUIREMENTS LIST Form Approved (2 Data Items) OMB No. 0704-0188
The public reporting burden for this collection of information is estimated to
average 220 hours per response, including the time for reviewing instructions,
searching existing data sources, gathering and maintaining the data needed, and
completing and reviewing the collection of information. Send comments regarding
this burden estimate or any other aspect of this collection of information,
including suggestions for reducing the burden, to the Department of Defense,
Executive Services Directorate (0704-0188). Respondents should be aware that
notwithstanding any other provision of law, no person shall be subject to any
penalty for failing to comply with a collection of information if it does not
display a currently valid OMB control number. Please do not return your form to
the above organization. Send completed form to the Government Issuing
Contracting Officer for the Contract/PR No. listed in Block E. A. CONTRACT LINE
ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM ____ Other General/Admin
Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR LARGE SCALE PRODUCTION OF
SARS-CoV-2 VACCINE W911QY-20-C-0100 Moderna TX, Inc. 1. DATA ITEM NO. 2. TITLE
OF DATA ITEM 3. SUBTITLE 17. Price Group A021 Report, Record of Meeting/Minutes
Meeting Minutes 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT
REFERENCE 6. REQUIRING OFFICE 18. Estimated Total Price DI-ADMN-81505 C.4.12,
C.5.4 ASPR BARDA 7. DD 250 REQ 9. DIST 10. FREQUENCY 12. DATE OF FIRST
SUBMISSION 14. DISTRIBUTION N/A STATEMENT ASREQ Refer to Block 16 REQUIRED 8.
APP CODE 11. AS OF DATE 13. DATE OF SUBSEQUENT b. COPIES C SUBMISSION a.
ADDRESSEE Final A 0 Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1
1 0 4. The Data Item Description (DID) may be obtained from
http://quicksearch.dla.mil/. CCAP-SCN** LT 1 0 8. The US Government (USG) will
respond with comments or approval within 10 calendar days after receipt. 9.
Distribution Statement C: Distribution authorized to U.S. Government agencies
and their Contractors (Administrative or Operational Use). Determination made
July 18, 2020. Distribution guidance is included in DoD Instruction 5230.24. 12.
Submit within 3 calendar days after conduct of meeting. 13. Post Award
Teleconference: The contractor shall incorporate USG comments and resubmit to
the USG within 3 business day after receipt and within 10 business days for
Kickoff Meeting. 14. Submit as an electronic file in Microsoft Office (i.e.
Word, Excel, Power Point) via email to the BARDA representative: Marva Taylor
([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT: Letter of
Transmittal (via email). 15. TOTAL → 2 2 0 1. DATA ITEM NO. 2. TITLE OF DATA
ITEM 3. SUBTITLE 17. Price Group A022 Presentation Material Presentation
Material 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT REFERENCE 6.
REQUIRING OFFICE 18. Estimated Total Price DI-ADMN-81373 C.5.4 ASPR BARDA 7. DD
250 REQ 9. DIST 10. FREQUENCY 12. DATE OF FIRST SUBMISSION 14. DISTRIBUTION N/A
STATEMENT ASREQ Refer to Block 16 REQUIRED 8. APP CODE 11. AS OF DATE 13. DATE
OF SUBSEQUENT b. COPIES C SUBMISSION a. ADDRESSEE Final A N/A Draft Refer to
Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item Description
(DID) may be obtained from http://quicksearch.dla.mil/. CCAP-SCN** 1 1 0 8. The
US Government (USG) will respond with comments or approval within 5 calendar
days after receipt. 9. Distribution Statement C: Distribution authorized to U.S.
Government agencies and their Contractors (Administrative or Operational Use).
Determination made July 18, 2020. Distribution guidance is included in DoD
Instruction 5230.24. 12. Submit concurrent with Agenda (CDRL A020). 13. The
contractor shall incorporate USG comments and resubmit to the USG within 5
calendar days after receipt. 14. Submit as an electronic file in Microsoft
Office (i.e. Word, Excel, Power Point) via email to the BARDA representative:
Marva Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT:
Letter of Transmittal (via email). 15. TOTAL → 2 2 0 G. PREPARED BY H. DATE I.
APPROVED BY J. DATE Pamela Serra July 18, 2020 Marva Taylor July 18, 2020

--------------------------------------------------------------------------------

 
[exhibit103068.jpg]
CONTRACT DATA REQUIREMENTS LIST Form Approved (2 Data Items) OMB No. 0704-0188
The public reporting burden for this collection of information is estimated to
average 220 hours per response, including the time for reviewing instructions,
searching existing data sources, gathering and maintaining the data needed, and
completing and reviewing the collection of information. Send comments regarding
this burden estimate or any other aspect of this collection of information,
including suggestions for reducing the burden, to the Department of Defense,
Executive Services Directorate (0704-0188). Respondents should be aware that
notwithstanding any other provision of law, no person shall be subject to any
penalty for failing to comply with a collection of information if it does not
display a currently valid OMB control number. Please do not return your form to
the above organization. Send completed form to the Government Issuing
Contracting Officer for the Contract/PR No. listed in Block E. A. CONTRACT LINE
ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM ____ Other General/Admin
Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR LARGE SCALE PRODUCTION OF
SARS-CoV-2 VACCINE W911QY-20-C-0100 Moderna TX, Inc. 1. DATA ITEM NO. 2. TITLE
OF DATA ITEM 3. SUBTITLE 17. Price Group A023 NOT USED 4. AUTHORITY (Data
Acquisition Document No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18.
Estimated Total Price A 7. DD 250 REQ 9. DIST 10. FREQUENCY 12. DATE OF FIRST
SUBMISSION 14. DISTRIBUTION STATEMENT REQUIRED 8. APP CODE 11. AS OF DATE 13.
DATE OF SUBSEQUENT b. COPIES SUBMISSION a. ADDRESSEE Final Draft Reg Repro 16.
REMARKS NOT USED 15. TOTAL → 1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE
17. Price Group A024 Operations Security (OPSEC) Plan Operational Security Plan
(OPSEC) SOP/Plan 4. AUTHORITY (Data Acquisition Document No.) 5. CONTRACT
REFERENCE 6. REQUIRING OFFICE 18. Estimated Total Price DI-MGMT-80934C C.6.3
ASPR BARDA 7. DD 250 REQ 9. DIST 10. FREQUENCY 12. DATE OF FIRST SUBMISSION 14.
DISTRIBUTION N/A STATEMENT ASREQ Refer to Block 16 REQUIRED 8. APP CODE 11. AS
OF DATE 13. DATE OF SUBSEQUENT b. COPIES C SUBMISSION a. ADDRESSEE Final A 0
Draft Refer to Block 16 Reg Repro 16. REMARKS ASPR BARDA* 1 1 0 4. The Data Item
Description (DID) may be obtained from http://quicksearch.dla.mil/. CCAP-SCN**
LT 1 0 8. The US Government (USG) will respond with comments or approval within
10 calendar days after receipt. 9. Distribution Statement C: Distribution
authorized to U.S. Government agencies and their Contractors (Administrative or
Operational Use). Determination made July 18, 2020. Distribution guidance is
included in DoD Instruction 5230.24. 12. Submit within 90 calendar days of
contract award. 13. The contractor shall incorporate USG comments and revisions
within 10 calendar days after receipt. Resubmit for any revisions to the
UGS-approved SOP/Plan. 14. Submit as an electronic file in Microsoft Office
(i.e. Word, Excel, Power Point) via email to the BARDA representative: Marva
Taylor ([***]) and the Contracting Officer** (KO), Danny Soto ([***]). LT:
Letter of Transmittal (via email). 15. TOTAL → 1 2 0 G. PREPARED BY H. DATE I.
APPROVED BY J. DATE Pamela Serra July 18, 2020 Marva Taylor July 18, 2020

--------------------------------------------------------------------------------

 
[exhibit103069.jpg]

--------------------------------------------------------------------------------

 
[exhibit103070.jpg]
CONTRACT DATA REQUIREMENTS LIST Form Approved (1 Data Item) OMB No. 0704-0188
The public reporting burden for this collection of information is estimated to
average 110 hours per response, including the time for reviewing instructions,
searching existing data sources, gathering and maintaining the data needed, and
completing and reviewing the collection of information. Send comments regarding
this burden estimate or any other aspect of this collection of information,
including suggestions for reducing the burden, to Department of Defense,
Washington Headquarters Services, Directorate for Information Operations and
Reports (0701-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA
22202-4302. Respondents should be aware that notwithstanding any other provision
of law, no person shall be subject to any penalty for failing to comply with a
collection of information if it does not display a currently valid OMB control
number. Please DO NOT RETURN your form to the above address. Send completed form
to the Government Issuing Contracting Officer for the Contract/PR No. listed in
Block E. A. CONTRACT LINE ITEM NO. B. EXHIBIT C. CATEGORY: 0002 A TDP_____ TM
____ Other General/Admin Data D. SYSTEM/ITEM E. CONTRACT/PR NO. F. CONTRACTOR
LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE W911QY-20-C-0100 Moderna TX, Inc.
1. DATA ITEM NO. 2. TITLE OF DATA ITEM 3. SUBTITLE 17. Price Group A025 Research
and Development of Medical Products Regulated Monthly Technical Progress Report
by the U.S. Food & Drug Administration 4. AUTHORITY (Data Acquisition Document
No.) 5. CONTRACT REFERENCE 6. REQUIRING OFFICE 18. Estimated DI-MGMT-80368A
(Tailored) C.4.6 ASPR BARDA Total Price 7. DD 250 REQ 9. DIST STATEMENT 10.
FREQUENCY 12. DATE OF FIRST SUBMISSION 14. DISTRIBUTION NA REQUIRED MTHLY Refer
to Block 16 8. APP CODE C 11. AS OF DATE 13. DATE OF SUBSEQUENT SUBMISSION b.
COPIES a. ADDRESSEE Final A 0 Refer to Block 16 Draft Reg Repro 16. REMARKS ASPR
BARDA* 1 1 0 CCAP-SCN** 1 1 0 4. The Data Item Description (DID) may be obtained
from http://quicksearch.dla.mil/. 8. The US Government (USG) will respond with
comments or approval within 10 calendar days after receipt. 9. Distribution
Statement C: Distribution authorized to U.S. Government agencies and their
Contractors (Administrative or Operational Use). Determination made July 18,
2020. Distribution guidance is included in DoD Instruction 5230.24. 12. Submit
within 30 calendar days of contract award. 13. The contractor shall incorporate
USG comments and revisions within 10 calendar days after receipt. Resubmit for
any revisions to the UGS-approved Plan. 14. Submit as an electronic file in
Microsoft Office (i.e. Word, Excel, Power Point) via email to the BARDA
representative: Marva Taylor ([***]) and the Contracting Officer** (KO), Danny
Soto ([***]). LT: Letter of Transmittal (via email)

--------------------------------------------------------------------------------

 
[exhibit103071.jpg]
15. TOTAL → 2 2 0 G. PREPARED BY H. DATE I. APPROVED BY J. DATE Pamela Serra
July 18, 2020 Marva Taylor July 18, 2020 INSTRUCTIONS FOR COMPLETING DD FORM
1423 (See DoD 5010.12-M for detailed instructions.) FOR GOVERNMENT PERSONNEL FOR
THE CONTRACTOR Item A. Self-explanatory. Item 17. Specify appropriate price
group from one of the following groups of effort in developing estimated prices
for each data item listed on the DD Item B. Self-explanatory. Form 1423. Item C.
Mark (X) appropriate category: TDP - Technical Data Package; TM - a. Group I.
Definition - Data which is not otherwise essential to the Technical Manual;
Other - other category of data, such as “Provisioning," contractor's performance
of the primary contracted effort "Configuration Management," etc. (production,
development, testing, and administration) but which is required by DD Form 1423.
Item D. Enter name of system/item being acquired that data will support. Item E.
Self-explanatory (to be filled in after contract award). Estimated Price - Costs
to be included under Group I are those applicable to preparing and assembling
the data item in conformance with Item F. Self-explanatory (to be filled in
after contract award). Government requirements, and the administration and other
expenses Item G. Signature of preparer of CDRL. related to reproducing and
delivering such data items to the Government. Item H. Date CDRL was prepared. b.
Group II. Definition - Data which is essential to the performance of the primary
contracted effort but the contractor is required to Item I. Signature of CDRL
approval authority. perform additional work to conform to Government
requirements Item J. Date CDRL was approved. with regard to depth of content,
format, frequency of submittal, preparation, control, or quality of the data
item. Item 1. See DoD FAR Supplement Subpart 4.71 for proper numbering. Item 2.
Enter title as it appears on data acquisition document cited in Item Estimated
Price - Costs to be included under Group II are those 4. incurred over and above
the cost of the essential data item without conforming to Government
requirements, and the administrative and Item 3. Enter subtitle of data item for
further definition of data item other expenses related to reproducing and
delivering such data item to the (optional entry). Government. Enter Data Item
Description (DID) number, military specification Item 4. c. Group III.
Definition - Data which the contractor must develop for number, or military
standard number listed in DoD 5010.12-L (AMSDL), or his internal use in
performance of the primary contracted effort one-time DID number, that defines
data content and format requirements. and does not require any substantial
change to conform to Item 5. Enter reference to tasking in contract that
generates requirement Government requirements with regard to depth of content,
for the data item (e.g., Statement of Work paragraph number). format, frequency
of submittal, preparation, control, and quality of the data item. Item 6. Enter
technical office responsible for ensuring adequacy of the data item. Estimated
Price - Costs to be included under Group III are the administrative and other
expenses related to reproducing and delivering Item 7. Specify requirement for
inspection/acceptance of the data item by such data item to the Government. the
Government. Item 8. Specify requirement for approval of a draft before
preparation of d. Group IV. Definition - Data which is developed by the
contractor as the final data item. part of his normal operating procedures and
his effort in supplying these data to the Government is minimal. Item 9. For
technical data, specify requirement for contractor to mark the appropriate
distribution statement on the data (ref. DoDD 5230.24). Estimated Price - Group
IV items should normally be shown on the Item 10. Specify number of times data
items are to be delivered. DD Form 1423 at no cost. Item 11. Specify as-of date
of data item, when applicable. Item 12. Specify when first submittal is
required. Item 18. For each data item, enter an amount equal to that portion of
the total price which is estimated to be attributable to the production or Item
13. Specify when subsequent submittals are required, when applicable.
development for the Government of that item of data. These estimated data prices
shall be developed only from those costs which will be incurred Item 14. Enter
addressees and number of draft/final copies to be delivered as a direct result
of the requirement to supply the data, over and above

--------------------------------------------------------------------------------

 
[exhibit103072.jpg]
to each addressee. Explain reproducible copies in Item 16. those costs which
would otherwise be incurred in performance of the contract if no data were
required. The estimated data prices shall not Item 15. Enter total number of
draft/final copies to be delivered. include any amount for rights in data. The
Government's right to use the Item 16. Use for additional/clarifying information
for Items 1 through 15. data shall be governed by the pertinent provisions of
the contract. Examples are: Tailoring of documents cited in Item 4;
Clarification of submittal dates in Items 12 and 13; Explanation of reproducible
copies in Item 14.; Desired medium for delivery of the data item.

--------------------------------------------------------------------------------

 
[exhibit103073.jpg]

--------------------------------------------------------------------------------

 
[exhibit103074.jpg]
Supply Chain Resiliency Plan for CDRL A010 Attachment 0001 As of 23 July 2020
W911QY-20-C-0100 Supply Chain Resiliency Plan Attachment 0001 Page 1 of 3

--------------------------------------------------------------------------------

 
[exhibit103075.jpg]
ATTACHMENT 0001 TO CONTRACT DATA REQUIREMENTS LIST A010 Supply Chain Resiliency
Plan The contractor shall provide a comprehensive Supply Chain Resiliency Plan
that provides for identification and reporting of critical components associated
with the secure supply of drug substance, drug product, and work-in- process
through to finished goods. 1. A critical component is defined as any material
that is essential to the product or the manufacturing process associated with
that product. Included in the definition are consumables and disposables
associated with manufacturing. NOT included in the definition are facility and
capital equipment. Consideration of critical components includes the evaluation
and potential impact of raw materials, excipients, active ingredients,
substances, pieces, parts, software, firmware, labeling, assembly, testing,
analytical and environmental componentry, reagents, or utility materials which
are used in the manufacturing of a drug, cell banks, seed stocks, devices and
key processing components and equipment. A clear example of a critical component
is one where a sole supplier is utilized. 2. The contractor shall identify key
equipment suppliers, their locations, local resources, and the associated
control processes at the time of award. This document shall address planning and
scheduling for active pharmaceutical ingredients, upstream, downstream,
component assembly, finished drug product and delivery events as necessary for
the delivery of product. a) Communication for these requirements shall be
updated as part of an annual review, or as necessary, as part of regular
contractual communications. b) For upstream and downstream processing, both
single-use and re-usable in-place processing equipment, and manufacturing
disposables also shall be addressed. For finished goods, the inspection,
labeling, packaging, and associated machinery shall be addressed taking into
account capacity capabilities. c) The focus on the aspects of resiliency shall
be on critical components and aspects of complying with the contractual delivery
schedule. Delivery methods shall be addressed, inclusive of items that are
foreign- sourced, both high and low volume, which would significantly affect
throughput and adherence to the contractually agreed deliveries. 3. The
contractor shall articulate in the plan, the methodology for inventory control,
production planning, scheduling processes and ordering mechanisms, as part of
those agreed deliveries. a) Production rates and lead times shall be understood
and communicated to the HHS/ASPR/BARDA Contracting Officer or the Contracting
Officer's Representative as necessary. b) Production throughput critical
constraints should be well understood by activity and by design, and
communicated to contractual personnel. As necessary, communication should focus
on identification, exploitation, elevation, and secondary constraints of
throughput, as appropriate. 4. Reports for critical items should include the
following information: a) Critical Material b) Primary vendor and secondary
vendor, if applicable c) Supplier, Manufacturing / Distribution Location d)
Supplier Lead Time e) Shelf Life f) Transportation / Shipping restrictions
W911QY-20-C-0100 Supply Chain Resiliency Plan Attachment 0001 Page 2 of 3

--------------------------------------------------------------------------------

 
[exhibit103076.jpg]
g) Comparability studies, if applicable h) Amount of material (dose equivalent)
in inventory W911QY-20-C-0100 Supply Chain Resiliency Plan Attachment 0001 Page
3 of 3

--------------------------------------------------------------------------------

 
[exhibit103077.jpg]

--------------------------------------------------------------------------------

 
[exhibit103078.jpg]
Security Plan Attachment 0002 As of 23 July 2020 W911QY-20-C-0100 Security Plan
Attachment 0002 Page 1 of 7

--------------------------------------------------------------------------------

 
[exhibit103079.jpg]
ATTACHMENT 0002 CONTRACT DATA REQUIREMENTS LIST A019 BARDA SECURITY REQUIREMENTS
The contractor shall provide a Security Plan which shall address the following:
[***] W911QY-20-C-0100 Security Plan Attachment 0002 Page 2 of 7

--------------------------------------------------------------------------------

 
[exhibit103080.jpg]
Data Rights Attachment 0004 As of 7 August 2020 Data Rights Attachment 0004 Page
1 of 3

--------------------------------------------------------------------------------

 
[exhibit103081.jpg]
Data Rights Restrictions Limited Rights Data The following are Modern’s
technical data assertions required by DFAR 252.227-7017 (“Identification and
assertion of use, release, or disclosure restrictions”). Notwithstanding any
contrary representation by the Contractor on the System for Award Management or
any contrary provision in the contract, the following categories of information
developed exclusively at private expense will, if provided to the Government, be
considered limited rights data subject to the restrictions specified in DFAR
227.7013. These restrictions apply to any component of information covered by
this provision, regardless of whether a component is included in a contract
deliverable. The Government will, as applicable, retain government purpose
rights or unlimited rights in technical data generated in performance or
included in a deliverable as required by DFARS 252.227-7013 or another
applicable data rights clause to the extent that any component of such technical
data (i) was developed in whole or in part with Government funds, (ii) pertains
to an item developed in whole in part with Government funds, or (iii) was first
produced in performance of a Government contract subject to FAR 52.227-14.
Nothing in this Contract or this Attachment affects any data rights that the
Government may already have under prior agreements between Moderna and the
Government, including with respect to Agreement Nos. [***] The Government will
not reverse engineer or otherwise evaluate materials provided under this
Contract to reproduce the type of information described below without Moderna’s
prior written consent. [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
W911QY-20-C-0100 Data Rights August 7, 2020 Attachment 0004 Page 2 of 3

--------------------------------------------------------------------------------

 
[exhibit103082.jpg]
[***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] [***] [***] [***] [***] [***] [***] August 7, 2020 W911QYData-20-C
Rights-0100 Attachment 0004 Page 3 of 3

--------------------------------------------------------------------------------

 
[exhibit103083.jpg]

--------------------------------------------------------------------------------

 
[exhibit103084.jpg]
[***] Attachment 0005 As of 7 August 2020 W911QY-20-C-0100 [***] Attachment 0005
Page 1 of 2

--------------------------------------------------------------------------------

 
[exhibit103085.jpg]
[***] August 7, 2020 W911QY-20-C-0100 [***] Attachment 0005 Page 2 of 2

--------------------------------------------------------------------------------

 
[exhibit103086.jpg]
Moderna Tx, Inc. Background Intellectual Property Attachment 0006 As of 6 August
2020 W911QY-20-C-0100 ModernaTx, Inc. Background Intellectual Property
Attachment 0006 Page 1 of 3

--------------------------------------------------------------------------------

 
[exhibit103087.jpg]
Description of Moderna, Inc. Representative Intellectual Property [***]
W911QY-20-C-0100 ModernaTx, Inc. Background Intellectual Property Attachment
0006 Page 2 of 3

--------------------------------------------------------------------------------

 
[exhibit103088.jpg]
Description of Moderna, Inc. Representative Intellectual Property [***]
W911QY-20-C-0100 ModernaTx, Inc. Background Intellectual Property Attachment
0006 Page 3 of 3

--------------------------------------------------------------------------------

 
[exhibit103089.jpg]
Performance Based Payment (PBP) Milestone Schedule Attachment 0007 As of 7
August W911QY-20-C-0100 PBP Milestone Schedule Attachment 0007 Page 1 of 2

--------------------------------------------------------------------------------

 
[exhibit103090.jpg]
Severable/ Milestone Price Milestone Completion Verification Method CLIN
Cumulative Moderna shall provide: 1) written confirmation from the CMO network
that sufficient capacity has Capacity been reserved; and, 2) written
confirmation of and Raw Severable $601,400,000 reservation of sufficient raw
materials along with a 001 Material manufacturing schedule. Reservation [***]
[***] [***] [***] [***] [***] [***] [***] [***] [***] W911QY-20-C-0100 PBP
Milestone Schedule Attachment 0007

--------------------------------------------------------------------------------

 
[exhibit103091.jpg]
Page 2 of 2

--------------------------------------------------------------------------------

 
[exhibit103092.jpg]
Performance Base Payment (PBP) Milestone Billing Plan Attachment 0008 As of 7
August 2020 W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008

--------------------------------------------------------------------------------

 
[exhibit103093.jpg]
Page 1 of 16

--------------------------------------------------------------------------------

 
[exhibit103094.jpg]
Page 2 of 16 [***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008

--------------------------------------------------------------------------------

 
[exhibit103095.jpg]

--------------------------------------------------------------------------------

 
[exhibit103096.jpg]
[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 3 of 16

--------------------------------------------------------------------------------

 
[exhibit103097.jpg]
[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 4 of 16

--------------------------------------------------------------------------------

 
[exhibit103098.jpg]
[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 5 of 16

--------------------------------------------------------------------------------

 
[exhibit103099.jpg]
[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 6 of 16

--------------------------------------------------------------------------------

 
[exhibit103100.jpg]
[***]

--------------------------------------------------------------------------------

 
[exhibit103101.jpg]
[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 7 of 16

--------------------------------------------------------------------------------

 
[exhibit103102.jpg]
[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008
ACTIVE/105609918.3

--------------------------------------------------------------------------------

 
[exhibit103103.jpg]
Page 8 of 16

--------------------------------------------------------------------------------

 
[exhibit103104.jpg]
[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 9 of 16
ACTIVE/105609918.3

--------------------------------------------------------------------------------

 
[exhibit103105.jpg]
[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 10 of 16

--------------------------------------------------------------------------------

 
[exhibit103106.jpg]
[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 11 of 16

--------------------------------------------------------------------------------

 
[exhibit103107.jpg]
[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 12 of 16

--------------------------------------------------------------------------------

 
[exhibit103108.jpg]
[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 13 of 16

--------------------------------------------------------------------------------

 
[exhibit103109.jpg]
[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 14 of 16

--------------------------------------------------------------------------------

 
[exhibit103110.jpg]
[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 15 of 16

--------------------------------------------------------------------------------

 
[exhibit103111.jpg]
[***] W911QY-20-C-0100 PBP Milestone Billing Plan Attachment 0008 Page 16 of 16

--------------------------------------------------------------------------------

 
[exhibit103112.jpg]
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED
WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT
BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO
THE COMPANY IF DISCLOSED. 1. CONTRACT ID CODE PAGE OF PAGES AMENDMENT OF
SOLICITATION/MODIFICATION OF CONTRACT 1 16 2. AMENDMENT/MODIFICATION NO. 3.
EFFECTIVE DATE 4. REQUISITION/PURCHASE REQ. NO. 5. PROJECT NO.(If applicable)
0011534693 6. ISSUED BY CODE W911QY 7. ADMINISTERED BY (If other than item 6)
CODE S2206A DEFENSE CONTRACT MANAGEMENT AGENCY W6QK ACC-APG NATICK DIVISION DCMA
BOSTON BLDG 1 GENERAL GREENE AVENUE 495 SUMMER STREET NATICK MA 01760-5011
BOSTON MA 02210-2138 8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County,
State and Zip Code) 9A. AMENDMENT OF SOLICIT AT ION NO. MODERNA US INC [***] 9B.
DATED (SEE ITEM 11) 200 TECHNOLOGY SQ CAMBRIDGE MA 02139-3578 10A. MOD. OF
CONTRACT/ORDER NO. X W911QY20C0100 10B. DATED (SEE ITEM 13) CODE 8PTM0 FACILITY
CODE X 09-Aug-2020 11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS The
above numbered solicitation is amended as set forth in Item 14. The hour and
date specified for receipt of Offer is extended, is not extended. Offer must
acknowledge receipt of this amendment prior to the hour and date specified in
the solicitation or as amended by one of the following methods: (a) By
completing Items 8 and 15, and returning copies of the amendment; (b) By
acknowledging receipt of this amendment on each copy of the offer submitted; or
(c) By separate letter or telegram which includes a reference to the
solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE
RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND
DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this
amendment you desire to change an offer already submitted, such change may be
made by telegram or letter, provided each telegramor letter makes reference to
the solicitation and this amendment, and is received prior to the opening hour
and date specified. 12. ACCOUNT ING AND APPROPRIATION DATA (If required) 13.
THIS ITEM APPLIES ONLY TO MODIFICAT IONS OF CONTRACT S/ORDERS. IT MODIFIES THE
CONT RACT /ORDER NO. AS DESCRIBED IN ITEM 14. A. THIS CHANGE ORDER IS ISSUED
PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN
THE CONTRACT ORDER NO. IN ITEM 10A. B. THE ABOVE NUMBERED CONTRACT/ORDER IS
MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying
office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE
AUTHORITY OF FAR 43.103(B). X C. THIS SUPPLEMENT AL AGREEMENT IS ENTERED INTO
PURSUANT TO AUTHORITY OF: Mutual Agreement of the parties, FAR 43.103(a)(3) &
H.14, Novation D. OTHER (Specify type of modification and authority) E.
IMPORTANT: Contractor is not, X is required to sign this document and return 1
copies to the issuing office. 14. DESCRIPTION OF AMENDMENT /MODIFICATION
(Organized by UCF section headings, including solicitat ion/contract subject
matter where feasible.) Modification Control Number: dsoto202575 The purpose of
this modification is to 1. Novation Change from Moderna TX to Moderna US 2.
Section C make administrative revisions to correct type-o and update company
name 3. Section G update company name, correct type-o in subCLINs, and revise
WAWF Clause inspect by from S2206A to W911QY 4. Section I add FAR 52.204-25 and
update information in FAR 252.232-7007 5. Section J revised page number on
Exhibits and Attachments The total obligated amount and contract price remains
the unchanged. Except as provided herein, all terms and conditions of the
document referenced in Item 9A or 10A, as heretofore changed, remains unchanged
and in full force and effect. 15A. NAME AND TITLE OF SIGNER (Type or print) 16A.
NAME AND TITLE OF CONT RACTING OFFICER (Type or print) CAMILLE B. CONNELL-MAGAW
[***] Stephane Bancel, CEO TEL: [***] EMAIL: (Signature of 15C. DATE SIGNED 16B.
UNITED 15B. CONTRACTOR/OFFEROR person STATES OF /s/ Stephane Bancel authorized
to 9/4/2020 sign) AMERICA BY

--------------------------------------------------------------------------------

 
[exhibit103113.jpg]
/s/ Camille B. Connell-Magaw 16C. DATE SIGNED (Signature of Contracting Officer)
9/08/2020 EXCEPTION TO SF 30 30-105-04 STANDARD FORM 30 (Rev. 10-83) APPROVED BY
OIRM 11-84 Prescribed by GSA FAR (48 CFR) 53.243

--------------------------------------------------------------------------------

 
[exhibit103114.jpg]
W911QY20C0100 (dsoto202575) Page 2 of 16 SECTION SF 30 BLOCK 14 CONTINUATION
PAGE SUMMARY OF CHANGES SECTION C - DESCRIPTIONS AND SPECIFICATIONS The
following have been modified: STATEMENT OF WORK LARGE SCALE PRODUCTION OF
SARS-CoV-2 VACCINE C.1 SCOPE. The Department of Defense and Health and Human
Services (HHS) require large scale manufacturing of vaccine doses in support of
the national emergency response to the Coronavirus Disease 2019 (COVID-19) for
the United States Government (USG) and the US population. C.1.1 Background. In
December 2019, a novel coronavirus now known as SARS-CoV-2 was first detected in
Wuhan, Hubei Province, People’s Republic of China, causing outbreaks of the
coronavirus disease COVID-19 that has now spread globally. The Secretary of
Health and Human Service declared a public health emergency on January 31, 2020,
under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response
to COVID-19. On March 1, 2020, the President of the United States, pursuant to
sections 01 and 301 of the National Emergencies Act (50 U.S.C. 1601 et seq.) and
consistent with section 1135 of the Social Security Act (SSA), as amended (42
U.S.C. 1320b-5), proclaimed that the COVID-19 outbreak in the United States
constitutes a national emergency. C.1.1.1 Under Operation Warp Speed (OWS), the
Department of Defense and HHS are leading a whole of nation effort to ensure
development of promising vaccine, diagnostic and therapeutic candidates and
ensure that these medical countermeasures are available in the quantities
required to reduce SARS-CoV-2 transmission, identify prior and/or current
infection, and improve patient care, thereby mitigating the impact of COVID-19
on the nation and its people. The DoD Joint Program Executive Office for
Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRD) is providing
expertise and contracting support to HHS, in compliance with PL 115-92
Authorization Letter for DoD Medical Priorities, through an Interagency
Agreement, signed April 23, 2020. As OWS products progress to clinical trials to
evaluate the safety and efficacy of vaccines and therapeutics, it is critical
that, in parallel, the USG supports large scale manufacturing so that vaccine
doses or therapeutic treatment courses are immediately available for nationwide
access as soon as a positive efficacy signal is obtained and the medical
countermeasures are authorized for widespread use. C.1.2 Objective: The
objective of this effort is to obtain the following: a. Base Period: Large scale
manufacturing of 100 million vaccine doses b. Option Period 1: Large scale
manufacturing of 100 million vaccine doses c. Option Period 2: Large scale
manufacturing of 100 million vaccine doses d. Option Period 3: Large scale
manufacturing of 100 million vaccine doses e. Option Period 4: Large scale
manufacturing of 100 million vaccine doses The Base Period is 9 months, with
overlapping options for a total of 20 months if all options are exercised. C.2
APPLICABLE DOCUMENTS. C.2.1 Federal Documents: C.2.1.1 Title 21 Code of Federal
Regulations (CFR), Food and Drugs: Part 210, Current Good Manufacturing Practice
in Manufacturing, Processing, Packing, or Holding of Drugs; General; and, Part
211, Current Good Manufacturing Practice In Manufacturing, Processing, Packing,
or Holding of Drugs; General.

--------------------------------------------------------------------------------

 
[exhibit103115.jpg]
W911QY20C0100 (dsoto202575) Page 3 of 16 (https://www.ecfr.gov/cgi-bin/text-
idx?SID=a95cab20f443897a400bb7e44a27cf4c&mc=true&tpl=/ecfrbrowse/Title21/21cfrv4_02.tpl#0)
C.3 REQUIREMENTS. Independently, and not as an agent of the USG, in accordance
with the Proposal submitted by Moderna US, Inc. in response to Solicitation
Number W911QY20R0043, Titled, “Advanced Procurement of mRNA-1273 Vaccine for
Prevention of SARS-CoV-2 Coronavirus (COVID-19)”), dated July 10, 2020 (and any
subsequent USG-approved revisions thereto), the contractor shall provide all
necessary services, qualified personnel, material, equipment and facilities (not
otherwise provided by the USG under the terms of this contract) to perform the
specific tasks set forth below. C.3.1 Contract Line Item Number (CLIN) 0001 -
Base Period: Large Scale Manufacturing of 100 Million Vaccine Doses. C.3.1.1 The
contractor shall complete all scope required for the production, release and
delivery use of 100 million Final Drug Product (FDP) doses of a SARS-CoV-2
mRNA-1273 vaccine. This shall include, the following tasks and other activities
reasonably contemplated by such task: C.3.1.1.1 Storage of FDP doses prior to
delivery consistent with all FDA requirements to ensure that the product remains
available for use in target populations. Storage and maintenance of the vaccine
prior to delivery shall be under conditions and at temperatures necessary to
retain stability for use as prescribed in this contract for a period of 12
months. (Based on FDP stability data that supports a 12-month shelf-life,
subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of
21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial
Distribution are met prior to distribution to the CDC. Documents shall be
provided under CDRL A002, FDA Interactions and Inspections Documentation.
C.3.1.1.2 cGMP manufacturing of 100 million doses fully compliant with 21 CFR
210 and 211. C.3.1.1.3 Ensuring that vial labeling and packaging is consistent
with FDA guidance for use in target populations and that labeling is updated as
appropriate. C.3.1.1.4 Coordinating with FDA to establish an approved commercial
vial label, carton and packaging insert (printed or electronic). C.3.1.1.5
Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA),
Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification,
serialization, traceability and detection and response requirements, subject to
any exceptions established by or the enforcement discretion of the FDA,
including “Exemption from Certain Product Tracing and Product Identification
Requirements Under Section 582 of the FD&C Act” (April 2020). C.3.1.1.6 In
coordination with the USG, the contractor shall conduct a demonstration of the
vaccine shipping process prior to the first delivery of FDP doses at a time
mutually agreed to by the contractor and the USG. Moderna shall provide
specifications and details associated with the shipping process and containers
(IAW CDRL A005) to enable the USG to adequately plan and prepare for potential
distribution of the vaccine. C.3.1.1.7 Following release of product the
contractor shall, promptly deliver product to the designated delivery site via a
qualified distribution vendor in accordance with Section F and paragraph C.7
below. In the unforeseen event that a designated delivery site cannot receive
product and the contractor provides storage beyond 20 days of product release,
the contract will be subject to modification for acceptance purposes. C.3.1.2
Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site
visits by BARDA and FDA representatives for required site visits and audits at
facilities used to support this contract throughout the period of performance of
the contract. C.3.1.2.1 BARDA Audits. If issues are identified during an audit,
the contractor shall submit a report detailing the finding and corrective
action(s) in accordance with CDRL A001.

--------------------------------------------------------------------------------

 
[exhibit103116.jpg]
W911QY20C0100 (dsoto202575) Page 4 of 16 C.3.1.2.2 FDA Audits. The Contractor
shall notify the Contracting Officer and Contracting Officer’s Representative
(COR) within [***] of a scheduled FDA audit or within [***] of an ad hoc site
visit or audit if the FDA does not provide advance notice. The contractor shall
provide copies of any FDA Audit Report received from subcontractors that occur
as a result of this contract or for this product within [***] of receiving
correspondence from the FDA or third party in accordance with CDRL A002. The
Contractor shall provide the Contracting Officer with a plan for addressing
areas of nonconformance, if any are identified, within [***] of submittal of the
audit report in accordance with CDRL A002. C.3.1.2.3 FDA Interactions. The
contractor shall provide copies of the plan and processes that will ensure the
USG has visibility and input on all FDA communications regarding the drugs and
biologics for the following, but not limited to: FDA interactions, FDA meetings,
communications, submissions, inspections, and enforcement documentation in
accordance with CDRL A002. C.3.2 CLIN 1001 - Option Period 1: Large Scale
Manufacturing of 100 Million Vaccine Doses. C.3.2.1 The contractor shall
complete all scope required for the production, release and delivery use of 100
million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the
following tasks and other activities reasonably contemplated by such tasks:
C.3.2.1.1 Storage of FDP doses prior to delivery consistent with all FDA
requirements to ensure that the product remains available for use in target
populations. Storage and maintenance of the vaccine prior to delivery shall be
under conditions and at temperatures necessary to retain stability for use as
prescribed in this contract for a period of 12 months. (Based on FDP stability
data that supports a 12-month shelf-life, subject to FDA confirmation of the
assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers
of Drugs and Listing of Drugs in Commercial Distribution are met prior to
distribution to the CDC. Documents shall be provided under CDRL A002, FDA
Interactions and Inspections Documentation. C.3.2.1.2 cGMP manufacturing of 100
million doses, subject to any exceptions established by or the enforcement
discretion of the FDA. C.3.2.1.3 Ensuring that vial labeling and packaging is
consistent with FDA guidance for use in target populations and that labeling is
updated. C.3.2.1.4 Ensuring the product complies with the Drug Supply Chain
Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including
product verification, serialization, traceability and detection and response
requirements subject to any exceptions established by or the enforcement
discretion of the FDA. C.3.2.1.5 Following release of the product the contractor
shall deliver the product to the designated distribution site via a qualified
distribution vendor in accordance with Section F and paragraph C.7 below. To the
extent a natural disaster or other emergency affecting a designated delivery
site restricts such site’s ability to receive product, the Contractor and the
USG will promptly agree on an alternate USG delivery location, or storage as
Vendor Managed Inventory (VMI) at the contractor site. C.3.2.2 Site Visits and
Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA
and FDA representatives for required site visits and audits at facilities used
to support this contract throughout the period of performance of the contract.
C.3.2.2.1 BARDA Audits. If issues are identified during an audit, the contractor
shall submit a report detailing the finding and corrective action(s) in
accordance with CDRL A001. C.3.2.2.2 FDA Audits. The Contractor shall notify the
Contracting Officer and COR within [***] of a scheduled FDA audit or within
[***] of an ad hoc site visit or audit if the FDA does not provide advance
notice. The contractor shall provide copies of any FDA Audit Report received
from subcontractors that occur as a result of this contract or for this product
within [***] of receiving correspondence from the FDA or third party in

--------------------------------------------------------------------------------

 
[exhibit103117.jpg]
W911QY20C0100 (dsoto202575) Page 5 of 16 accordance with CDRL A015. The
Contractor shall provide the Contracting Officer with a plan for addressing
areas of nonconformance, if any are identified, within [***] of submittal of the
audit report in accordance with CDRL A002. C.3.2.2.3 FDA Interactions. The
contractor shall provide copies of the plan and processes that will ensure the
USG has visibility and input on all FDA communications regarding the drugs and
biologics for the following, but not limited to: FDA interactions, FDA meetings,
communications, submissions, inspections, and enforcement documentation in
accordance with CDRL A002. C.3.3 CLIN 2001 - Option Period 2: Large Scale
Manufacturing of 100 Million Vaccine Doses. C.3.3.1 The contractor shall
complete all scope required for the production, release and delivery use of 100
million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the
following tasks and other activities reasonably contemplated by such tasks:
C.3.3.1.1 Storage of FDP doses prior to delivery consistent with all FDA
requirements to ensure that the product remains available for use in target
populations. Storage and maintenance of the vaccine prior to delivery shall be
under conditions and at temperatures necessary to retain stability for use as
prescribed in this contract for a period of 12 months. (Based on FDP stability
data that supports a 12-month shelf-life, subject to FDA confirmation of the
assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers
of Drugs and Listing of Drugs in Commercial Distribution are met prior to
distribution to the CDC. Documents shall be provided under CDRL A002, FDA
Interactions and Inspections Documentation. C.3.3.1.2 cGMP manufacturing of 100
million doses, subject to any exceptions established by or the enforcement
discretion of the FDA. C.3.3.1.3 Ensuring that vial labeling and packaging is
consistent with FDA guidance for use in target populations and that labeling is
updated as appropriate. C.3.3.1.4 Ensuring that the product complies with the
Drug Supply Chain Security Act (DSCSA), Sections 581- 585 of PL 113-54 (Nov. 27,
2013), including product verification, serialization, traceability and detection
and response requirements, subject to any exceptions established by or the
enforcement discretion of the FDA. C.3.3.1.5 Following release the contractor
shall deliver product to the nearest designated distribution site via a
qualified distribution vendor in accordance with Section F and paragraph C.7
below. To the extent a natural disaster or other emergency affecting a
designated delivery site restricts such site’s ability to receive product, the
Contractor and the USG will promptly agree on an alternate USG delivery
location, or storage as Vendor Managed Inventory (VMI) at the contractor site.
C.3.3.2 Site Visits and Audits. The contractor shall accommodate periodic or ad
hoc site visits by BARDA and FDA representatives for required site visits and
audits at facilities used to support this contract throughout the period of
performance of the contract. C.3.3.2.1 BARDA Audits. If issues are identified
during an audit, the contractor shall submit a report detailing the finding and
corrective action(s) in accordance with CDRL A001. C.3.3.2.2 FDA Audits. The
Contractor shall notify the Contracting Officer and COR within [***] of a
scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA
does not provide advance notice. The contractor shall provide copies of any FDA
Audit Report received from subcontractors that occur as a result of this
contract or for this product within [***] of receiving correspondence from the
FDA or third party in accordance with CDRL A002. The Contractor shall provide
the Contracting Officer with a plan for addressing areas of nonconformance, if
any are identified, within [***] of submittal of the audit report in accordance
with CDRL A002.

--------------------------------------------------------------------------------

 
[exhibit103118.jpg]
W911QY20C0100 (dsoto202575) Page 6 of 16 C.3.3.2.3 FDA Interactions. The
contractor shall provide copies of the plan and processes that will ensure the
USG has visibility and input on all FDA communications regarding the drugs and
biologics for the following, but not limited to: FDA interactions, FDA meetings,
communications, submissions, inspections, and enforcement documentation in
accordance with CDRL A002. C.3.4 CLIN 3001 - Option Period 3: Large Scale
Manufacturing of 100 Million Vaccine Doses. C.3.4.1 The contractor shall
complete all scope required for the production, release and delivery use of 100
million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the
following tasks and other activities reasonably contemplated by such tasks:
C.3.4.1.1 Storage of FDP doses prior to delivery consistent with all FDA
requirements to ensure that the product remains available for use in target
populations. Storage and maintenance of the vaccine prior to delivery shall be
under conditions and at temperatures necessary to retain stability for use as
prescribed in this contract for a period of 12 months. (Based on FDP stability
data that supports a 12-month shelf-life, subject to FDA confirmation of the
assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers
of Drugs and Listing of Drugs in Commercial Distribution are met prior to
distribution to the CDC. Documents shall be provided under CDRL A002, FDA
Interactions and Inspections Documentation. C.3.4.1.2 cGMP manufacturing of 100
million doses, subject to any exceptions established by or the enforcement
discretion of the FDA. C.3.4.1.3 Ensuring that vial labeling and packaging is
consistent with FDA guidance for use in target populations and that labeling is
updated. C.3.4.1.4 Ensuring the product complies with the Drug Supply Chain
Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including
product verification, serialization, traceability and detection and response
requirements subject to any exceptions established by or the enforcement
discretion of the FDA. C.3.4.1.5 Following release of the product the contractor
shall deliver the product to the designated distribution site via a qualified
distribution vendor in accordance with Section F and paragraph C.7 below. To the
extent a natural disaster or other emergency affecting a designated delivery
site restricts such site’s ability to receive product, the Contractor and the
USG will promptly agree on an alternate USG delivery location, or storage as
Vendor Managed Inventory (VMI) at the contractor site. C.3.4.2 Site Visits and
Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA
and FDA representatives for required site visits and audits at facilities used
to support this contract throughout the period of performance of the contract.
C.3.4.2.1 BARDA Audits. If issues are identified during an audit, the contractor
shall submit a report detailing the finding and corrective action(s) in
accordance with CDRL A001. C.3.4.2.2 FDA Audits. The Contractor shall notify the
Contracting Officer and COR within [***] of a scheduled FDA audit or within
[***] of an ad hoc site visit or audit if the FDA does not provide advance
notice. The contractor shall provide copies of any FDA Audit Report received
from subcontractors that occur as a result of this contract or for this product
within [***] of receiving correspondence from the FDA or third party in
accordance with CDRL A015. The Contractor shall provide the Contracting Officer
with a plan for addressing areas of nonconformance, if any are identified,
within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.4.2.3 FDA Interactions. The contractor shall provide copies of the plan and
processes that will ensure the USG has visibility and input on all FDA
communications regarding mRNA-1273 for the following, but not limited to: FDA
interactions, FDA meetings, communications, submissions, inspections, and
enforcement documentation in accordance with CDRL A002.

--------------------------------------------------------------------------------

 
[exhibit103119.jpg]
W911QY20C0100 (dsoto202575) Page 7 of 16 C.3.5 CLIN 4001 - Option Period 4:
Large Scale Manufacturing of 100 Million Vaccine Doses. C.3.5.1 The contractor
shall complete all scope required for the production, release and delivery use
of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include
the following tasks and other activities reasonably contemplated by such tasks:
C.3.5.1.1 Storage of FDP doses prior to delivery consistent with all FDA
requirements to ensure that the product remains available for use in target
populations. Storage and maintenance of the vaccine prior to delivery shall be
under conditions and at temperatures necessary to retain stability for use as
prescribed in this contract for a period of 12 months. (Based on FDP stability
data that supports a 12-month shelf-life, subject to FDA confirmation of the
assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers
of Drugs and Listing of Drugs in Commercial Distribution are met prior to
distribution to the CDC. Documents shall be provided under CDRL A002, FDA
Interactions and Inspections Documentation. C.3.5.1.2 cGMP manufacturing of 100
million doses, subject to any exceptions established by or the enforcement
discretion of the FDA. C.3.5.1.3 Ensuring that vial labeling and packaging is
consistent with FDA guidance for use in target populations and that labeling is
updated. C.3.5.1.4 Ensuring the product complies with the Drug Supply Chain
Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including
product verification, serialization, traceability and detection and response
requirements subject to any exceptions established by or the enforcement
discretion of the FDA. C.3.5.1.5 Following release of the product the contractor
shall deliver the product to the designated distribution site via a qualified
distribution vendor in accordance with Section F and paragraph C.7 below. To the
extent a natural disaster or other emergency affecting a designated delivery
site restricts such site’s ability to receive product, the Contractor and the
USG will promptly agree on an alternate USG delivery location, or storage as
Vendor Managed Inventory (VMI) at the contractor site. C.3.5.2 Site Visits and
Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA
and FDA representatives for required site visits and audits at facilities used
to support this contract throughout the period of performance of the contract.
C.3.5.2.1 BARDA Audits. If issues are identified during an audit, the contractor
shall submit a report detailing the finding and corrective action(s) in
accordance with CDRL A001. C.3.5.2.2 FDA Audits. The Contractor shall notify the
Contracting Officer and COR within [***] of a scheduled FDA audit or within
[***] of an ad hoc site visit or audit if the FDA does not provide advance
notice. The contractor shall provide copies of any FDA Audit Report received
from subcontractors that occur as a result of this contract or for this product
within [***] of receiving correspondence from the FDA or third party in
accordance with CDRL A015. The Contractor shall provide the Contracting Officer
with a plan for addressing areas of nonconformance, if any are identified,
within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.5.2.3 FDA Interactions. The contractor shall provide copies of the plan and
processes that will ensure the USG has visibility and input on all FDA
communications regarding the drugs and biologics for the following, but not
limited to: FDA interactions, FDA meetings, communications, submissions,
inspections, and enforcement documentation in accordance with CDRL A002. C.4
CLIN 0002: Data Deliverables. The contractor shall provide the following in
accordance with the Contract Data Requirements List (CDRL), DD Forms 1423,
provided at Appendix A. C.4.1 Monthly Inventory Report (CDRL A003), detailing at
a minimum, raw materials, Bulk mRNA, formulated LNPs, and the fill, finish, and
released product.

--------------------------------------------------------------------------------

 
[exhibit103120.jpg]
W911QY20C0100 (dsoto202575) Page 8 of 16 C.4.2 Quality Management Plan. The
contractor shall provide a Quality Management Plan, in accordance with CDRL
A004, describing the quality policy and objectives, management review,
competencies and training, process document control, feedback, evaluation,
corrective action and preventive action, process improvement, measurement, and
data analysis processes. The framework is normally divided into infrastructure,
senior management responsibility, resource management, lifecycle management, and
quality management system evaluation. C.4.3 Shipping Documentation (CDRL A005)
for all Finished Drug Product (FDP) transferring from the contractor’s
fill/finish facility to a USG facility. The contractor shall obtain concurrence
on planned shipment protocols prior to transport. C.4.4 Expiring Items Report
(CDRL A006) for all FDP in the USG’s possession. C.4.5 Key Personnel Listing
(CDRL A007). C.4.6 Monthly Technical Progress Report (CDRL A008), to include an
Integrated Master Schedule, identifying key activities and contract status.
C.4.7 Final Technical Report (CDRL A009), documenting the work performed and
results obtained for the entire contract period of performance. C.4.8 Supply
Chain Resiliency Plan (SCRP). The contractor shall provide, in accordance with
CDRL A010 and CDRL Attachment 0001, a comprehensive SCRP that provides for
identification and reporting of critical components associated with the secure
supply of drug substance, drug product, and work-in-process through to finished
goods, and key equipment suppliers and their locations, including addresses,
points of contact, and work performed per location, to include subcontractors.
C.4.9 Risk Management Plan (RMP). The Contractor shall provide an RMP in
accordance with CDRL A011 that outlines the impacts of each risk in relation to
the cost, schedule, and performance objectives. The plan shall include risk
mitigation strategies. Each risk mitigation strategy shall capture how the
corrective action will reduce impacts on cost, schedule and performance. C.4.10
Manufacturing Reports and Dose Tracking. The Contractor shall provide, in
accordance with CDRL A013, manufacturing reports and manufacturing dose tracking
projections and actuals utilizing the USG-provided “COVID-19 Dose Tracking
Template” (CDRL Attachment 0003). C.4.11 Product Acceptance Report (for each lot
of Drug Product). The contractor shall provide, in accordance with CDRL A014,
pictures of the drug product with lot number, drug product lot tree, list of
associated deviations (from drug substance and product), and a Certificate of
Analysis. C.4.12 Incident Report. The contractor shall communicate to BARDA and
document all critical programmatic concerns, issues, or probable risks that have
or are likely to significantly impact project schedule and/or cost and/or
performance in accordance with CDRL A016. “Significant” is frequently defined as
a 10% or greater cost or schedule variance within a control account, but should
be confirmed in consultation with the COR. Incidents that present liability to
the project even without cost/schedule impact, such as breach of GCP during a
clinical study, shall also be reported. C.4.13 FDA Correspondence. The
contractor shall provide any correspondence between Contractor and FDA relevant
to the scope of this contract and submit in accordance with CDRL A017. C.4.14
Press Releases. The contractor shall accurately and factually represent the work
conducted under this contract in all press releases. The contractor shall
provide an advance copy of any press release in accordance with CDRL A018.

--------------------------------------------------------------------------------

 
[exhibit103121.jpg]
W911QY20C0100 (dsoto202575) Page 9 of 16 C.4.15 Manufacturing Development Plan.
The contractor shall provide a Manufacturing Development Plan, in accordance
with CDRL A025, describing the manufacturing process for the drug/biologic
product to ensure conformity with §501(a)(2)(B) of the Food, Drug, and Cosmetics
Act (FD&C Act, Title 21 United States Code (USC) §351 (a)(2)(B)), regarding good
manufacturing practices (GMP). C.5 Administration. C.5.1 Post Award
Teleconference. The contractor shall host a Post Award Teleconference within 15
7 calendar days after contract award. C.5.1.1 The contractor shall provide an
Agenda, IAW CDRL A020, detailing the planned activities for the subsequent 30
calendar days and shall discuss agenda items for the Post Award Kickoff Meeting.
C.5.1.2 The contractor shall provide Meeting Minutes IAW CDRL A021. C.5.2 Post
Award Kickoff Meeting. The contracting officer may request the contractor host a
contract Kick-Off Meeting within 30 calendar days after contract award via
teleconference. The contracting officer shall establish the date and time of the
conference and prepare the agenda to include discussion on contract activities
and schedule. C.5.3 Bi-Weekly Teleconference. The contractor shall participate
in bi-weekly teleconferences (or more frequent meetings required by the USG if
warranted based on contract activities) to discuss performance on the contract.
C.5.4 The contractor shall provide an Agenda, IAW CDRL A020; Meeting Minutes in
accordance with CDRL A021; and, Presentation Material in accordance with CDRL
A022 for each of the aforementioned teleconferences or meetings throughout the
contract period of performance. C.5.5 Daily “Check-In”. The contractor shall
participate in a daily “check-in” (via teleconference or email) to address key
cost, schedule and technical updates. Daily updates may be shared with senior
USG leaders during the COVID- 19 response and should be provided on a
non-confidential basis, unless the update includes confidential information in
which case, the contractor shall provide the update in both confidential and
non-confidential formats. Daily check-ins may occur on weekdays, excluding
federal holidays. Upon request of the USG, check-ins may also occur on weekends
and on federal holidays, provided at least 24 hours’ notice. C.6 Security. C.6.1
Access and General Protection/Security Policy and Procedures. The contractor
shall provide all information required for background checks necessary to access
critical information related to OWS, and to meet USG installation access
requirements to be accomplished by the installation Director of Emergency
Services or Security Office. The contractor employees shall comply with all
personnel identity verification requirements as directed by the USG and/or local
policy. In addition to the changes otherwise authorized by the changes clause of
this contract, should the security status of OWS change the USG may require
changes in the contractor’s security matters or processes. In addition to the
industry standards for employment background checks, the contractor shall be
willing to have key individuals, in exceptionally sensitive positions,
identified for additional vetting by the United States USG. C.6.2 Security
Program and Plan. The contractor shall implement a comprehensive security
program that provides overall protection of personnel, information, data, and
facilities associated with fulfilling the USG’s requirement. The contractor’s
security practices and procedures shall be detailed in a Security Plan, in
accordance with CDRL A019, and shall demonstrate how the contractor shall meet
and adhere to the security requirements outlined in CDRL Attachment 0002. This
plan shall be delivered to the USG within 45 days of award, and the USG will
review in detail and submit comments within ten (10) business days to the
Contracting Officer (CO) to be forwarded to the Contractor. The Contractor shall
review the Security Plan comments, and, submit a final Security Plan to the U.S.
USG within thirty (30) calendar days after receipt of the comments. The Security
Plan shall include a timeline for compliance of all the required security
measures outlined in CDRL Attachment 0002.

--------------------------------------------------------------------------------

 
[exhibit103122.jpg]
W911QY20C0100 (dsoto202575) Page 10 of 16 C.6.3 Operational Security (OPSEC).
The contractor shall develop and submit an OPSEC Standard Operating Procedure
(SOP)/Plan IAW CDRL A024. The contractor shall identify in the SOP/Plan critical
information related to this contract, why it needs to be protected, where it is
located, who is responsible for it, and how to protect it. C.7 CLIN 0002 Vendor
Managed Inventory (VMI). The Contractor shall provide the capability to store
the vaccine for up to 52 weeks, up to 100M doses of mRNA-1273 vaccine, in
accordance with product labeling. The contractor shall, in accordance with
paragraph C.3.1.1.6, ensure the product storage of FDP doses for up to 12 months
prior to delivery consistent with all FDA requirements to ensure that the
product remains available for use in target populations . [***] The contractor
shall store the product to insure product quality with audible alarms and
contacting. The contractor shall notify the USG within [***] of detection of an
incident with the potential to impact product quality, and implement corrective
actions to mitigate the incident. . BARDA/JPEO- CBRND personnel may conduct
Quality Audits of the storage facility, when deemed necessary. The contractor
shall notify the USG of Corrective/Preventive actions within [***] of detection
of an incident with potential to impacts product quality. BARDA/JPEO-CBRND
personnel may conduct Quality Audits of the storage facility, when deemed
necessary. C.7.1 The USG will provide the contractor advance notice of the
required delivery locations for the vaccine. The contractor shall ship mRNA-1273
vaccines to designated locations in up to [***] in the United States. The
contractor shall be responsible for shipment of all vaccine product whether
acceptance is conducted at origin or destination. [***] C.7.2 The vaccine
product shall be shipped and tracked by the distribution vendor’s shipping
tracking number, to the USG-designated sites within the continental United
States. C.7.3 [***] Implementation of a Vendor Managed Inventory Plan/SOP (CDRL
A012) shall be provided to the USG. [***] Notwithstanding either of the
foregoing sentences, the contractor shall not be liable for loss of or damage to
supplies caused by the negligence of officers, agents, or employees of the USG
acting within the scope of their employment. SECTION G - CONTRACT ADMINISTRATION
DATA The following have been modified: G.1 GOVERNMENT CONTRACT ADMINISTRATION In
no event shall any understanding or agreement, contract modification, change
order, or other matter in deviation from the terms of this contract between the
Contractor and a person other than the Contracting Officer be effective or
binding upon the Government. All such actions must be formalized by a proper
contractual document executed by the Contracting Officer. Procuring Contracting
Officer: Camille Connell-Magaw / [***] / [***] [***] [***]

--------------------------------------------------------------------------------

 
[exhibit103123.jpg]
W911QY20C0100 (dsoto202575) Page 11 of 16 Contract Specialist: Danny Soto /
[***] / [***] [***] [***] G.2 GOVERNMENT TECHNICAL POINT OF CONTACT Marva Taylor
/ [***] / [***] Biologist/Project Officer [***] [***] G.3 CONTRACTOR’S CONTRACT
ADMINISTRATION [***] ModernaTX, Inc. 200 Technology SQ. Cambridge, MA 02139-3578
G.4 PLACES OF PERFORMANCE Moderna US, Inc. 200 Technology SQ. Cambridge, MA
02139-3578 G.5 NOTIFICATION OF REVISIONS AND CHANGE Notification of revision or
changes to names or email addresses will be provided by official correspondence
from the PCO/ACO or office of the PCO/ACO in lieu of a contract modification.
This does not apply to any such revisions or changes in the event this contract
includes a key personnel clause. G.6 PERFORMANCE BASED PAYMENT Performance-based
payments (PBP) are authorized under this contract in accordance with FAR
52.232-32. The contractor shall bill for the PBP upon achievement of the
completion criteria identified in Attachment 0007, Performance-based Payment
Milestone Table. Upon achievement of the completion criteria, the contractor
shall bill for the PBP for the base and each option IAW the following schedule:
CLIN PERIOD AMOUNT 0001AA BASE $ 90,210,000 0001AB BASE $ 132,308,000 0001AC
BASE $ 180,420,000 0001AD BASE $ 198,462,000 TOTAL $ 601,400,000 [***] [***]
[***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]

--------------------------------------------------------------------------------

 
[exhibit103124.jpg]
W911QY20C0100 (dsoto202575) Page 12 of 16 [***] [***] [***] [***] [***] [***]
[***] [***] Delivery Invoicing: PBPs are a type of contract financing and are
recouped by the Government through deductions of payments otherwise due to the
contractor for the partial or complete delivery of contract items. The
deductions are made by applying a liquidation rate to the price of delivered
contract items. Attachment 0008, Performance- based Payment Milestone Billing
Plan, identifies the contractor invoicing schedule for liquidation. The
contractor shall submit all invoices IAW Attachment 0008. 252.232-7006 WIDE AREA
WORKFLOW PAYMENT INSTRUCTIONS (DEC 2018) (a) Definitions. As used in this
clause-- “Department of Defense Activity Address Code (DoDAAC)” is a six
position code that uniquely identifies a unit, activity, or organization.
“Document type” means the type of payment request or receiving report available
for creation in Wide Area WorkFlow (WAWF). “Local processing office (LPO)” is
the office responsible for payment certification when payment certification is
done external to the entitlement system. “Payment request” and “receiving
report” are defined in the clause at 252.232-7003, Electronic Submission of
Payment Requests and Receiving Reports. (b) Electronic invoicing. The WAWF
system provides the method to electronically process vendor payment requests and
receiving reports, as authorized by Defense Federal Acquisition Regulation
Supplement (DFARS) 252.232- 7003, Electronic Submission of Payment Requests and
Receiving Reports. (c) WAWF access. To access WAWF, the Contractor shall— (1)
Have a designated electronic business point of contact in the System for Award
Management at https://www.sam.gov; and (2) Be registered to use WAWF at
https://wawf.eb.mil/ following the step-by-step procedures for self-registration
available at this web site. (d) WAWF training. The Contractor should follow the
training instructions of the WAWF Web-Based Training Course and use the Practice
Training Site before submitting payment requests through WAWF. Both can be
accessed by selecting the “Web Based Training” link on the WAWF home page at
https://wawf.eb.mil/. (e) WAWF methods of document submission. Document
submissions may be via web entry, Electronic Data Interchange, or File Transfer
Protocol. (f) WAWF payment instructions. The Contractor shall use the following
information when submitting payment requests and receiving reports in WAWF for
this contract or task or delivery order: (1) Document type. The Contractor shall
submit payment requests using the following document type(s): COMBO

--------------------------------------------------------------------------------

 
[exhibit103125.jpg]
W911QY20C0100 (dsoto202575) Page 13 of 16 (ii) For fixed price line items— (A)
That require shipment of a deliverable, submit the invoice and receiving report
specified by the Contracting Officer. Invoice and receiving report document type
(B) For services that do not require shipment of a deliverable, submit either
the Invoice 2in1, which meets the requirements for the invoice and receiving
report, or the applicable invoice and receiving report, as specified by the
Contracting Officer. N/A (iii) For customary progress payments based on costs
incurred, submit a progress payment request. (iv) For performance based
payments, submit a performance based payment request. (v) For commercial item
financing, submit a commercial item financing request. (2) Fast Pay requests are
only permitted when Federal Acquisition Regulation (FAR) 52.213-1 is included in
the contract. (3) Document routing. The Contractor shall use the information in
the Routing Data Table below only to fill in applicable fields in WAWF when
creating payment requests and receiving reports in the system. Routing Data
Table Field Name in WAWF Data to be entered in WAWF Pay Official DoDAAC HQ0337
Issue By DoDAAC W911QY Admin DoDAAC** S2206A Inspect By DoDAAC W911QY / BARDA
Acceptor W911QY Ship To TDB (4) Payment request. The Contractor shall ensure a
payment request includes documentation appropriate to the type of payment
request in accordance with the payment clause, contract financing clause, or
Federal Acquisition Regulation 52.216-7, Allowable Cost and Payment, as
applicable. (5) Receiving report. The Contractor shall ensure a receiving report
meets the requirements of DFARS Appendix F. (g) WAWF point of contact. (1) The
Contractor may obtain clarification regarding invoicing in WAWF from the
following contracting activity’s WAWF point of contact. Orlando Ortiz / DCMA
Boston-AFAW, Administrative Contracting Officer / [***]

--------------------------------------------------------------------------------

 
[exhibit103126.jpg]
W911QY20C0100 (dsoto202575) Page 14 of 16 (2) Contact the WAWF helpdesk at
866-618-5988, if assistance is needed. (End of clause) FOR REFERANCE: DFARS PGI
204.7108 Payment Instructions Table
https://www.acq.osd.mil/dpap/dars/pgi/pgi_htm/current/PGI204_71.htm#payment_instructions
SECTION I - CONTRACT CLAUSES The following have been added by reference:
52.204-25 Prohibition on Contracting for AUG 2020 Certain Telecommunications and
Video Surveillance Services or Equipment. The following have been modified:
252.232 7007 LIMITATION OF GOVERNMENT'S OBLIGATION (APR 2014) (a) Contract line
item 0003 is incrementally funded. For this item, the sum of $0.00 of the total
price is presently available for payment and allotted to this contract. An
allotment schedule is set forth in paragraph (j) of this clause. (b) For
items(s) identified in paragraph (a) of this clause, the Contractor agrees to
perform up to the point at which the total amount payable by the Government,
including reimbursement in the event of termination of those item(s) for the
Government's convenience, approximates the total amount currently allotted to
the contract. The Contractor is not authorized to continue work on those item(s)
beyond that point. The Government will not be obligated in any event to
reimburse the Contractor in excess of the amount allotted to the contract for
those item(s) regardless of anything to the contrary in the clause entitled
"TERMINATION FOR THE CONVENIENCE OF THE GOVERNMENT." As used in this clause, the
total amount payable by the Government in the event of termination of applicable
contract line item(s) for convenience includes costs, profit and estimated
termination settlement costs for those item(s).

--------------------------------------------------------------------------------

 
[exhibit103127.jpg]
W911QY20C0100 (dsoto202575) Page 15 of 16 (c) Notwithstanding the dates
specified in the allotment schedule in paragraph (j) of this clause, the
Contractor will notify the Contracting Officer in writing at least ninety days
prior to the date when, in the Contractor's best judgment, the work will reach
the point at which the total amount payable by the Government, including any
cost for termination for convenience, will approximate 85 percent of the total
amount then allotted to the contract for performance of the applicable item(s).
The notification will state (1) the estimated date when that point will be
reached and (2) an estimate of additional funding, if any, needed to continue
performance of applicable line items up to the next scheduled date for allotment
of funds identified in paragraph (j) of this clause, or to a mutually agreed
upon substitute date. The notification will also advise the Contracting Officer
of the estimated amount of additional funds that will be required for the timely
performance of the item(s) funded pursuant to this clause, for subsequent period
as may be specified in the allotment schedule in paragraph (j) of this clause,
or otherwise agreed to by the parties. If after such notification additional
funds are not allotted by the date identified in the Contractor's notification,
or by an agreed substitute date, the Contracting Officer will terminate any
item(s) for which additional funds have not been allotted, pursuant to the
clause of this contract entitled "TERMINATION FOR THE CONVENIENCE OF THE
GOVERNMENT". (d) When additional funds are allotted for continued performance of
the contract line item(s) identified in paragraph (a) of this clause, the
parties will agree as to the period of contract performance which will be
covered by the funds. The provisions of paragraph (b) through (d) of this clause
will apply in like manner to the additional allotted funds and agreed substitute
date, and the contract will be modified accordingly. (e) If, solely by reason of
failure of the Government to allot additional funds, by the dates indicated
below, in amounts sufficient for timely performance of the contract line item(s)
identified in paragraph (a) of this clause, the Contractor incurs additional
costs or is delayed in the performance of the work under this contract and if
additional funds are allotted, an equitable adjustment will be made in the price
or prices (including appropriate target, billing, and ceiling prices where
applicable) of the item(s), or in the time of delivery, or both. Failure to
agree to any such equitable adjustment hereunder will be a dispute concerning a
question of fact within the meaning of the clause entitled "disputes." (f) The
Government may at any time prior to termination allot additional funds for the
performance of the contract line item(s) identified in paragraph (a) of this
clause. (g) The termination provisions of this clause do not limit the rights of
the Government under the clause entitled "DEFAULT." The provisions of this
clause are limited to work and allotment of funds for the contract line item(s)
set forth in paragraph (a) of this clause. This clause no longer applies once
the contract if fully funded except with regard to the rights or obligations of
the parties concerning equitable adjustments negotiated under paragraphs (d) or
(e) of this clause. (h) Nothing in this clause affects the right of the
Government to this contract pursuant to the clause of this contract entitled
"TERMINATION FOR CONVENIENCE OF THE GOVERNMENT." (i) Nothing in this clause
shall be construed as authorization of voluntary services whose acceptance is
otherwise prohibited under 31 U.S.C. 1342.

--------------------------------------------------------------------------------

 
[exhibit103128.jpg]
W911QY20C0100 (dsoto202575) Page 16 of 16 (j) The parties contemplate that the
Government will allot funds to this contract in accordance with the following
schedule: On execution of contract $0.00 Upon successful completion of CLIN 0003
$300,000,000 (End of clause) SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER
ATTACHMENTS The following have been modified: Document Type Description Page #
Date Exhibit A CDRLs 15 18 July 2020 Attachment 0001 Supply Chain Resiliency
Plan for CDRL A010 3 23 July 2020 Attachment 0002 Security Plan 7 23 July 2020
Attachment 0003 Dose Tracking Template Draft Moderna Excel 15 July 2020
Attachment 0004 Data Rights 3 7 August 2020 Attachment 0005 [***] 2 7 August
2020 Attachment 0006 ModernaTx, Inc. Background Intellectual Property 3 6 August
2020 Attachment 0007 Performance Base Payment Milestone Schedule 2 7 August 2020
Attachment 0008 Performance Base Payment Milestone Billing Plan 16 7 August 2020
(End of Summary of Changes)

--------------------------------------------------------------------------------

 
[exhibit103129.jpg]
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED
WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT
BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO
THE COMPANY IF DISCLOSED. 1. CONTRACT ID CODE PAGE OF PAGES AMENDMENT OF
SOLICITATION/MODIFICATION OF CONTRACT 1 3 2. AMENDMENT/MODIFICATION NO.
EFFECTIVE 4. REQUISITION/PURCHASE REQ. NO. 5. PROJECT NO.(If applicable) DATE
0011534693 11-Sep-2020 6. ISSUED BY CODE W911QY 7. ADMINISTERED BY (If other
than item 6) CODE S2206A DEFENSE CONTRACT MANAGEMENT AGENCY W6QK ACC-APG NATICK
DIVISION DCMA BOSTON BLDG 1 GENERAL GREENE AVENUE 495 SUMMER STREET NATICK MA
01760-5011 BOSTON MA 02210-2138 8. NAME AND ADDRESS OF CONTRACTOR (No., Street,
County, State and Zip Code) 9A. AMENDMENT OF SOLICITATION NO. MODERNA US, INC.
[***] 9B. DATED (SEE ITEM 11) 200 TECHNOLOGY SQ CAMBRIDGE MA 02139-3578 10A.
MOD. OF CONTRACT/ORDER NO. X W911QY20C0100 10B. DATED (SEE ITEM 13) CODE 8PTM0
FACILITY CODE X 09-Aug-2020 11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF
SOLICITATIONS The above numbered solicitation is amended as set forth in Item
14. The hour and date specified for receipt of Offer is extended, is not
extended. Offer must acknowledge receipt of this amendment prior to the hour and
date specified in the solicitation or as amended by one of the following
methods: (a) By completing Items 8 and 15, and returning copies of the
amendment; (b) By acknowledging receipt of this amendment on each copy of the
offer submitted; or (c) By separate letter or telegram which includes a
reference to the solicitation and amendment numbers. FAILURE OF YOUR
ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS
PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If
by virtue of this amendment you desire to change an offer already submitted,
such change may be made by telegram or letter, provided each telegramor letter
makes reference to the solicitation and this amendment, and is received prior to
the opening hour and date specified. 12. ACCOUNT ING AND APPROPRIAT ION DATA (If
required) 13. THIS ITEM APPLIES ONLY TO MODIFICAT IONS OF CONTRACT S/ORDERS. IT
MODIFIES THE CONT RACT /ORDER NO. AS DESCRIBED IN ITEM 14. A. THIS CHANGE ORDER
IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE
MADE IN THE CONTRACT ORDER NO. IN ITEM 10A. B. THE ABOVE NUMBERED CONTRACT/ORDER
IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying
office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE
AUTHORITY OF FAR 43.103(B). X C. THIS SUPPLEMENT AL AGREEMENT IS ENTERED INTO
PURSUANT TO AUT HORIT Y OF: 45 CFR part 101, Health Resources and Priorities
Allocations System (HRPAS) D. OTHER (Specify type of modification and authority)
E. IMPORTANT: Contractor is not, X is required to sign this document and return
1 copies to the issuing office. 14. DESCRIPTION OF AMENDMENT /MODIFICAT ION
(Organized by UCF section headings, including solicitation/contract subject
matter where feasible.) Modification Control Number: tscott202802 OBLIGATION
AMOUNT: $0.00 See Block 14 continuation page Except as provided herein, all
terms and conditions of the document referenced in Item 9A or 10A, as heretofore
changed, remains unchanged and in full force and effect. 15A. NAME AND TITLE OF
SIGNER (Type or print) 16A. NAME AND TITLE OF CONT RACTING OFFICER (Type or
print) [***] Stephane BANCEL, CEO Christine F. Sordillo TEL: [***] EMAIL: 15B.
CONTRACTOR/OFFEROR 15C. DATE SIGNED 16B. UNIT ED STATES OF AMERICA 16C. DATE
SIGNED /s/ Stephane Bancel 9/10/2020 BY /s/ Christine F. Sordillo 11 Sept 2020
(Signature of person authorized to sign) (Signature of Contracting Officer)
EXCEPTION TO SF 30 30-105-04 STANDARD FORM 30 (Rev. 10-83) APPROVED BY OIRM
11-84 Prescribed by GSA FAR (48 CFR) 53.243

--------------------------------------------------------------------------------

 
[exhibit103130.jpg]
W911QY20C0100 (tscott202802) Page 2 of 3 SECTION SF 30 BLOCK 14 CONTINUATION
PAGE SUMMARY OF CHANGES SECTION SF 30 - BLOCK 14 CONTINUATION PAGE The following
have been added by full text: The purpose of this modification is to: 1. Add a
Health Resources Priorities and Allocations System (HRPAS) priority rating of
DO-HR to this contract: This is a DO rated contract for the purpose of emergency
preparedness and the Contractor shall follow all the provisions of the Health
Resources Priorities and Allocations System regulation (45 CFR Part 101). If the
contractor needs to utilize industrial resources to fulfill this rated order for
a health resource, it is authorized pursuant to 45 CFR §101.36(b) to place the
same priority rating and program identification symbol for health resources on
its orders for industrial resources with its suppliers. 2. Add a Defense
Priorites and Allocation System (DPAS) priority rating of DO-C9 to this contract
to act as the equivalent to the HRPAS priority rating of DO-HR. 3. Add FAR
52.211-15, Defense Priority and Allocation Requirements This is a rated order
certified for national defense, emergency preparedness, and energy program use,
and the Contractor shall follow all the requirements of the Defense Priorities
and Allocations System regulation (15 CFR 700). 4. Add Attachment 0009 - HRPAS
Moderna Letter to Section J The total funded amount and total contract price
remain unchanged. SECTION A - SOLICITATION/CONTRACT FORM The DPAS code DO-C9 has
been added. The contractor organization has changed from MODERNATX, INC. [***]
200 TECHNOLOGY SQ CAMBRIDGE MA 02139-3578 to MODERNA US, INC. [***] 200
TECHNOLOGY SQ CAMBRIDGE MA 02139-3578 SECTION I - CONTRACT CLAUSES

--------------------------------------------------------------------------------

 
[exhibit103131.jpg]
W911QY20C0100 (tscott202802) Page 3 of 3 The following have been added by full
text: 52.211-15 DEFENSE PRIORITY AND ALLOCATION REQUIREMENTS (APR 2008) This is
a rated order certified for national defense, emergency preparedness, and energy
program use, and the Contractor shall follow all the requirements of the Defense
Priorities and Allocations System regulation (15 CFR 700). (End of clause)
SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS The following have
been modified: Document Type Description Page # Date Exhibit A CDRLs 15 18 July
2020 Attachment 0001 Supply Chain Resiliency Plan for CDRL A010 3 23 July 2020
Attachment 0002 Security Plan 7 23 July 2020 Attachment 0003 Dose Tracking
Template Draft Moderna Excel 15 July 2020 Attachment 0004 Data Rights 3 7 August
2020 Attachment 0005 [***] 2 7 August 2020 Attachment 0006 ModernaTx, Inc.
Background Intellectual Property 3 6 August 2020 Attachment 0007 Performance
Base Payment Milestone Schedule 2 7 August 2020 Attachment 0008 Performance Base
Payment Milestone Billing Plan 16 7 August 2020 Attachment 0009 HRPAS Moderna
Letter 1 3 September 2020 (End of Summary of Changes)

--------------------------------------------------------------------------------